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Abstract 
Antimicrobial photodynamic therapy (aPDT) uses photosensitiser (PS) molecules in 
combination with visible light to generate reactive oxygen species (ROS; e.g. 
1
O2 and 
•OH) that kill bacteria. The approach is highly suited to skin and other body surface 
infections, where photosensitisers and light can easily be applied directly to infection 
sites. As examples, the phenothiazinium PS methylene blue (MB) has been used in 
aPDT for the sterilisation of blood products, and aPDT with a related compound 
toluidine blue O (TBO) has been used for oral disinfection of dental cavities and for 
treating periodontitis. 
 It has been shown that membrane efflux pumps can limit bacterial cell killing 
during aPDT with MB, probably by lowering the levels of intracellular ROS produced. 
This observation suggests that combination approaches, where MB is used alongside 
small molecule efflux pump inhibitors (EPIs), might potentiate the aPDT effects of MB, 
allowing its use to be extended to multi-drug resistant (MDR) skin and soft-tissue 
infections, such as those mediated by methicillin-resistant Staphylococcus aureus 
(MRSA). Studies have confirmed that combinations of EPIs with MB do indeed show 
increased aPDT potency relative to MB. 
 This thesis explored a novel approach where MB was covalently linked to EPIs 
to create MB-EPI hybrid molecules. The rationale for the approach (Chapter 1) was 
based on prior studies showing that conjugation of the weak antibacterial berberine to 
the MDR inhibitor INF55 produced berberine-INF55 hybrids that show increased 
potency over berberine alone and berberine/INF55 combinations. The similarities 
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between berberine and MB (both planar, aromatic, hydrophobic cations) suggested a 
similar MB-EPI approach might be successfully adapted for use in aPDT. To explore 
this hypothesis, a 16 member MB-EPI hybrid library was conceived (compounds 47-
62), where members incorporated one of four known inhibitors of the NorA efflux 
pump in S. aureus; reserpine (47-50), pterostilbene (51-54), INF55 (55-58) or INF271 
(59-62). The library contained four examples of each MB-EPI type that carried 
variations in the linker group between the EPI and MB. Two principal linker groups 
were employed; piperazine and N,N’-dimethylethylenediamine, and these were linked 
directly to the C7 position of MB and to EPIs through either N-alkyl (2 compounds) or 
N-acyl (2 compounds) linkages. It was rationalised that production of a library of this 
type, which scanned photophysical, EPI, physicochemical and other properties of 
hybrids, would maximise the chances of identifying one or more effective compounds. 
 Synthesis of the hybrids (Chapter 2) employed a convergent strategy that made 
use of a phenothiazinium salt common intermediate 63, which had previously been used 
for the synthesis of asymmetric MB derivatives. The approach required that advanced 
secondary amine intermediates containing pre-assembled EPI and linker portions be 
synthesised first, before submitting these individually to reactions with common 
intermediate 63, giving the target hybrids in the final step. The approach was used 
successfully to produce all 16 hybrids in pure form and in quantities suitable for the 
study. 
 In Chapter 3, the hybrids were first studied using UV/Vis spectroscopy for the 
effects of attaching the EPI-linker groups to MB on the absorption properties of their 
constituent MB chromophores. The wavelength maxima and extinction coefficients of 
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the MB absorption bands in all hybrids were found to change very little from those in 
MB, indicating that the structural changes introduced had not significantly impacted the 
chromophore. Chapter 3 also explored production of ROS 
1
O2 and •OH from the 
hybrids upon illumination with 652 nm red light. All hybrids were observed to produce 
1
O2 and •OH, albeit at lower levels than MB. Levels of 
1
O2 were in general higher than 
•OH. As a class, the INF55-containing hybrids showed the strongest production of 
1
O2. 
All hybrids were next screened for aPDT activity using the test organism MRSA 
USA300 (Chapter 3). Pterostilbene-containing compounds 51-54 were found to be 
devoid of activity and only one reserpine-containing compound, 50, showed slight 
activity at the highest concentration tested (20 M). Three of the four INF271-
containing hybrids 59, 60 and 62, on the other hand, showed enhanced aPDT activity 
relative to MB, as did two of the INF55-containing hybrids (56 and 58). Compound 58 
was the most potent compound identified, producing an impressive 6-log reduction in 
MRSA USA300 cells at 20 M (fluence = 6 J/cm
2
) in this assay. 
 Based on the preliminary screening results, four hybrids (56 and 58 from the 
INF55-containing compounds and 59 and 60 from the INF271 series) were advanced to 
further in vitro studies. The four leads were next studied for their aPDT effects against 
S. aureus strains expressing reduced (NorA-), basal (wild-type, WT) and high 
(NorA++) levels of the NorA efflux pump (Chapter 3). MB (20 M) showed aPDT 
activity against these cells in the following order: NorA- > WT > NorA++, consistent 
with it being a substrate for the NorA pump, where pump activity removes the 
compound from cells resulting in lower intracellular ROS upon illumination. Hybrids 
56, 58, 59 and 60 at 20 M all showed enhanced aPDT effects against the WT and 
vii 
 
NorA++ strains relative to MB, whilst showing similar effects to MB against the NorA- 
strain. This was consistent with the compounds functioning as designed; i.e. with their 
attached EPIs serving to reduce NorA-mediated efflux of the appended MB moiety, 
leading to increased intracellular ROS upon illumination and greater cell killing. 
Subsequent dose-response aPDT experiments with three of these hybrids (56, 58 and 
60, Chapter 3) revealed very high potency for the INF55-containing compounds 56 and 
58, which produced total eradication of NorA- and NorA++ cells at 40-80 M. 
 Uptake of 56, 58 and 60 into NorA-, WT and NorA++ S. aureus cells (Chapter 
3) was found to be virtually unchanged across the three compounds and strains, 
consistent with these hybrids being poor substrates for NorA, and possibly acting to 
block the pumps. In comparison, MB showed high uptake into NorA- cells, which 
reduced in WT cells and was very low in NorA++ cells, consistent with it being a NorA 
substrate. 
 The question of whether active hybrids were (a) blocking the NorA pump in S. 
aureus cells or (b) simply evading its action, was addressed in two experiments. In the 
first of these, a series of synthetic intermediates containing INF55 or INF271 attached 
to the various linker types used in hybrids, while lacking the terminal MB moiety, were 
examined for their abilities to potentiate aPDT effects of co-administered MB in 
NorA++ cells. In all cases, the intermediates produced similar potentiation effects to the 
parent EPIs INF55 and INF271, suggesting that the structural changes introduced 
through attachment of linkers did not abrogate their pump-blocking activities. In the 
second type of experiments, the antibacterial activity of ciprofloxacin, a known 
substrate for NorA, was examined in the dark against a bioluminescent S. aureus strain, 
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both alone and in the presence of hybrids 56, 58 and 60. Each hybrid was found to 
potentiate the activity of ciprofloxacin, consistent with the hybrids inhibiting its efflux 
by blocking NorA activity. 
 The final part of the thesis (Chapter 4) explored the aPDT activity of lead hybrid 
58 in a murine MRSA wound infection model. The primary goal of this study was to 
demonstrate superior efficacy of 58 over MB. Infections were established by inoculating 
bioluminescent MRSA into 1 cm
2
 scratch wounds on the shaved dorsal surfaces of 
BALB/c female mice and monitored using real time bioluminescence imaging. 
Infections were studied in the presence/absence of MB and 58, both with and without 
application of 652 nm light. aPDT treatment with 58 produced dramatically enhanced 
effects relative to MB. At very low fluence (12 J/cm
2
), 58 reduced the bacterial load by 
~ 98%, whereas a much higher fluence (~ 96 J/cm
2
) was required to effect similar 
reductions with MB. Furthermore, a rebound in bacterial load was observed 1 day after 
treatment in the MB/aPDT group that was not observed in the group treated with 58. 
Moreover, total clearance of the infection took only 4 days with 58 (7 days for MB) and 
the wounds healed faster (~ 4 days for 58; ~ 7 days for MB). 
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1.1 Bacterial Resistance - A Global Health Threat 
In today’s world, no nation’s health is secure due to the increasing threat posed 
by drug-resistant pathogens. Antimicrobial resistance arises when pathogens, including 
bacteria, fungi, viruses and parasites, no longer respond to drugs to which they were 
formerly sensitive.
1
 For example, the Gram-positive bacteria Staphylococcus aureus and 
Gram-negatives like Staphylococcus epidermis and Staphylococcus hemolyticus have 
demonstrated an ability to develop resistance to each new generation of antibiotics. 
Methicillin-resistant S. aureus (MRSA) and vancomycin-resistant Enterococcus 
faecium (VRE) are two examples that are causing great clinical concern.
2
 In some 
settings, as many as 90% of S. aureus infections are reported to arise from MRSA 
leading to ineffective treatments with standard antibiotics. This hospital-derived 
(nosocomial) ‘superbug’  has been estimated to increase the likelihood of patient death 
by 64%.
3
 Of over two million people who contract antibiotic-resistant infections 
annually, at least 23,000 die directly from the infection and another 100,000 die from 
related complications.
3
 According to the U.S. Centers for Diseases Control and 
Prevention (CDC), antibiotic-resistant pathogens cost the U.S. health care system 
between  $21-34 billion each year.
4
 
The glycopeptide antibiotic vancomycin is considered the last line of defense 
antibiotic against Gram-positives resistant to all β-lactams. These days, however, 
vancomycin-resistant S. aureus (VRSA) is recognised as a “concerning threat” by the 
CDC.
5 Many countries are also reporting high rates of resistance to third-generation 
cephalosporins, carbapenems and fluoroquinolones in Escherichia coli and Klebsiella 
pneumoniae, which are responsible for pneumonia and bloodstream infections.
3
 Social 
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factors contributing to the problem include unnecessary prescribing of antibiotics, 
addition of antibiotics to feedstuffs, transmission of infections via international 
travellers and the rise in poverty in some countries. These factors in combination with 
cellular bacteria resistance mechanisms have created the worrying scenario we face 
today.
6
 
A great concern is that we will enter a post-antibiotic era where standard 
antibiotic treatments no longer work and infections become more and more difficult or 
impossible to control. To counter this threat there is a continuing and urgent need to 
discover new antibiotics and antimicrobial strategies, preferably acting via novel 
mechanisms. 
1.2 Bacterial Resistance Mechanisms 
Existence on earth for more than three billion years
7
 has allowed bacteria to 
evolve multiple mechanisms for surviving in diverse and challenging environments. 
They have learned how to detoxify harmful substances, like naturally occurring toxins 
and, in more recent times, antibiotics developed by humans. When we create new 
antibiotics, mankind encourages resistance development and expands the survival 
mechanisms available to bacteria.
8
 Thus, while effective new antimicrobials are clearly 
needed it is imperative that they be developed in parallel with new tactics that address 
the problem of resistance.
9
 
Three of the major cellular mechanisms that bacteria use to resist antimicrobials 
are summarized in Figure 1.1. Firstly, enzymatic inactivation of antibiotics can occur 
when bacteria express enzymes to detoxify compounds before they reach their 
 
4 
 
target(s).
10
     β-lactamases, for examples, serve to deactivate β-lactam antibiotics by 
hydrolysing their essential β-lactam ring.
10-11
 Both Gram-positive (e.g. S. aureus and 
Bacillus cereus) and Gram-negative (e.g. Pseudomonas sp and Acinetobacter sp) 
species produce β-lactamases.
12
 
 
 
Figure 1.1 Three major bacterial antibiotic resistance mechanisms: (A) enzymatic 
inactivation, (B) drug target alteration and (C) expression of efflux pumps. Figure 
modified from Nordmann et al.
13
  
 
A second mechanism that bacteria use to resist antimicrobials is to alter their 
drug targets through mutation. By modifying their targets, bacteria render antibiotics 
ineffective by reducing their target affinity, which nullifies their ability to inhibit 
microbial cell functions. As an example, when the peptidoglycan precursors used by 
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enterococci for cell wall synthesis are mutated from D-Ala-D-Ala to D-Ala-D-Lac, the 
binding of vancomycin is impaired.
14
  
Expression of efflux pumps is a third major resistance mechanism and the focus 
of this PhD project. The role of efflux pumps in preventing molecules, including those 
produced by the host organism (e.g. bile) from accumulating in bacterial cells, was first 
described in 1980.
15
 It is now accepted that efflux pumps are responsible for importing 
essential nutrients into cells and exporting a wide variety of toxic agents, such as dyes, 
drugs, cationic agents and metabolites.
16
 Efflux pumps essentially serve as gatekeepers 
that shuttle molecules between the cell cytoplasm and the extracellular environment.
17
 
1.3 Efflux Pumps - General 
Membrane-bound efflux transporter proteins (pumps) are found in both 
prokaryotic and eukaryotic organisms.
16
 The term Multi-Drug Resistance (MDR) 
pumps is used to differentiate pumps that are capable of transporting a wide variety of 
structurally diverse compounds from those that selectively extrude specific molecules. 
Based on sequence similarity and structural homology, efflux systems have been 
classified into six super-families. These include the ATP-binding cassettes (ABC), 
major facilitators (MFS), resistance-nodulation cell division (RND), small multidrug-
resistance family (SMR), multi-antimicrobial extrusion protein family (MATE) and 
multidrug endosomal transporters (MET). The first five families are found in 
microorganisms, while the MET family appears to be restricted to higher eukaryotes. 
Representatives of all families are found in mammalian cells.
18
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1.4 Bacterial Efflux Pumps 
Evidence that MDR pumps contribute to antibiotic resistance in bacteria comes 
from experiments showing that there is an increase in the minimum inhibitory 
concentration (MIC) of multiple antibiotics against a particular bacterium, compared to 
the MICs of the same antibiotics against non-MDR expressing parent strains.
19
 It is well 
accepted that the ‘intrinsic resistance’ of Gram-negative bacteria to certain antibiotics is 
a result of efflux systems.
20
  
A summary of bacterial efflux systems that illustrates their biological 
complexity, overlapping specificity and evolutionary adaptability to antimicrobials, is 
provided in Figure 1.2. 
 
Figure 1.2 Summary of efflux systems found in Gram-positive and Gram-negative 
bacteria. Examples of individual proteins that comprise each class are shown, along 
with their typical substrates. MDRs expressed by Gram-negatives contain several 
components, with the outer membrane protein normally being TolC. Figure modified 
from Piddock et al.
21
 
 
Both Gram-positive and Gram-negative bacteria can produce a variety of efflux 
systems that contribute to multidrug resistance, virulence and pathogenesis.
22 
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Mechanisms that induce upregulation of efflux pumps include: (1) mutations in 
promoter regions or insertion elements located upstream from efflux pump genes, (2) 
mutations in local repressor genes and (3) mutations in global regulatory genes.  
Substrates for individual efflux pumps vary depending on the pump and the 
bacteria. A typical substrate profile of an MDR pump might include chloramphenicol, 
quinolones (e.g. nalidixic acid, ciprofloxacin and norfloxacin), polycyclic dyes (e.g. 
acriflavine and ethidium bromide), some detergents (e.g. sodium dodecyl sulfate and 
Triton X-100) and biocides (e.g. cetrimide and triclosan).
23
  
1.4.1 Efflux Pumps in Clinically Important Gram-Positive Bacteria 
The major efflux systems implicated in Gram-positive bacterial drug resistance 
are comprised of six chromosomally encoded transporters, including MFS members 
NorA, NorB, NorC and MdeA, the MATE multidrug export protein mepRAB
24
 and the 
SMR member SepA.
25
 Three plasmid encoded pumps QacA, QacB,
26
 and Tet(K) are 
also important.
27
 These systems have broad and overlapping substrate specificities, 
extruding quinolones, tetracyclines, monovalent and divalent antimicrobial cations (i.e. 
intercalating dyes, quaternary ammonium compounds, diamidines, biguanidines) and 
plant secondary metabolites.
28
  
Pumps belonging to the MFS superfamily in S. aureus are NorA, NorB, NorC, 
SdrM and Tet38. One study showed that 50% of 232 blood-borne S. aureus isolates 
were able to efflux more than two substrates. Overexpressed genes identified were 
mepA 4%, mdeA 11%, norA 23%, norB 25% and norC 17%. Another 20% of strains 
over-expressed two or more efflux genes.
29
 Other genes, such as mepA (belonging to the 
 
8 
 
MATE family) and sepA (belonging to the SMR family), are also present in the S. 
aureus genome. Sav1866 is an ATP-binding cassette protein from the pathogen S. 
aureus which is frequently used to homology model human and microbial ABC 
multidrug transporters. The structure of the Sav1866 ABC pump from S. aureus is 
shown in Figure 1.3.  
 
 
Figure 1.3 Ribbon representation of the Sav1866 ABC pump in S. aureus. Two of six 
transmembrane helical domains and two intracellular nucleotide-binding domains are 
shown. Figure modified from Dawson and Locher.
30
  
 
The clinical relevance of efflux pumps in S. aureus is best understood for NorA. 
The NorA pump confers resistance to fluoroquinolone antibiotics, as well as dyes and 
biocides.
31
 While nafcillin, ciprofloxacin, vancomycin and linezolid are typically used 
for treatment of methicillin-susceptible S. aureus (MSSA) and MRSA infections, the 
MICs of these agents are generally not affected by NorA, except for ciprofloxacin.  
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Enterococcus faecium is a commensal (innocuous, coexisting) organism in the 
human intestine that can cause diseases such as neonatal meningitis. Analysis of food-
borne infections revealed that Tet(L), Tet(M) and Tet(K) pumps are present in E. 
faecium. MsrC pumps (belonging to the ABC transporters) have been shown to confer 
resistance to macrolides and quinupristin in E. faecium, while EfmA pumps (MFS 
family) have been shown to confer intrinsic resistance to many fluoroquinolones and 
tetraphenylphosphonium ions. EmeA (a NorA homologue) has also been identified in E. 
faecalis.
32
  
S. pneumonia infections can lead to fatal pneumonia, bronchitis and meningitis, 
particularly in the young and elderly. The MFS pumps in S. pneumonia MefA, MefE 
and PmrA, have been implicated in macrolide and fluoroquinolone resistance.
33
 The 
PmrA (MFS family) pump in S. pneumonia shares 42% identity with NorA and 43% 
with Bmr pumps. It can export ciprofloxacin and norfloxacin, as well as the dyes 
acriflavine and ethidium bromide.
29,34
 Overexpression of pmrA is not exclusively 
associated with norfloxacin-resistant S. pneumonia as it is also found in norfloxacin-
susceptible isolates.
35
 
The mef (MFS pump Mef) and mel (ABC pump Mel) genes, which are located 
on a conjugative transposon-related element in the genome of S. pneumonia, confer 
resistance to macrolides and are responsible for increasing resistance problems 
worldwide.
36
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1.4.2 Efflux Pumps in Clinically Important Gram-Negative Bacteria 
The most clinically significant efflux systems in Gram-negative bacteria are the 
RND tripartite transporters, which show exceptionally broad substrate recognition 
profiles. These proton-driven pumps are highly conserved across representative 
proteobacteria and a representative example, AcrAB-TolC from E. coli, is shown in 
Figure 1.4. Several members of the RND superfamily encoded in the human genome are 
homologues of bacterial RND pumps (16% identity).
37
  
 
Figure 1.4 Model of the TolC-MexA-AcrB pump in E. coli. The pump comprises the α-
helical domain of a nonameric MexA complex that accommodates the periplasmic end 
of the TolC efflux channel (pale orange), α/β barrel domain (blue), a “lipoyl” domain 
(red), an extended α-helical domain (green) and the AcrB pump (grey). Figure modified 
from Cuthbertson et al.
38
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Pseudomonas aeruginosa, E. coli, Salmonella enterica, Campylobacter jejuni 
and Neisseria gonorrhoeae are clinically relevant Gram-negative bacteria known to 
express MDR pumps. P. aeruginosa can cause pneumonia and other opportunistic 
infections (e.g. skin and soft-tissue infections in burns patients). Several antibiotics, 
including chloramphenicol, fluoroquinolones and tetracycline, as well as other 
substances like acriflavine, ethidium bromide and even some organic solvents, are 
exported by P. aeruginosa pumps. The clinically relevant pumps in P. aeruginosa are 
MexAB-OprM, MexCD-OprJ, MexEF-OprN and MexXY-OprM. These are expressed 
at basal levels in wild-type cells and can confer intrinsic resistance to many 
antimicrobials.
39
 Expression of MexCD-OprJ and MexEF-OprN has only been observed 
in multi-drug resistant strains and is induced by pump substrates.
40
 P. 
aeruginosa  carries twelve related Mex efflux systems but only the above four have 
been shown to be clinically significant for resistance.
41
  
Overexpression of pumps can occur as a result of mutations in operons within 
transcriptional regulatory regions.
42
 For example, overexpression of mexAB-OprM in 
nalB strains due to mutations in the mexR gene confers multi-drug resistance in P. 
aeruginosa.
43
 Other genes involved in the overexpression of MexAB-OprM include 
nalC and nalD. Hyperexpression of MexCD-OprJ in nfxB mutants of P. aeruginosa 
contributes resistance to fluoroquinolones and fourth generation cephems (e.g. 
cefpriome and cefozopran).
44
 
Decisions on which antibiotics to use when treating P. aeruginosa infections 
depends on whether the compounds are Mex pump substrates.
45
 For instance, the 
MexXY-OprM system exports aminoglycosides, the MexAB-OprM system certain β-
 
12 
 
lactams and the MexCD-OprJ system novobiocin and cefsulodin. Another RND 
transporter, MexGHI-OpM, has been shown to facilitate quorum sensing and antibiotic 
susceptibility in P. aeruginosa, and to promote virulence and contribute to persistence.
45
 
Although E. coli is a commensal organism found in the human gut it is often 
responsible for urinary-tract infections. Enteropathogenic E. coli (EPEC) and 
enterotoxigenic E. coli (ETEC) can cause severe diarrhoea.
21
 Pumps in E. coli include 
EmrB, MdfA, TetA and Acr. Acr (i.e. AcrB) functions as a multi-subunit complex in 
association with the outer membrane channel TolC and the membrane fusion protein 
AcrA.
21
 Figure 1.5 shows the structure of the AcrAB-TolC pump in E. coli. 
 
 
Figure 1.5 Example of an MDR efflux pump in E. coli. The pump is an AcrAB-TolC 
complex. The TolC trimer (orange, red, and yellow subunits with grey equatorial 
domains and membrane regions) was docked onto the AcrA (green) and AcrB trimer 
(blue/light blue subunits with grey membrane regions). Figure modified from Symmons 
et al.
46
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AcrAB-TolC from the RND family is remarkably polyspecific
47
 and can be 
overexpressed in some clinical isolates.
48
 Overexpression of AcrAB-TolC does not 
generally confer clinical resistance on its own. As with RND pumps in P. aeruginosa, 
AcrAB-TolC in E. coli is a tripartite complex formed between the RND pump AcrB, the 
membrane fusion protein AcrA and the low permeability outer membrane protein 
TolC.
37a
 While a crystal structure has been reported and a model of the pump 
assembled
46
 the exact role of each component during efflux remains largely unknown.  
The AcrAB-TolC complex is capable of extruding a very broad range of 
substances that differ in both structure and charge. Examples include antibiotics like 
chloramphenicol, lipophillic β-lactams, tetracycline, rifamipicin, novabicin, fusidic acid 
and nalidixic acid.
47
 Non-antibiotic substrates include disinfectants and detergents,
 
bile 
salts, cationic dyes, ethidium bromide
 
and some solvents.
49
  
Treatment of E. coli infections usually involves administration of co-
trimoxazole (trimethoprim-sulfamethoxazole), a nitrofurantoin or a fluoroquinolone. 
Ceftriaxone, a third-generation cephalosporin, is used for invasive or life-threatening E. 
coli infections.
50
  
Salmonella enterica serovar Typhimurium and Salmonella enterica serovar 
Enteritidis can cause gastroenteritis, with invasive salmonellosis occurring in 1-4% of 
human infections.
51
 When treatment is required the antibiotics most commonly used are 
fluoroquinolones (e.g. ciprofloxacin) or the cephalosporin ceftriaxone. The AcrAB-
TolC system of S. Typhimurium is similar to that of E. coli. It has been shown that 
overexpression of AcrB in human and veterinary isolates and laboratory mutants of S. 
Typhimurium are associated with MDR.
52
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C. jejuni contains RND-family members and is the most common cause of 
bacterial gastroenteritis in developed countries. Overexpression of CmeB confers 
resistance to ciprofloxacin, erythromycin, ampicillin, chloramphenicol and tetracycline 
and decreases susceptibility to bile salts, SDS, Triton X-100 and triclosan.
53
 Both 
human and veterinary isolates of C. jejuni have been found to overexpress cmeB.
54
  
Resistance of N. gonorrhoeae to some antibiotics (i.e. erythromycin, penicillin 
and tetracycline) due to multiple transferable resistance (mtr) was first identified in the 
1970s.
55
 The mtr property is due to the action of the MtrC-MtrD-MtrE pump, which 
expels structurally diverse hydrophobic antimicrobial agents by an energy-dependent 
process.
56
 Recently, overexpression of MtrC-MtrD-MtrE pumps due to an mtrR 
mutation was shown to confer chromosomally mediated penicillin resistance in N. 
gonorrhoeae.
57 N. gonorrhoeae is responsible for the sexually transmitted infection 
gonorrhoea but can also cause conjunctivitis, pharyngitis, prostatitis and orchitis.
58
  
1.5 Strategies for Inhibiting Microbial Efflux Pumps 
Strategies that have been investigated to date for overcoming efflux-mediated 
bacterial resistance are of three types: (1) biological inhibition of efflux pumps using 
neutralizing antibodies or antisense approaches. For example, use of small interfering 
RNAs (siRNAs) have been used for inhibition of the AcrAB efflux pump in E. coli;
59
 
(2) evasion of efflux systems, where the structure of antimicrobials is modified such 
that they are no longer substrates for pumps. For instance, newer antibiotics like 
sparfloxacin and trovafloxacin were purposely engineered to be less susceptible to 
efflux than their parent compounds, nalidixic acid and norfloxacin;
60
 (3) 
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pharmacological inhibition of pumps, where small molecule inhibitors are used to 
selectively block pumps and restore potency of co-administered antibacterials.  
1.6 Small Molecule Efflux Pump Inhibitors  
Many of the small molecule inhibitors identified to date have been natural 
products, and it has been proposed that these compounds may have evolved to protect 
plants from infections by acting synergistically with other plant antibacterial 
compounds.
61
 A potential clinical strategy that mimics this approach from nature is to 
use small molecule MDR pump inhibitors in combination with antibacterial agents. 
Whilst an attractive strategy, only a small numbers of lead chemotypes have been 
advanced to preclinical and clinical studies to date. Lack of broad activity and selective 
action against bacterial pumps over mammalian pumps appear to be key challenges for 
adopting the approach in the clinic. 
Phenotypic assays with efflux systems have been used extensively in microbial 
efflux pump inhibitor (EPI) discovery. These functional assays typically employ a 
fluorescent dye pump substrate to report on efflux activity and have been successfully 
established in low- and mid-throughput formats.
62
 Fluorescence microscopy and high-
resolution multi-parametric flow cytometry are gradually superseding fluorimeters and 
plate readers in these assays because of their capacity for increased throughput and 
sensitivity.
62b
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1.6.1 EPIs against Gram-Negative Bacteria 
The number of EPI chemotypes targeting Gram-negatives identified to date is 
much smaller than the number against Gram-positives. Phenyl-arginine-beta-
naphthylamide (PaβN), also called MC-207 110 1 (Figure 1.6), was the first EPI 
identified against Gram-negatives.
63
 It was discovered by testing an array of synthetic 
and natural compounds against P. aeruginosa strains over-expressing the three intrinsic 
efflux systems (i.e. MexAB-OprM, MexCD-OprJ, MexEF-OprN) in the presence of 
levofloxacin.
64
 Results of various microbiological assays suggested that MC-207 110 
promoted a competition-like process during the recognition/transport of antibiotic 
molecules.
65
 A derivative of PaβN, MC-04 124 2, showed improved EPI activity, 
pharmacokinetic properties and increased stability.
66
 Both inhibitors were studied in 
preclinical work by Mpex Pharmaceuticals.
67
 Recent investigations suggested the 
compounds show toxicity due to effects on membrane function.
68
 PaβN/MC-207 110 
remains as a valuable probe for exploring bacterial efflux systems.  
 
Figure 1.6 Examples of EPIs against Gram-negative bacteria.  
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EPI activity against RND pumps can be assessed using a microfluidic channel 
device and fluorescence microscope.
69
 In these assays, fluorescein-di-β-D-
galactopyranoside (FDG) is hydrolyzed by β-galactosidase in the cytoplasm of E. coli to 
produce the fluorescent dye fluorescein. Both FDG and fluorescein are effluxed in E. 
coli, allowing the effects of EPIs to be measured. This assay was used to validate the 
activity of MexB-specific tert-butyl thiazolyl aminocarboxyl pyridopyrimidine (ABI-
PP) 3 and PaβN 1.
70
 Pyridopyrimidine-based EPIs carrying acrylic acid (e.g. 4) were 
shown to be more soluble than 3 and showed acceptable safety profiles but they 
displayed only moderate activity in vivo.
71
 Recently, co-crystallization of the MexB 
pump with PaβN and ABI-PP revealed tighter binding for the latter, leading the authors 
to propose a set of physicochemical parameters for development of EPIs.
72
 
1.6.2 Natural Product EPIs 
Numerous phytochemicals have been shown to act as EPIs in combination with 
antimicrobials against Gram-positive bacteria.
73
 A selection of phenolic natural product 
EPIs is shown in Figure 1.7.  
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Figure 1.7 Examples of phenolic EPIs discovered from natural sources. Reserpine 8 
and pterostilbene 10 were important compounds in this PhD project. 
  
Epigallocatechin gallate (EGCG) 5, a major polyphenol extracted from green 
tea,
74
 shows resistance-modifying activities when used with norfloxacin and tetracycline 
at low concentrations.
75
 At less than half its MIC (100 μg/mL) EGCG was able to 
reverse tetracycline resistance in staphylococcal isolates.
75
 EGCG was also identified as 
a resistance-modifying agent in Campylobacter spp.
76
 
 The flavonolignan 5’-methoxyhydnocarpin (5’-MHC 6) and its 5-desmethoxy 
analogue 7 (Figure 1.7) were isolated from Hydnocarpus wightiana.
77
 Both compounds 
were shown to be MDR inhibitors without showing antibacterial activity on their own.
78
 
The compounds were evaluated against 20 clinical isolates of MRSA in combination 
with ampicillin or oxacillin, where they reduced MICs more than 4-fold.
79
 Subinhibitory 
concentrations of the weak antibacterial alkaloid berberine with 1.2 µg/mL of 6 
completely inhibited growth of S. aureus growth.
78a
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1.6.2.1 Reserpine  
Reserpine 8 (Figure 1.7) is an anti-hypertensive alkaloid that was first extracted 
from the roots of Rauwolfia vomitoria in 1954.
80
 The compound was originally shown 
to be a potent inhibitor of mammalian P-glycoprotein
81
 but later investigations revealed 
its MDR inhibitory properties in the Gram-positive bacterium Bacillus subtilis,
82
 where 
it was shown to inhibit tetracycline efflux by the Bmr pump. The study revealed that 
reserpine interacts directly with the Bmr protein at a hydrophobic site formed around 
Phe143, Val286 and Phe306.
82
 
Reserpine reversal of NorA-mediated efflux in S. aureus was shown to enhance 
the potency of fluoroquinolones,
83
 where it lowered MICs by up to 4-fold when present 
at 20 µg/mL.
84
 In a study by Schmitz et al. MICs and LC50 values were measured 
against 102 clonally non-related S. aureus strains from eight different countries for 
ciprofloxacin, sparfloxacin and moxifloxacin in the presence and absence of reserpine.
84
 
The potentiation effect of reserpine on the hydrophilic variants (e.g. ciprofloxacin) was 
greater than for the hydrophobic compounds (e.g. moxifloxacin and sparfloxacin).  
Fluoroquinolone resistance mediated by the PmrA pump in S. pneumoniae (43% 
amino acid similarity to NorA) was shown to decrease in the presence of reserpine.
85
 In 
an investigation by Markham et al, a single-step mutant of S. pneumoniae resistant to 3-
4 fold MICs of ciprofloxacin was studied in vitro in the presence and absence of 
reserpine.
85b
 A pronounced inhibition of selection of S. pneumoniae ATCC 49619 
mutants resistant to ciprofloxacin was noted when reserpine (20 μg/mL) was present. In 
the absence of reserpine, 135 colonies of S. pneumoniae showed 3 x baseline MIC and 
19 colonies showed 4 x baseline MIC. In the presence of reserpine only 3 colonies were 
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resistant to 3 x MIC (45-fold reduction) and no colonies were resistant to 4 x MIC 
(complete suppression). In these experiments reserpine affected neither the colony size 
nor the colony-forming ability of S. pneumoniae when plated in the absence of 
ciprofloxacin.
85b
 
A significant problem with many natural product EPIs is their toxicity, which 
hinders their potential for clinical applications.
67,86
 Reserpine is neurotoxic at the 
concentrations required to inhibit MDR pumps (20 µg/mL) and is thus not suitable as an 
antibacterial adjuvant in humans.
67
 It remains, however, a widely used tool for 
evaluating bacterial efflux mechanisms.
87
  
1.6.2.2 Pterostilbene 10 
Organic extracts of Dalea versicolor in the presence of berberine showed strong 
potentiation effects against S. aureus.
88
 Two pterostilbene derivatives 9 and 10 (Figure 
1.7) were contained in the extract fractions and co-extracted with berberine. It was 
hypothesized that the MDR inhibitory properties of these molecules was being exploited 
by the plant to potentiate the antibacterial effects of berberine; that is, the compound 
combination was acting as the plant’s antibacterial defence mechanism.
88-89
 Both 9 and 
10 showed only weak activity alone (MICs 250 and 500 µg/mL, respectively)
90
 but 10 
caused complete growth inhibition at low concentrations (~ 3.3 µg/mL) in combination 
with berberine. Compound 10 was also tested alone and in combination with berberine 
against the opportunistic pathogen Bacillus cereus and was shown to increase the 
activity of berberine 16-fold.
90
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1.6.3 Synthetic EPIs 
An investigation aimed at exploring the effects of NorA inhibition in S. aureus 
studied the activities of fluoroquinolones (i.e. levofloxacin, ciprofloxacin and 
norfloxacin) in the presence and absence of various synthetic NorA inhibitors.
91
 The 
H
+
/K
+
 ATPase pump inhibitor omeprazole 11 (Figure 1.8) was found to have moderate 
activity (less than reserpine) but significantly greater activity than verapamil. The 
compound decreased the frequency of ciprofloxacin resistance almost 100-fold.
92
 
When the mammalian MDR inhibitor timcodar (VX-853) 12 was evaluated for 
EPI activity in a variety of bacteria,
93
 it was found to potentiate the activity of ethidium 
bromide against S. aureus
94
 and to decrease the MIC of fluoroquinolones. Against a 
NorA-overproducing strain (SA-1199B), VX-853 12 reduced the MIC of norfloxacin 
32-fold and 8-fold for ciprofloxacin.
93a
  
A new generation of MDR modulators that included tariquidar 13 and elacridar 
14 (Figure 1.8) was identified during screening for inhibitors of mammalian ABC-type 
transporters and breast cancer resistance proteins (BCRP, ABCG2).
95
 Elacridar 14 had 
previously shown equipotent activity with reserpine in ciprofloxacin/norfloxacin 
combinations against S. aureus strains in vitro.
96
 The potency of tariquidar 13 was also 
investigated in combination with ciprofloxacin and showed potent inhibitory effects 
against some efflux pumps.
97
 The compound produced 10-fold reductions in the 
ciprofloxacin MIC against S. aureus while no effect was observed with P. aeruginosa. 
 An investigation by Influx Inc. aimed at discovering inhibitors of the NorA 
pump in S. aureus saw the screening of over 9,600 structurally distinct synthetic 
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compounds in the late 1990s.
98
 The compounds were screened at 20 µg/mL and those 
that reversed NorA-mediated efflux of ethidium bromide whilst being nontoxic to 
bacteria on their own were considered hits. Initial efforts identified 399 compounds 
showing activity above threshold. Twenty-eight of the hits were at least as potent as 
reserpine, with eleven showing higher potency (effective at 5 µg/mL or less). Thirty of 
the compounds contained an indole moiety, while a significant number contained the 
toxic trichloromethylaminal group. However, seven compounds were relatively non-
toxic nitroindoles. Out of 32 bisaryl ureas in the library eleven compounds were found 
to be active. Two of the most active EPIs from the investigation were the 5-nitroindole 
derivative INF55 15 and bis-aryl urea INF271 16 (Figure 1.8). Both compounds have 
since been studied further for their EPI effects in Gram-positive bacteria.
99
  
 
 
Figure 1.8 Representative synthetic EPIs identified to date. INF55 15 and INF271 16 
were important compounds in this PhD project.  
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1.6.3.1 5-Nitro-2-phenylindole (INF55) 15 
Markham et al described several indole-based inhibitors of multidrug transport 
proteins that showed potential for use in combination with existing antibacterial or 
antifungal agents.
100
 The compounds were identified as inhibitors in bacteria expressing 
the NorA pump and fungi expressing another multidrug transport protein. A theoretical 
structure-activity study using COMFA (3D-QSAR) analysis suggested that replacement 
of the indole 5-nitro group of INF55 15 with other electron-withdrawing substituents 
should be favourable for EPI inhibitory activity.
99b
 A separate study identified a series 
of 2-arylbenzo[b]thiophenes related to INF55 as NorA inhibitors, suggesting that the 
indole NH group is not essential for activity.
101
 Most of the compounds exhibited no 
antibiotic activity alone and several were shown to be inhibitors of the NorA pump in S. 
aureus. 
An SAR study by Samosorn et al showed that various substituents around the 2-
aryl ring of INF55 can affect NorA inhibitory potency.
102
 For example, the INF55 
analogue 5’-benzyloxy-2’-hydroxymethyl-5-nitroindole 17 (Figure 1.9) potentiated the 
activity of berberine (a known substrate of NorA) more than 15-fold against the NorA 
overexpressing S. aureus strain K2361 at a concentration of 0.8 µg/mL.
102
 In later work 
the same group reported more SAR explorations around the 2-aryl ring of INF55 as well 
as the effects of substituting the indole 5-nitro group.
103
 The study identified three new 
potent indole-based NorA EPIs, 18, 19, and 20 (Figure 1.9), along with a new indole 
derivative 21 that showed direct antibacterial activity against S. aureus.  
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Figure 1.9 2-Arylindole-based inhibitors of the NorA pump in S. aureus related to 
INF55 15. 
 
1.6.2.2 INF271  
The bis-aryl urea INF271 16 (Figure 1.8) inhibits the NorA pump in S. aureus at 
concentrations less than 1.5 µg/mL. It was shown to potentiate the action of 
ciprofloxacin,
98
 where it decreased the IC50 2.5-fold at an 8-fold lower concentration 
than reserpine. A decrease in cell viability recorded during these experiments using 
OD600 measurements showed that viability in the presence of 0.13 µg/mL 
ciprofloxacin alone was 3 x 10
7
 CFU/mL. In the presence of reserpine (20 µg/mL) the 
number was reduced to 5 x 10
4
 CFU/mL
 
and to 1.2 x 10
5
 CFU/mL with INF 271 (2.5 
µg/mL) present.  
Isoflavones 22-28 (Figure 1.10) isolated from Lupinus argenteus potentiate the 
activity of berberine and norfloxacin.
104
 In one report INF271 16 was studied alongside 
isoflavones to compare their EPI activities and berberine potentiation effects.
105
 
Accumulation of berberine in S. aureus cells alone and in the presence of the 
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isoflavones and INF271 16 showed that INF271 was more potent. The results also 
suggested that there may be MDR pumps in S. aureus other than NorA that are inhibited 
by INF271.
105
 
 
 
Figure 1.10 Examples of isoflavone-based EPIs.
105
 
 
Studies have shown that INF271 and some plant-based EPIs strongly increase 
the penetration rate and accumulation of berberine in S. aureus cells.
98,106
 This synergy 
has also been observed in some Gram-negative bacteria.
107
 A study by Lewis et al 
examined the effects of INF271 16 and MC-207 110 1 on berberine accumulation in S. 
enterica, S. typhimurium, Pseudomonas syringae, Xanthomonas campestris, E. 
carotovora and Sinorhizobium meliloti.
107
 Strongly elevated rates of accumulation of 
berberine were observed with MC-207 110, INF271 and both compounds together, and 
similar results were observed with other weak antibacterial compounds. For instance, 
coumestrol alone showed very little antibacterial activity against Agrobacterium 
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tumefaciens (MIC 500 µg/mL) but in the presence of INF271 and MC-207 110 its MIC 
decreased to 125 µg/mL. Greater increases in coumestrol activity were observed with 
other bacteria. For example, p. aeruginosa strains (MIC 500 µg/mL) expressing the 
MexAB pump showed 300-fold increases in sensitivity when INF271 and MC-207 110 
were present.
107
 
German et al have described hybrid compounds containing fluoroquinolone 
antibacterials covalently linked to various EPIs, including INF271-based hybrids 29 and 
30, as well as dipeptide-based hybrids 31 and 32 (Figure 1.11).
108
 One of the conjugates 
significantly inhibited MexAB-mediated ethidium bromide efflux in P. aeruginosa and 
dipeptide-based conjugates 31 and 32 showed no inhibition of ethidium efflux in either 
NorA or MepA expressing S. aureus and P. aeruginosa strains. In contrast, the 
ofloxacin-based conjugate 29 was a potent inhibitor of NorA and MepA-mediated 
efflux in S. aureus. One conclusion from this study was that inhibition of NorA by 
conjugates 29 and 30 was not simply due to the attached INF271, but was probably a 
consequence of the entire structure of the molecules.  
 
Figure 1.11 Fluoroquinolone-EPI hybrids reported by German et al.
108
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1.7 Photodynamic Therapy 
Photodynamic therapy (PDT) uses the combined action of visible light of 
specific wavelengths and a dye or photosensitizer (PS) to generate cytotoxic reactive 
oxygen species (ROS), including singlet oxygen (
1
O2) and free radicals, to kill cells. In 
this approach, the administered photosensitizing compound is allowed to accumulate in 
and around target cells and visible light is applied
109
 (Figure 1.12). The majority of PDT 
investigations to date have focused on its use in treating of solid tumours. 
The mechanisms involved in obtaining selectivity against tumour cells during 
PDT are not well understood. Some characteristics of tumour cells that may play a role 
include high expression of low-density protein (LDL) receptors, involvement of 
macrophages, greater cellular proliferative rates and leaky vasculature.
110
 Low pH and a 
high level of newly synthesized collagen in tumours have also been implicated.
111
 
 
 
Figure 1.12 In PDT for cancer a photosensitizing compound is applied locally to 
lesions or injected intravenously. Healthy cells shed the drug allowing the agent to 
concentrate in and around cancer cells. The tumour is illuminated with an appropriate 
wavelength of visible light and the resulting ROS destroy tumour cells. 
 
Lipson and Schwartz originally developed PDT at the Mayo Clinic (USA) in the 
1960’s to treat tumours during surgery.
112
 When using a fluorescent tumour localizing 
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hematoporphyrin derivative they found that injecting crude preparations of the 
compound led to fluorescence of neoplasms upon illumination. Schwartz later treated 
the hematoporphyrin preparations with acetic acid and sulphuric acid to create a 
porphyrin mixture with improved tumour-localizing properties.
113
 The mixture, termed 
hematoporphyrin derivative (HPD), was less active,
114
 however, as it contained 
porphyrin monomers, dimers and oligomers. Partial purification to remove the less 
active porphyrins led to Photofrin
®
,
115
 which remains the most widely used 1
st
-
generation PS for clinical PDT.  
One shortcoming of Photofrin
® 
is that it causes long-lasting skin 
phototoxicity.
116
 Another issue is that it absorbs light only up to about 640 nm, which 
cannot penetrate well through tissues. Second generation PSs were thus created to 
absorb light of longer wavelengths (650-850 nm). Examples include porphyrin 
derivatives and other compounds made after the late 1980’s.
114
 Third generation agents 
for anti-tumour PDT are showing increasing complexity, where PSs have been 
conjugated to tumour targeting monoclonal antibodies and other biologicals.
117
 
The therapeutic uses of PDT continue to expand into various non-oncological 
indications, which include macular degeneration, autoimmune disorders and dermal 
pathologies.
118
 A more recent area of research is antimicrobial photodynamic therapy 
(aPDT), where PDT is used to treat localized bacterial, fungal, viral and yeast 
infections.
119
 A key driver of efforts to create effective aPDT treatments as alternative to 
antibiotics has been the global emergence of antibiotic resistance.
120
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1.8 Antimicrobial Photodynamic Therapy (aPDT) 
The concept of aPDT was first described in 1900 by Oskar Raab in Munich.
121
 
Very little further work was done in the early 20
th
 century, however, due to the 
discovery of antibiotics, starting with penicillin in 1929.
122
 The Golden Age of 
antibiotics followed when over half of today’s commonly used drugs were discovered. 
Concerns about antibiotic resistance have catalysed research into novel approaches for 
managing bacterial infections leading to a resurgence in interest in PDT.
123
  
A major advantage of aPDT is that antibiotic-resistant bacteria are as susceptible 
to aPDT as their non-resistant counterparts.
124
 The non-specific nature of cell killing 
through ROS-mediated photooxidative damage means there is little possibility for 
resistant strains to survive during aPDT.
125
 
Other advantages of aPDT that have been identified include: (1) efficacy 
independent of antibiotic resistance patterns, (2) extensive pathogen reduction with 
limited damage to host tissues, (3) removal of photoresistant strains after multiple 
treatments, (4) absence of microorganism recovery following treatment, (5) direct 
application of PSs to infected areas, (6) low cost light sources and (7) more rapid 
inactivation of bacterial cells compared to traditional antimicrobials.
124c,126
  
While aPDT shows promise as an alternative to antibiotics for treating localized 
infections, key issues still need to be addressed. These are: (1) ensuring that the 
treatment destroys sufficient numbers of disease-causing pathogens, (2) selectivity of 
PSs for bacterial cells over mammalian cells and (3) preventing recurrence of infections 
due to regrowth of small numbers of cells that survive treatment.
127
  
 
30 
 
In aPDT for localized infections, the PSs can be directly applied to the infected 
area via topical application, instillation, interstitial injection or through use of 
aerosols.
127
 For a PS to be effective it should selectively accumulate around (or even 
better inside) target cells. Selective localization is facilitated by the net charge on PSs 
and the surface charges present on targeted cells. Gram-positive bacteria have a thick 
cell wall composed largely of peptidoglycan (~ 90%, c.f. 20% for Gram-negatives), 
along with teichoic acids, polysaccharides and peptidoglycolipids. The net negative 
charge of bacterial cell walls thus enables favourable electrostatic interactions with 
cationic PSs.
118
 Indeed cationic PSs have been shown to be more effective at lower 
concentrations than neutral or anionic compounds in aPDT.
118,128
 
Ideally, aPDT produces selective killing of pathogens whilst leaving host cells 
unharmed. Techniques for achieving selective killing include short incubation times, 
low PS concentrations and soft irradiation.
118
 The external structures of bacteria targeted 
by ROS lead to cell death, so the PSs don’t actually need to penetrate into bacteria. 
However, if the compounds could be concentrated inside bacterial cells it is predicted 
that the aPDT would become more effective due to increased potency and selectivity.
129
  
1.9 Mechanisms of aPDT 
The basic premise of aPDT is to use photoactive dyes that upon irradiation with 
visible light are able to generate toxic ROS to kill bacterial cells. When the dye absorbs 
light it is excited from the ground state to an excited singlet state that subsequently loses 
energy via three pathways: (1) non-radiative processes, where the excited state species 
release excess energy as heat through vibrational relaxation, internal conversion and 
intersystem crossing; (2) radiative processes, where excess energy is lost through 
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fluorescence and/or phosphorescence and (3) other processes, where the excited 
molecules undergo photochemical or photophysical reactions (i.e. photosensitization). 
When molecular oxygen is involved in the photosensitisation event such processes are 
called photodynamic action. Two different mechanisms of photodynamic action are 
possible and are termed Type I and Type II processes (Figure 1.13). 
In Type I processes, the PS in its singlet or triplet excited state reacts with a 
substrate through electron transfer or via a hydrogen abstraction to yield unstable and 
reactive radicals (i.e. hydroxyl radicals and superoxide), which can further react with 
molecular O2 to form peroxyl radicals. In Type II processes, the PS in its triplet excited 
state transfers energy to ground-state molecular oxygen and produces highly reactive 
singlet oxygen (
1
O2).  
 
 
Figure 1.13 Type I and Type II processes in aPDT. PS = photosensitizer. 
 
In bacterial cells both mechanisms lead to photooxidation of amino acids, 
nucleobases and lipids, leading to damaged proteins, DNA and membranes. Reactions 
based on Type I mechanisms have been shown to effect membrane permeability through 
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lipid peroxidation, causing loss of fluidity and increased ion permeability.
130
 It has been 
suggested that Type I processes could potentially be employed in aPDT against 
anaerobic gut pathogens (e.g. Clostridium difficile) where O2 is absent.
131
 In Type II 
reactions, the resulting 
1
O2 targets cell wall and membrane components (i.e. lipids, 
sterols and peptides). The individual reaction products from the two mechanisms can 
vary considerably. For instance, during Type I reactions, cholesterol is converted to 
cholesterol-7α and 7β-hydroperoxide but is converted to the 5α-isomer by 
1
O2 in Type 
II reactions.
132
  
Nucleic acids are targeted by both Type I and Type II processes. Hydroxyl 
radicals formed in Type I mechanisms can attack the sugar moiety of nucleic acids, 
while 
1
O2 from Type II reactions targets guanine bases. These genotoxic events can 
cause base substitutions, strand cleavage, mutations and inhibition of replication.
130,133
  
The types of mechanisms at play during aPDT depend on the PS used. Most 
photosensitizers are highly conjugated aromatic molecules capable of forming long-
lived triplet states. The amount of energy required for production of ROS depends on 
the individual structures.
124a
  
1.10 Photosensitizers in aPDT 
Photosensitizers are defined as molecules that when activated by radiation or 
light cause nearby molecules to undergo chemical reactions.
119a
 PSs for use in aPDT 
ideally display the following properties:
118,134
 
(1) Efficacy against several classes of microorganisms at relatively low 
concentrations and low light fluence. 
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(2) Low toxicity in the absence of light (i.e. low dark toxicity). 
(3) Selectivity for microbial cells over human cells. 
(4) Hydrophilic character and net positive charges to allow better interactions 
with microbial cell walls. 
(5) High extinction coefficients that allow efficient absorption of blue or red 
light.  
(6) High superoxide and/or singlet oxygen quantum yields. 
Over 400 compounds are known to exhibit photosensitizing properties, including 
dyes, drugs, cosmetics and many natural substances. The majority of PSs can be divided 
into three structural classes; the tricyclic dyes, tetrapyrroles and furocoumarins.
119a
 The 
class relevant to this PhD project was the tricyclic phenothiazinium dyes. 
1.10.1 Phenothiazinium Dyes as Photosensitizers 
Phenothiazinium dyes have been reported as effective photosensitisers that 
inactivate a wide range of microorganisms upon illumination with red light. An 
important property of aPDT with these dyes is that bacteria that show resistance to 
frontline antibiotics like methicillin and vancomycin are easily inactivated.
135
 
Importantly, members of the class are also known to be relatively nontoxic to humans
136
 
and are currently used for aPDT disinfection of blood products.
137
 
Phenothiazinium dyes are hydrophobic cationic salts that show limited 
permeability across cell membranes. They exhibit strong reactivity towards proteins, 
lipoproteins and nucleic acids upon illumination. Methylene blue (MB) 33 (Figure 1.14) 
is the parent member of the class. Various substituents around the phenothiazinium core 
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can have a pronounced effect on photochemical properties, e.g. maximum absorption 
wavelength and lipophilicity.
138
 Variations in these properties can affect the type and 
cellular location of photodamage. Cellular uptake is also affected by a combination of 
charge type/distribution and lipophilicity, which vary with substituents patterns.
139
 
 
 
Figure 1.14 Methylene blue (MB) and related phenothiazinium photosensitizers. 
 
Phenothiazinium PSs related to MB include toluidine blue O (TBO) 34, thionin 
35, azure A 36, azure B 37, azure C 38, new methylene blue (NMB) 39, dimethyl 
methylene blue (DMMB) 40 and methylene orange (MO) 41 (Figure 1.14). The 
compounds are all planar, tricyclic, aromatic molecules with an intrinsic positive charge 
and they all show an intense absorption band between 600 - 680 nm. MB and TBO are 
used clinically in aPDT.
137a
  
1.10.1.1 aPDT with Methylene Blue (MB) 
aPDT with MB is used to sterilize blood products, where it serves to inactivate 
HIV, hepatitis B and C and other viruses.
137e
 MB has also been used to treat 
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methemoglobinemia in humans and has been investigated clinically as a PDT 
photosensitizer in the treatment of bladder cancers, adenocarcinomas, inoperable 
esophageal tumours and psoriasis.
140
 TBO is predominantly used in aPDT as an oral 
disinfectant for sterilizing dental cavities and root canals and for treating periodontitis
141
  
aPDT with intravenously administrated MB has been examined against various 
Gram-positive and Gram-negative bacteria.
142
 Wainwright et al have demonstrated the 
photobactericidal activity of MB during aPDT against VRE and MRSA.
143
 The 
hydrophilicity of MB along with its low molecular weight and positive charge are 
thought to facilitate its passage across porin channels in the outer membrane of Gram-
negative bacteria. Studies have demonstrated the promising photodynamic action of MB 
on E. coli.
144
  
Inactivation of bacteria by MB during aPDT can occur via both Type I and/or 
Type II processes, depending on the cell type being studied and the experimental 
conditions. For example, Type I processes occur when the photodynamic action of MB 
is coupled to reduction of the photoexcited dye by nicotinamide adenine dinucleotide 
(NADH).
145
 
The photochemical properties of MB (and its analogues) make it highly suitable 
for aPDT. It exhibits 
1
O2 quantum yield upwards of 0.5, it has a low reduction potential 
and shows an intense absorption maximum around 664 nm in water.
146
  
The absorption spectrum of MB is concentration-dependent due to dimerisation, 
with the equilibrium constant for dimerization in water being 3.8×10
3
 M
−1
.
146c
 MB 
monomers and dimers show different absorbtion spectra, with monomers showing a 
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maximum at 664 nm that shifts to 590 nm for dimers. Monomers and dimers can be 
involved in different kinds of photochemical reactions and can affect the mechanisms 
and efficiency of cell killing.
146c,147
 Use of MB to treat a patient with an arm tumour 
revealed that in 20 µM aqueous solutions only MB monomers were present, while after 
local injections of a 2% MB solution the absorption maximum shifted to 580 nm, 
indicating the presence of dimers.
146c
  
Singlet oxygen is produced in Type II processes from MB where its triplet state 
energy is transferred to oxygen. Singlet oxygen is also formed from MB in Type I 
processes when reducing agents donate an electron to triplet MB to form semi-reduced 
radicals.
146c
 Different concentrations of MB can influence which mechanisms 
predominate. At high MB concentrations, where the compound exists mostly as dimers, 
Type I reactions are limited.
146c
 In homogeneous monomer solutions MB produces a 
high quantum yield of singlet oxygen.
148
 The pH of solutions can also influence whether 
MB undergoes Type I or Type II processes. MB has been shown to be less active at 
lower pHs due to lower 
1
O2 quantum yields.
149
 
MB can distribute into subcellular compartments like lysosomes and 
mitochondria. As a cation, MB is attracted to the negative electrochemical environment 
of the mitochondrial matrix.
150
 Once localized in mitochondria, the optical density of 
MB at the excitation wavelength changes, as does its 
1
O2 quantum yield.
151
 It is thought 
that decreases in 
1
O2 as MB accumulates in and around mitochondria is due to 
formation of MB dimers. MB is sometimes referred to as a mitochondrial sensitizer as it 
is the only PS that can selectively oxidize mitochondrial NAD(P)H.
152
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Upon irradiation with visible light MB has been shown to liberate lysosomal 
enzymes from human fibroblast cells. One interesting study showed that MB localized 
in lysosomes can actually migrate to the nucleus, but only after light activation. The cell 
nucleus is also a known site of localization of MB
153
 and it has been suggested that 
when the compound enters cells it increases the effectiveness of aPDT.
154
 
1.12 Microbial Resistance in aPDT 
In section 1.6 it was discussed how plants appear to use synergistic 
combinations of weak antibacterials and EPIs as a defence against bacterial 
pathogens.
155
 A study by Lewis et al showed that the alkaloid berberine 42 (Figure 
1.15), widely found in Barberry (Berberis) plants, co-extracts with 5-methoxy-
hydnocarpin (5’-MHC). Berberine is a hydrophobic cation that exhibits weak 
antibacterial effects by increasing membrane permeability and via interactions with 
DNA.
156
 Due to its positive charge it could conceivably accumulate in bacterial cells 
due to the electrochemical gradient across the membrane. However, hydrophobic 
cations are the preferred substrates of many classes of MDR pumps,
157
 which is 
probably why its antibacterial activity is weak. Lewis & Stermitz showed that 5’-MHC, 
which has no antimicrobial activity on its own, strongly potentiates the antibacterial 
activity of berberine against S. aureus through inhibition of efflux,
158
 indicating that it is 
the berberine/5’-MHC combination that provides plants with antibacterial defence 
(Figure 1.15). 
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Figure 1.15 Structures of berberine (antibacterial) and 5’-MHC (EPI).  
 
Like berberine, MB 33 is a planar, aromatic hydrophobic cation, which suggests 
it too might be a preferred substrate for microbial efflux systems. A comprehensive 
study by Tegos et al revealed that the three cationic phenothiazinium photosensitizers 
MB 33, TBO 34, and DMMB 40 are indeed all susceptible to efflux, whereas the  
neutral PS Rose Bengal is not.
154
 The study demonstrated that MB 33 shows different 
uptake levels in three S. aureus strains varying in expression of the NorA MDR pump: 
i.e. NorA knockout, wild-type and NorA-overexpressing. The NorA knockout strain 
took up 1.22 ± 0.22 × 10
9
 molecules/cell of MB, compared to 0.06 ± 0.01 × 10
9
 for the 
wild type and 0.021 ± 0.003 × 10
9
 for the NorA-overexpressing strain.
154
 Other non-
phenothiazinium PSs showed equivalent uptake across all three NorA phenotypes, 
demonstrating that these non-phenothiaziniums are not NorA substrates. It was 
suggested that efflux of phenothiazinium PSs from cells by MDRs reduces their 
phototoxicity upon illumination.
154
  
1.13 Combination aPDT with MB and EPIs 
The discovery that bacterial MDRs contribute to aPDT resistance through efflux 
of MB, combined with studies showing that plants use the hydrophobic cation berberine 
in combination with 5’-MHC to provide antibacterial defence, suggested that 
combinations of MB with an MDR inhibitor might increase aPDT activity.  
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Tegos et al demonstrated that the effectiveness of photodynamic inactivation  
mediated by MB in S. aureus was inversely proportional to the level of NorA 
expression using three S. aureus strains; wild-type 8325-4, NorA knockout K1758 and 
NorA overexpresser K2378.
154
 The same strains were then used to test whether the 
NorA inhibitors INF271 16, reserpine 8 and INF55 15 potentiate the aPDT activity of 
MB. 
Wild-type cells incubated with MB in the presence of INF271 and illuminated at 
635 nm showed light-dependent cell killing increases 2-5 log units above levels 
observed when INF271 was absent. No significant killing in the presence of INF271 
alone was observed in the light or dark. Reserpine showed slightly better activity while 
similar results were obtained with INF55.
154
  
Tegos et al showed that Gram-positive bacteria tend to show better potentiation 
effects in aPDT than Gram-negatives when using combinations of phenothiazinium 
salts and EPIs.
99a
 An interesting observation was that pre-incubation of strains with EPIs 
produced a stronger aPDT effect than when EPIs and PSs are added together.
99a
 It was 
suggested that this may be because of competition between EPIs and PSs for pump 
binding sites. 
The simplest application of a combination therapy aPDT approach would be in 
localized dermal infections, where both the PS and light could easily be delivered to the 
infection site. Although some work has been done towards discovering and optimizing 
EPI structures for use in combination with PSs, no clinical studies have been reported. 
This may be because some EPIs show unacceptable toxicity when tested in rodent 
infection models, possibly due to the multitude of normal physiological roles of related 
 
40 
 
pumps in eukaryotic cells (e.g. p-glycoprotein).
159
 Clinical development of drug 
combinations also presents higher regulatory barriers due to the need to prove efficacy 
and safety in not one, but two active agents. 
1.14 MB-EPI Hybrids for use in aPDT 
One strategy being explored to address the clinical challenges associated with 
co-administering antibacterials with EPIs is to covalently link the EPI and antibacterial 
components together into a single (non-cleavable) hybrid molecule.
160
 Such hybrids 
carry the potential advantage of delivering equimolar quantities of the two agents to 
infection sites whilst avoiding some of the complications arising through multi-agent 
co-dosing.
161
 
Bremner et al described the first such hybrid, termed SS14-O 43 in 2006 (Figure 
1.16), consisting of berberine substituted at its 13-position via a methylene linkage to 
INF55 15.
162
 In designing the hybrid it was reasoned that the berberine portion could 
show enhanced antibacterial effects due to higher intracellular concentrations arising 
through inhibition of NorA-mediated efflux by the appended INF55 15 component. The 
hybrid was shown to accumulate in wild-type, norA-knockout and NorA overexpressing 
strains of S. aureus and showed higher antibacterial potency than berberine alone or in 
combination with INF55.  
A follow-up study investigated the effects of varying the relative orientations of 
the berberine and INF55 components by comparing the activities of isomers SS14-O 43, 
SS14-M 44 and SS14-P 45 (Figure 1.16).
99e
 The isomers showed surprisingly similar 
MICs given their structural differences, which remained almost unchanged across wild-
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type, norA-knockout, and NorA overexpressing S. aureus cells. A important conclusion 
from these studies was that berberine-INF55 hybrids are not substrates for NorA, 
although ethidium bromide uptake experiments suggested that they might also block the 
NorA pump.
99e
 In another study, an SS14 analogue bearing an extended methylene ether 
linkage (46, Figure 1.16) was shown to have similar antibacterial properties to the other 
hybrids against the S. aureus panel.
99d
  
 
 
Figure 1.16 Berberine-INF55 hybrid antibacterials 43-46.
99d,e,160a
 
 
As mentioned previously, berberine 42 and methylene blue 33 are both 
amphipatic cations and thus share similar physicochemical properties. Evidence has 
revealed that both are also substrates for NorA efflux pumps in S. aureus, hinting that 
an MB-EPI hybrid strategy analogues to the berberine-INF55 approach might be 
successfully adapted in aPDT.
99a
 Hybrids formed by linking MB to EPIs may decrease 
efflux of the PS, leading to increased intracellular concentrations and therefore 
increased microbial cell killing upon illumination. This idea is summarized in Figure 
1.17. 
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Figure 1.17 Adapting the berberine-INF55 hybrid antibacterial concept to MB-EPI 
hybrids for use in aPDT. 
 
1.15 Thesis Aims 
This PhD project aimed to synthesise a 16 compound library of MB-EPI hybrids 
and explore their potential as agents for use in aPDT. Methylene blue 33 was chosen as 
the PS for inclusion in the hybrids, along with the NorA pump inhibitors reserpine 8 
(Section 1.6.2.1), pterostilbene 10 (Section 1.6.2.2), INF55 15 (Section 1.6.3.1) and 
INF271 16 (Section 1.6.3.2). Four different linkages between the MB and EPI portions 
were also incorporated into the target structures, which are shown in Figure 1.18. 
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Figure 1.18 Structures of target MB-EPI hybrids. EPI portions are coloured red, linker 
regions black and the MB moiety blue. 
 
We hypothesized that MB-EPI conjugates 47-62 might show enhanced aPDT 
activity (relative to MB) against S. aureus, which carries the NorA pump. In designing 
the hybrids, it was considered important that only minimal modifications be made to the 
phenothiazinium core to retain the photochemical properties of MB. In this way hybrids 
would be more likely to elicit similar spectral properties to MB and be able to undergo 
analogous Type I and Type II aPDT processes. Substituting the N-(CH3)2 group at the 
 
45 
 
C-7 position of MB with alkyl linkages appeared to be the best way to maintain these 
properties. 
At the outset of the project it was not known what effect substituting EPIs with 
linker moieties to MB so that they could be attached would have on their NorA 
inhibitory activity. It was therefore considered important to prepare a library of MB-EPI 
hybrids with different EPIs and linkages to maximise the chances of identifying active 
hybrid compounds. The effects of attaching large groups to MB on its photochemical 
properties were also unknown, further justifying the need for a library of hybrids. 
Additionally, it was considered vital to explore hybrids with a range of physicochemical 
properties.  
Four classes of hybrids carrying four different EPIs were designed giving a total 
of 16 target hybrids. Two examples from each EPI class were tethered to MB via N,N’-
dimethylethylenediamine linkages. These two differed from each other by incorporating 
either alkyl or acyl attachments to the EPI. The other two examples from each EPI class 
carried a piperazine linker, one with an alkyl and one with an acyl attachment to the 
EPI. Comparing piperazine- versus ethylenediamine-linked hybrids allowed 
examination of the effects of rigidifying the linker, while exploring alkyl versus acyl 
attachments allowed modulation of physiochemical properties, especially polarity. 
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Chapter 2 
Synthesis of MB-EPI Hybrids 
 
 
 
 
 
 
 
 
47 
 
2.1 General Synthetic Strategy 
The synthetic strategy towards MB-EPI hybrids 47-62 made use of chemistry 
reported by Strekowski et al for the preparation of asymmetric MB derivatives.
163
 
Strekowski discovered that reactions of secondary amines with the triiodide salt of N,N-
dimethylaminophenothiazinium 63 installed the amine at the 7-position (Scheme 2.1 
(a)). Adapting this chemistry to the synthesis of MB-EPI hybrids required that the 
requisite EPI-alkyl/acyl-piperazine and EPI-alkyl/acyl-ethylenediamine-based 
precursors be independently prepared and then reacted with the triiodide salt 63 in the 
final step (Scheme 2.1 (b)). 
 
 
Scheme 2.1 (a) Strekowski’s chemistry for the synthesis of asymmetric MB derivatives. 
(b) Adapting Strekowski’s chemistry to the synthesis of MB-EPI hybrids containing 
piperazine and N,N’-dimethylethylenediamine-based linkers. 
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2.2 Synthesis of 3-(dimethylamino)phenothiazine-5-ium triiodide 63  
Key intermediate 63 was synthesized via an adaptation of Strekowski’s 
method.
163
 In the first step, commercially available phenothiazine 64 was stirred with I2 
in wet chloroform at 5 
o
C for 4 h before being allowed to warm to room temperature. 
The resulting dark precipitate was washed with large volume of chloroform until no 
yellow washings were obtained. The tetraiodide salt 65 was obtained in 83% yield after 
overnight air drying (Scheme 2.2). 
The salt 65 was then reacted using Strekowski’s procedure with 2 eq of 
dimethylamine to provide 63 in 24% yield. This method involved stirring 65 for 3 h in 
MeOH at room temperature.
163
 Strekowski reported a 24% yield for this reaction while 
New and Dolphin reported a 48% yield under the same conditions.
164
 It was found that 
the yield of 63 could be improved to 60% simply by changing the reaction solvent from 
MeOH to 15% MeOH in CHCl3. This change also yielded the pure product after simple 
filtration.  
 
  
Scheme 2.2 Synthesis of intermediate 63.  
Reagents and Conditions: (a) I2, CHCl3, rt, 4 h, 83%; (b) (CH3)2NH, MeOH/CHCl3, rt, 4 
h, 60%. 
Carrying out this reaction required preparation of a methanolic solution of 
NH(CH3)2 of known concentration. This was achieved by bubbling the gas into MeOH 
over several minutes and determining the exact molar ratio of NH(CH3)2 to MeOH by 
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1
H NMR. The required volume was then gradually added to a stirring solution of 65 in 
15% MeOH in CHCl3 over 4 h at 23 
o
C. Stirring for a further 1 h at room temperature 
gave the desired product as a dark solid. Reaction progress was monitored by thin layer 
chromatography (TLC) using a solution containing 3% aqueous NH4OAc(aq) in MeOH 
(15:85) as eluent. Under these conditions, the product 63 appeared as a dark spot with Rf 
= 0.43. A clear and sharp NMR spectrum was obtained for 63 in DMSO-d6, whereas a 
poorer spectrum was obtained in D2O, the NMR solvent reported by Strekowski.  
2.3 Synthesis of Reserpine-Containing Intermediates 66, 67, 68 and 69 
Selective demethylation of the central methyl ether in the gallic acid portion of 
reserpine had been reported previously using Lewis acids (BBr3, AlCl3 and pyridinium 
chloride Py-HCl) in a variety of solvents, including petroleum ether and EtOAc/HCl.
165
 
Availability of this phenolic reserpine derivative 70 indicated that MB-EPI hybrids 
incorporating reserpine should be obtainable by attaching linker moieties via O-
alkylation.  
After testing several reported conditions it was observed that AlCl3 in CH2Cl2 
provided the best yield of the demethylated reserpine 70. Adding an excess (~ 50 mol 
eq) of finely ground AlCl3 in one portion to a stirring solution of reserpine 8 in CH2Cl2 
and then stirring for an additional 2 h at room temperature afforded 70 in 95% (lit. yield 
47%).
165
  The structure of 70 was confirmed by 
1
H NMR and mass spectrometry. The 
1
H spectrum showed the central phenolic methyl ether at 3.92 ppm had been lost and a 
peak at m/z 595.2671 was observed in the high resolution electrospray mass spectrum 
(HRESI-MS) corresponding to the expected C32H38N2O9 [M+H]
+
 ion for 70. 
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Scheme 2.3 Synthesis of reserpine-containing intermediates 66, 67, 68 and 69 
Reagents and Conditions: (a) AlCl3, CH2Cl2, rt, 2 h, 95%; (b) 2-bromoethanol, K2CO3, 
DMF, 80 
o
C,16 h, 96%; (c) CBr4/PPh3, THF, rt, 3 h, 91%; (d) 73, Et3N, THF, reflux, 24 
h, 80%; (e) Boc2O, Et3N/MeOH, 16 h, 45%; (f) 75, Et3N, THF, reflux, 48 h, 75%; (g) 
Bromoacetyl chloride, N,N-diethylaniline, acetone, 0 
o
C → rt, 16 h, 35%; (h) 76, 
K2CO3, DMF, 80 
o
C, 16 h, 64%; (i) Bromoacetyl chloride, N,N-diethylaniline, acetone, 
0 
o
C → rt, 48 h, 40%; (j) 77, Cs2CO3, DMF, 80 
o
C, 24 h 70%. 
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O-alkylation of 70 with 2-bromoethanol was carried out in the presence of 
K2CO3 in DMF with stirring at 80 
o
C overnight. The desired alcohol 71 was isolated as 
a yellowish solid after silica gel column chromatography in 96% yield. The structure of 
71 was confirmed by 
1
H NMR spectroscopy, where two new coupled triplets were 
observed at 4.25 and 3.73 ppm (J = 10.0 Hz), corresponding to the new CH2 groups. A 
peak at m/z 639.2844 was observed in the HRESI-MS corresponding to the expected 
C34H42N2O10 [M+H]
+
 ion for 71.  
Bromination of alcohol 71 was achieved using standard Appel conditions
166
 with 
CBr4/PPh3 in dry THF. Stirring for 3 h at room temperature gave 72 in 91% yield. The 
compound showed 99% purity by 
1
H NMR and the HRESI-MS revealed a peak at m/z 
701.2645 corresponding to the expected C34H41BrN2O9 [M]
+
 ion for 72. 
N-Alkylation of N-Boc-piperazine 73 with bromide 72 in dry THF with Et3N at 
reflux provided analytically pure 66 in 80% yield after 24 h. The structure of 66 was 
confirmed by 
1
H NMR spectroscopy, where piperazine CH2 peaks were observed as 
doublets at 3.41 and 2.56 ppm (J = 8.5 Hz). A peak at m/z 807.4188 was observed in the 
HRESI-MS corresponding to the expected C43H58N4O11 [M+H]
+
 ion for 66.  
Analogous chemistry was used to prepare reserpine-containing intermediate 67 
bearing an N-alkyl-N,N’-dimethylethylenediamine linker. N-Boc-N,N’-
dimethylethylenediamine 75 was synthesized from the commercially available N,N’-
dimethylethylenediamine 74 using literature procedure.
167
 Briefly, 74 was reacted with 
Boc2O in MeOH in the presence of Et3N and after overnight stirring (monitored by 
TLC; EtOAc:MeOH:Et3N, 87:10:3; stained with ninhydrin) the product 75 was isolated 
in 45% yield after silica gel column chromatography (Scheme 2.3). Reaction of 75 with 
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bromide 72 in dry THF in the presence of Et3N at reflux afforded intermediate 67 in 
75% (Scheme 2.3). The structure of 67 was confirmed by 
1
H NMR spectroscopy, where 
N-methyl peaks were observed at 2.94 and 2.92 ppm  as singlets and CH2 peaks as 
triplets at 3.22 and 2.55 ppm (J = 10 Hz). A peak at m/z 809.4369 was observed in the 
HRESI-MS corresponding to the expected C43H60N4O11 [M+H]
+
 ion for 67.  
Similar strategies were applied in the synthesis of intermediates 68 and 69, 
which carried amide linkages from the piperazine and N,N’-dimethylethylenediamine 
groups to the EPIs. Commercially available N-Boc-piperazine 73 and the synthesized N-
Boc-N,N’-dimethylethylenediamine 75 were coupled to bromoacetyl chloride in the 
presence of N,N-diethylaniline to give 76  and 77 in 35% and 40% yields, respectively. 
The reactions were carried out by stirring in acetone (0 
o
C to room temperature) for 16 h 
for 76 and 48 h for 77.  
Intermediates 68 and 69 were synthesized from phenolic reserpine derivative 70 
by O-alkylation with 76 and 77, respectively. The reactions were carried out using 
K2CO3 or Cs2CO3 in DMF at 80 
o
C and provided respective yields of 64% and 70%. A 
peak at m/z 821.3987 observed in the HRESI-MS corresponded to the expected 
C43H56N4O12 [M+H]
+
 ion for 68. A peak was similarly observed at m/z 823.4135 
corresponding to the expected C43H58N4O12 [M+H]
+
 ion for 69. 
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2.4 Synthesis of Pterostilbene-Containing Intermediates 78, 79, 80 and 81 
Intermediates 80 and 81 were synthesized from the commercially available 
phenolic pterostilbene derivative 9 by O-alkylation reactions using N-bromoacetyl-N’-
Boc-piperazine 76 and N-bromoacetyl-N’-Boc-N,N’-dimethylethylenediamine 77, 
respectively (Scheme 2.4). The reactions were carried out using K2CO3 in DMF at 80 
o
C and gave identical yields of 77%. Intermediate 80 showed a peak at m/z 505.2331 in 
the HRESI-MS, corresponding to the expected C27H34N2O6 [M+Na]
+
 ion. A peak at m/z 
507.2486 was observed for 81, corresponding to the expected C27H36N2O6 [M+Na]
+
 ion. 
O-Alkylation of 9 with 2-bromoethanol in the presence of K2CO3 afforded the 
phenoxyethyl alcohol 82 in 90% yield after overnight stirring in DMF at 80 
o
C. The 
1
H 
spectrum of 82 showed two characteristic triplets for the new ethyl group at 4.31 and 
3.65 ppm (J = 12 Hz). The Appel reaction was used for bromination of alcohol 82, 
where stirring with CBr4/PPh3 in THF for 3 h at room temperature afforded bromide 83 
in 94% yield. A peak at m/z 362.0524 observed in the HRESI-MS corresponded to the 
expected C18H19BrO3 [M]
+
 ion for 83 (Scheme 2.4). 
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Scheme 2.4 Synthesis of pterostilbene-containing intermediates 78, 79, 80 and 81 
Reagents and Conditions: (a) N-bromoacetyl-N’-Boc-piperazine 76, K2CO3, DMF, 100 
o
C, 48 h, 77%; (b) N-bromoacetyl-N’-Boc-N,N’-dimethylethylenediamine 77, K2CO3, 
DMF, 80 
o
C, 24 h, 77%; (c) 2-bromoethanol, K2CO3, DMF, 80 
o
C, 16 h, 90%; (d) 
CBr4/PPh3, THF, rt, 3 h, 94%; (e) N-Boc-piperazine, KI (40 mol %), THF, reflux, 48 h, 
87%; (f) N-Boc-N,N’-dimethylethylenediamine, K2CO3, CH2Cl2, reflux, 48 h, 81%. 
 
N-alkylation of N-Boc-piperazine and N-Boc-N,N’-dimethylethylenediamine 
with bromide 83 afforded 78 and 79 in 87% and 81% yields, respectively. The 
1
H 
spectrum of 78 showed characteristic CH2 signals for piperazine at 3.43 and 2.65 ppm 
and the Boc CH3 group at 1.46 ppm. A peak at m/z 491.4487 observed in the HRESI-
MS corresponded to the expected C27H36N2O5 [M+Na]
+
 ion for 78.  For compound 79, 
the 
1
H spectrum showed characteristic signals for N-CH3 protons at 2.57 and 2.19 ppm 
and Boc CH3 protons at 1.45 ppm. Ethyl CH2 signals were also observed at 3.13 and 
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2.43 ppm. A peak at m/z 493.2364 in the HRESI-MS corresponded to the expected 
C27H38N2O5 [M+Na]
+
 ion for 79.  
2.5 Synthesis of INF55-Containing Intermediates 84, 85, 86 and 87 
INF55 methyl ester derivative 88 was synthesized by Naveen Dolla (PhD 
student in the Kelso Group) using the reported method.
168
 Ester 88 was quantitatively 
reduced to the benzylic alcohol 89 using NaBH4 in THF and bromination of 89 using 
CBr4/PPh3 in Et2O/THF afforded 90 in 85% yield. The bromination reaction was carried 
out by stirring at room temperature for 3 h. Purification was achieved by silica gel 
column chromatography (Scheme 2.5).  
 
Scheme 2.5 Synthesis of INF55-containing intermediates 84, 85, 86 and 87. 
Reagents and Conditions: (a) NaBH4, THF, rt, 24 h, quant.; (b) CBr4/PPh3, Et2O/THF, 
rt, 3 h, 85%; (c) N-Boc-piperazine, KI (45 mol%), THF, reflux, 48 h, 96%;  (d) N-Boc-
N,N’-dimethylethylenediamine, KI (50 mol%), THF, reflux, 48 h, 78%; (e) NaOH, 
MeOH/CH2Cl2, rt, 30 min, then reflux, overnight, 96% (f) N-Boc-piperazine, HATU, 
DIEA, THF, rt, 5 h, 85%; (g) N-Boc-N,N’-dimethylethylenediamine, HATU, DIEA, 
THF, rt, 7 h, 78%. 
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Bromide 90 was reacted separately with commercial N-Boc-piperazine and N-
Boc-N,N’-dimethylethylenediamine 75 in anhydrous THF in the presence of KI. After 
48 h at reflux the alkylated products 84 and 85 were isolated in 96% and 78% yields, 
respectively, after silica gel column chromatography. The 
1
H spectrum of 84 showed 
characteristic CH2 signals for piperazine at 3.30 and 2.33 ppm and a peak at m/z 
435.2043 observed in the HRESI-MS corresponded to the expected C24H28N4O4 [M-H]
-
 
ion. For intermediate 85, the 
1
H spectrum showed characteristic signals for the ethyl 
group at 3.37 and N-CH3 groups at 2.66 ppm and 1.96 ppm. A peak at m/z 437.2180 in 
the HRESI-MS corresponded to the expected C24H30N4O4 [M-H]
-
 ion for 85. 
Similar strategies were applied in the synthesis of INF55-containing intermediates 
86 and 87 containing amide linkages between the piperazine and N,N’-
dimethylethylenediamine groups and the EPI. INF55 acid derivative 91 was obtained by 
hydrolysing 90 with NaOH. The crude acid 91 was coupled to N-Boc-piperazine and N-
Boc-N,N’-dimethylethylenediamine  using HATU with diisopropylethylamine (DIPEA) 
as base. Stirring at room temperature in THF for 5 h and 7 h gave the Boc-protected 
intermediates 86 and 87 in 85% and 78% yields, respectively. The 
1
H spectrum of 86 
showed characteristic CH2 signals for piperazine at 3.35 and 2.13 ppm and the 
13
C 
spectrum showed a carbonyl signal at 171.1 ppm. A peak at m/z 449.1826 observed in 
the HRESI-MS corresponded to the expected C24H26N4O5 [M-H]
-
 ion for 86. For 87, the 
1
H spectrum showed characteristic CH2 signals for the ethyl group at 3.76-3.32 ppm and 
N-CH3 signals at 2.76 ppm and 1.67 ppm. The 
13
C spectrum showed a characteristic 
signal for the amide carbonyl at 174.0 ppm and a peak at m/z 451.1988 observed in the 
HRESI-MS corresponded to the expected C24H28N4O5 [M-H]
-
 ion for 87. 
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2.6 Synthesis of INF271-Containing Intermediates 92, 93, 94 and 95 
Synthesis of INF271-containing intermediates 92, 93, 94 and 95 commenced 
with the chlorination of 2-naphthoic acid 96 using thionyl chloride (Scheme 2.6).  
 
 
Scheme 2.6 Synthesis of INF271-containing intermediates 92, 93, 94 and 95. 
Reagents and Conditions: (a) SOCl2, C6H6, reflux, 16 h, 95%; (b) NaN3, 5% HCl, N,N-
diethylaniline, C6H6/H2O, rt, 16 h, 76%; (c) C6H6, reflux, 4 h, quant.; (d) O-
aminophenol, CH2Cl2, rt, 48 h, 80%; (e) 3-bromopropanol, K2CO3, DMF, rt, 16 h, 75%; 
(f) CBr4/PPh3, THF, 40 
o
C, 16 h, 85%; (g) N-Boc-piperazine 73, K2CO3, KI (25 mol%), 
THF, reflux, 16 h, 85%; (h) N-Boc-N,N’-dimethylethylenediamine 75, K2CO3 KI (30 
mol%), THF, 80 
o
C, 48 h, 85%; (i) N-bromoacetyl-N’-Boc-piperazine 76, K2CO3, DMF, 
80 
o
C, overnight, 66%; (j) N-bromoacetyl-N’-Boc-N,N’-dimethylethylenediamine 77, 
K2CO3, DMF, 80 
o
C, overnight, 80%. 
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Thionyl chloride was gradually added to the solution of 2-naphthoic acid in 
benzene before stirring the reaction at reflux overnight. Upon consumption of the 
starting material (TLC; Pet. Spirit:EtOAc, 50:50) the solvent was evaporated and the 
residue used without further purification. The crude acyl chloride was reacted with 
NaN3/HCl in a two phase solvent system (C6H6/H2O) using the phase transfer catalyst 
N,N’-diethylaniline. After stirring overnight at room temperature the desired acyl azide 
was obtained in 76% yield. Quantitative conversion to isocyanate 97 was then achieved 
by heating the acyl azide at reflux in benzene for 4 h (Scheme 2.6). These procedures 
were based on the method reported by Rineh et al.
169
  
Reaction of 2-naphthylisocyanate 97 with O-aminophenol in anhydrous CH2Cl2 
at room temperature for 48 h afforded the substituted urea 98 in 80% yield. Urea 98 
formed as a white precipitate that was filtered, dried under reduced pressure and used 
without further purification. In cases where O-aminophenol starting material was 
observed in the 
1
H NMR spectrum of the product the mixture was washed with 1 M 
HCl. The 
1
H NMR spectrum of 98 showed characteristic urea NH signals at 9.50 and 
8.24 ppm and a peak at m/z 277.0973 observed in the HRESI-MS corresponded to the 
expected C17H14N2O2 [M-H]
-
 ion.  
O-Alkylation of 98 with 3-bromopropanol was achieved by stirring overnight at 
room temperature with K2CO3 in DMF, affording 99 in 75% yield. The 
1
H NMR 
spectrum confirmed alkylation with the appearance of new CH2 signals at 4.27, 3.65 
and 1.97 ppm. A peak at m/z 335.1396 observed in the HRESI-MS corresponding to the 
molecular formula C20H20N2O3 [M-H]
-
 supported formation of 99.  Bromination of 99 
under Appel conditions using CBr4/PPh3 in dry THF at 40 
o
C gave the desired halide 
 
59 
 
100 in 85% yield after silica gel column chromatography. The 
1
H NMR spectrum 
confirmed loss of the OH signal at 4.70 ppm and downfield shifting of the CH2OH 
signal from 3.65 to 3.80 ppm, consistent with a CH2Br signals. A peak at m/z 397.0552 
observed in the HRESI-MS corresponded to the expected C20H19BrN2O2 [M]
-
 ion for 
100.  
Reaction of N-Boc-piperazine 73 with bromide 100 in the presence of K2CO3 
and KI (25 mol%) in anhydrous THF afforded 92 in 85% yield after overnight heating 
at reflux (Scheme 2.6). A peak at m/z 505.2834 observed in the HRESI-MS 
corresponding to the molecular formula C29H36N4O4 [M+H]
+
 supported formation of 92. 
Intermediate 93 was synthesized by reacting N-Boc-N,N’-dimethylethylenediamine 75 
with bromide 100 in the presence of K2CO3 and KI (30 mol%) in dry THF. A yield of 
85% was obtained after heating overnight at reflux (Scheme 2.6). A peak at m/z 
507.2971 observed in the HRESI-MS corresponded to the molecular formula 
C29H38N4O4 [M+H]
+
 for 93.  
Alkylation of N-bromoacetyl-N’-Boc-piperazine 76 and N-bromoacetyl-N’-Boc-
N,N’-dimethylethylenediamine 77 with the phenolic urea derivative 98 in DMF at 80 
o
C 
in the presence of Cs2CO3 gave 94 and 95 in 66% and 80% yields, respectively, after 
silica gel column chromatography. The 
1
H NMR spectra for both compounds showed 
the presence of a Boc CH3 group at 1.41 ppm. The 
13
C NMR spectra showed signals for 
the amide carbonyl groups at 166.0 and 168.2 ppm, consistent with formation of 94 and 
95, respectively. Additional confirmation of the structures was obtained by HRESI-MS, 
which showed peaks at m/z 505.2827 corresponding to the C28H32N4O5 [M+H]
+
 ion for 
94, and m/z 507.2598, corresponding to the C28H34N4O5 [M+H]
+
 ion for 95.  
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2.7 Synthesis of MB-EPI Hybrids  
Completion of the synthesis of hybrids 47, 49, 51, 53, 55, 57, 59 and 61 with 
piperazine-based linkers and hybrids 48, 50, 52, 54, 56, 58, 60 and 62 with N,N’-
dimethylethylenediamine-based linkers was achieved using Strekowski’s chemistry.
163
 
The Boc group was quantitatively removed from intermediates 66-69, 78-81, 84-87 and 
92-95 using TFA in CH2Cl2 and the crude products were subsequently reacted with 
phenothiazinium intermediate 63. Stirring the deprotected amine with 63 at room 
temperature for 48-96 h in anhydrous CH2Cl2 provided the target hybrids as dark blue 
powders in modest yields (11-30%). Adequate quantities (25-95 mg) were obtained in 
all cases for photochemical and biological studies (Chapters 3-4). The quantities of 
hybrids produced (mg) and yield’s for the Strekowski reactions are provided in Tables 
2.1 and 2.2. 
 
 
61 
 
Table 2.1 Synthesis of hybrids with piperazine-based linkers. 
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Table 2.2 Synthesis of hybrids with N,N’-dimethylethylenediamine-based linkers.
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2.7.1 Hybrids with Piperazine-Based Linkers 
Synthesis of reserpine-containing hybrids 47 and 49 with piperazine-based 
linkers was carried out by deprotecting the Boc groups of intermediates 66 and 68 and 
coupling the resulting amine trifluoroacetate salts to the C-7 position of 
phenothiazinium precursor 63. Stirring for 72 h and 96 h, respectively, at room 
temperature in dry CH2Cl2 gave hybrids 47 and 49 as dark blue powders in 18% and 
14% yields after preparative TLC and anion exchange to the chloride salt (Table 2.1, 
Entries 1 and 2). Structures of the hybrids were confirmed by HRESI-MS, which 
showed a peak at m/z 946.4276 corresponding to the C52H61N6O9S [M]
+
 ion for hybrid 
47 and a peak at m/z 960.4063 corresponding to the C52H59N6O10S [M]
+
 for hybrid 49. 
1
H and 
13
C NMR spectra for 47 and 49 were of poor quality. At this point it was 
noted that other papers describing related asymmetric phenothiazinium salts failed to 
report NMR spectra.
170
 Y. Lu et al reported that changing the counter ion of 
phenothiazinium gave better NMR spectra, while J. Jahnchen used a mixture of normal 
and deuterium solvent to reduce peak broadening in the phenothiazinium.
170a,b
 The 
1
H 
NMR spectrum of 3-(dimethylamino)phenothiazine-5-ium triiodide 63 was found to be 
as expected in DMSO-d6 solution (Figure 2.1A). However, the aromatic region of 47 
and 49 showed only broadened phenothiazinium signals in all solvents. The same effect 
was noted for all other hybrids, except 51. Figure 2.1B highlights this for a model 
compound, which contains only phenothiazine aryl protons for clarity, where the 
phenothiazinium peaks were noticeably broadened. Due to this effect, all hybrids except 
51 were unable to be completely characterized by NMR spectroscopy. Nevertheless, all 
synthesized hybrids showed clean ESI mass spectra that supported their structure and 
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purity, as exemplified by the ESI-MS of 50 and 57 shown in Figure 2.2. LRESI-MS for 
some selected hybrids are provided in Appendix 2.1.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.1 (A) 
1
H NMR spectrum of 3-(dimethylamino)phenothiazine-5-ium triiodide 
63 in DMSO-d6; (B) 
1
H NMR spectrum of model asymmetric substituted 
phenothiazinium highlighting the broadened aryl signals. Similar spectra with 
broadened phenothiazinium signals were observed for all hybrids, except 51. 
A 
 
Phenothiazinium signals 
broadened 
B 
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Figure 2.2 LRESI-MS of hybrids 50 and 57 
For unknown reasons the 
1
H NMR spectrum of hybrid 51 was an exception, 
clearly showing the phenothiazinium signals in CD2Cl2 (Figure 2.3A). The structure of 
this hybrid was supported by its correct in the LRESI-MS (Figure 2.3B). 
 
 
A 
B 
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Figure 2.3 (A) 
1
H NMR spectrum of 51 in CD2Cl2 clearly showing the presence of 
phenothiazinium signals (B) LRESI-MS of 51. 
A 
B 
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Pterostilbene-containing intermediates 78 and 80 with piperazine-based linkers 
were quantitatively deprotected with TFA in dry CH2Cl2 by stirring for 3 h at room 
temperature. The crude residues were submitted to reactions with 63. After 72 h stirring 
at room temperature in the presence of K2CO3 (0.3 eq and 0.2 eq, respectively) the 
hybrids 51 and 53 were isolated in 26% and 30% yields after preparative TLC and anion 
exchange (Table 2.1, Entries 3 and 4). A peak at m/z 607.2764 observed in HRESI-MS 
corresponding to the molecular formula C36H39N4O3S [M]
+
 supported formation of 51. 
Hybrid 53 was also confirmed using HRESI-MS, where a peak at m/z 621.2546 
corresponding to the expected C36H37N4O4S [M]
+
 ion was observed. 
1
H NMR spectra 
lacking phenothiazine peaks were observed for these hybrids. 
Synthesis of INF55-containing hybrids with piperazine-based linkers was initiated 
by quantitatively removing the Boc group from intermediates 84 and 86 by stirring with 
TFA in dry CH2Cl2 at room temperature for 3 h. The resulting amines were reacted with 
63 in the standard way to afford hybrids 55 and 57 in 23% and 22% yields, respectively, 
after preparative TLC and anion exchange (Table 2.1, Entries 5 and 6). The structures 
were confirmed by HRESI-MS, where a peak at m/z 575.2229 corresponding to the 
C33H31N6O2S [M]
+
 ion for hybrid 55 was observed. A peak at m/z 589.2048 
corresponding to the C33H29N6O3S [M]
+
 ion was observed for 57. The 
1
H NMR spectra 
lacked phenothiazine signals for these hybrids. 
Synthesis of INF271-containing hybrids with piperazine-based linkers was 
carried out as above to provide 92 and 94 in 25% and 17% yields, respectively, after 
preparative TLC and anion exchange resin. A peak at m/z 643.2870 observed in the 
HRESI-MS corresponding to the molecular formula C38H39N6O2S [M]
+
 supported 
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formation of 92. Hybrid 94 showed a peak at m/z 643.2508 corresponding to the 
expected C37H35N6O3S [M]
+
 ion. 
1
H NMR spectra lacking phenothiazine peaks were 
observed for these hybrids. 
2.7.2 Hybrids with N,N’-Dimethylethylenediamine-Based Linkers 
Synthesis of reserpine-containing hybrids 48 and 50 was initiated by removing 
the Boc group from intermediates 67 and 69. The secondary amines were then coupled 
to the C-7 position of 63 by stirring in the presence of K2CO3 (0.4 eq) at room 
temperature for 72 h and 96 h, respectively, giving  48 and 50 in 18% and 11% yields 
after preparative TLC and anion exchange. Structures of the hybrids were confirmed 
using HRESI-MS, where a peak at m/z 948.4423 corresponding to the C52H63N6O10S 
[M]
+
 ion for 48 was observed, as was a peak at m/z 961.4199 corresponding to the 
C52H61N6O10S [M]
+
 ion for 50. Poor 
1
H NMR spectra lacking phenothiazine peaks were 
observed with these hybrids. 
Synthesis of pterostilbene-containing hybrids 52 and 54 carrying N,N’-
dimethylethylenediamine linkers involved Boc-deprotection of 79 and 81, followed by 
coupling of the crude amine TFA salts to 63. Both reactions were stirred at room 
temperature for 96 h in the presence of K2CO3 (0.4 and 0.2 eq, respectively) to give 52 
and 54 in 14% yields. Structures of the hybrids were confirmed using HRESI-MS, 
which showed peaks at m/z 609.2901, corresponding to the C36H41N4O3S [M]
+
 ion for 
52, and at m/z 623.2703, corresponding to the C36H41N4O3S [M]
+
 ion for 54. 
1
H NMR 
spectra with broadened phenothiazine peaks were observed with these hybrids. 
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The Boc-group was quantitatively removed from INF55-containing intermediates 
85 and 87 as above before reacting each resulting amine TFA salt with 63. The coupling 
reactions were carried out by stirring for 76 h at room temperature in dry CH2Cl2, 
giving hybrids 56 and 58 in identical 18% yields. The structures were confirmed using 
HRESI-MS, which showed peaks at m/z 577.2400, corresponding to the C33H33N6O2S 
[M]
+
 ion for 56 and m/z 591.2183, corresponding to the C33H31N6O3S [M]
+
 ion for 58. 
INF271-containg hybrid 60 was obtained in 25% yield after stirring at room 
temperature in dry CH2Cl2 for 48 h with Boc-deprotected amine 93. A peak at m/z 
645.2993 observed in HRESI-MS corresponding to the molecular formula C38H41N6O2S 
[M]
+
 supported formation of 60. 
Intermediate 95 carrying an amide linkage was deprotected in the usual way and 
then coupled to the C-7 position of 63. Hybrid 62 was obtained in 15% after preparative 
TLC and anion exchange and its structure was confirmed using HRESI-MS, where a 
peak was observed at m/z 645.2663 corresponding to the C37H37N6O3S [M]
+
 ion for 62. 
A total of 16 MB-EPI hybrids were synthesized in this work. All compounds were 
purified by preparative TLC and converted to chloride salts using a Cl
- 
anion exchange 
resin. All coupling reactions were carried out in the absence of light to minimize 
photodegradation. Hybrids with N,N’-dimethylethylenediamine linkers tended to be 
more polar than those with piperazine linkers and more difficult to isolate. More than 35 
mg of each hybrid was obtained in pure form for characterization and biological testing.  
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3.1 UV/Vis Spectrophotometry  
The efficiency of aPDT with phenothiazinium PSs is influenced by their UV/Vis 
absorption properties across the range of wavelengths applied. In general, 
phenothiazinium PSs must exhibit significant light absorption at wavelengths > 630 nm 
and show high chemical stability in the presence of visible light. MB shows strong 
absorbance in the range 550-700 nm, with an intense maximum at λmax1 = 668 nm and a 
shoulder at λmax2 = 609 nm.
171
  
To be an effective photosensitiser a phenothiazinium must be able to reside for a 
significant amount of time in the excited triplet state following excitation and 
intersystem crossing from the exited singlet state. For MB, the triplet excited state is 
sufficiently populated via conversion both radiatively (fluorescence) and non-radiatively 
from its relatively long-lived excited singlet state.
172
 Relaxation is promoted by 
structural flexibility in donor-acceptor chromophoric system (i.e. the acceptor being the 
cationic nucleus and the donors the auxochromic amino groups), while formation of 
twisted intramolecular charge transfer (TICT) complexes between the phenothiazinium 
core and amino auxochromes has also been proposed as a relaxation route.
173
 This 
complex allows charge separation and non-radiative relaxation and is particularly strong 
with N-aryl and N,N-dialkyl auxochromes.
174
 For phenothiazinium PSs, benzannelation 
and the presence of heavy atoms increase the maximum absorption wavelength, while 
modifications at the phenothiazinium side chains tend to have lesser effects.
173
 
When designing hybrids it was considered important to maintain as much of the 
structural features of MB as possible, making only minimal changes to one of the 
auxochromes. In this way the hybrids would be expected to maintain the photosensitizer 
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properties of MB. As discussed in Chapter 1.14, substitution of one of the C-7 N-Me 
groups of MB with N-alkyl or piperazinyl linkages was considered the best way to 
introduce the linker groups without significantly modifying MB’s core structure and 
photophysical properties.  
The effects of the structural changes introduced to MB on its absorption 
properties were examined by comparing the λmax1 and λmax2 values of hybrids to those of 
MB. These two maxima arise from the phenothiazinium chromophore, so it was 
predicted that these would be excellent indicators of whether the structural changes 
introduced in the hybrids were affecting the absorption properties of the MB portion. 
UV/Vis spectra of hybrids 47-62 and MB were recorded at the same 
concentration (10 µM) and at the same temperature (23 
o
C) in methanol. The spectra are 
presented in Figure 3.1. For ease of comparison, the spectra were clustered according to 
the attached EPI and referred to as, for example, reserpine-containing hybrids (Figure 
3.1 (a), compounds 47-50). To facilitate further comparisons between the four different 
types of linkages, the following colour scheme has been applied in Figure 3.1: 
 red = N-alkyl piperazine (compounds 47, 51, 55, 59) 
 pink = N-acyl piperazine (compounds 49, 53, 57, 61) 
 light blue = N-alkyl-N,N’-dimethylethylenediamine (compounds 48, 52, 56, 
60) 
 dark blue = N-acyl-N,N’-dimethylethylenediamine (compounds 50, 54, 58, 62) 
This same colour coding system has also been applied in subsequent figures in the 
chapter. 
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Figure 3.1 UV/Visible absorption spectra of MB 33 and: (a) reserpine-containing 
hybrids 47-50, (b) pterostilbene-containing hybrids 51-54, (c) INF55-containing hybrids 
55-58 and (d) INF271-containing hybrids 59-62. All spectra were recorded using 10 µM 
solutions in MeOH at 23 
o
C.  
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As shown in Figure 3.1, expected changes in lower wavelength bands (250-400 
nm) were observed with the different hybrids. These arise from the different EPIs and 
linker groups attached to MB. The key finding was that the λmax1 and λmax2 bands arising 
from the MB portion of the hybrids varied only slightly from MB in wavelength and 
extinction coefficients across the series. This provided a clear indication that the 
absorption properties of the MB chromophore had not been drastically changed by 
introduction of the appended linker-EPI structures. A summary of the λmax1, λmax2 and 
extinction coefficient (log ε) data for MB and hybrids 47-62 is provided in Table 3.1.  
Under the conditions used, MB showed λmax1 = 653 nm and λmax2 = 612 nm. The 
respective extinction coefficients for the two maxima were log ε1 = 4.04 and log ε2 = 
3.73. To better visualise the results, the λmax data are presented graphically in Figure 3.2 
and the log ε data in Figure 3.3. 
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Table 3.1 Summary of λmax1, λmax2 and extinction coefficient (log ε) data for MB 33 and 
hybrids 47-62. 
 Compound λmax1 [nm](log ε) λmax2 [nm](log ε) 
MB 653 (4.04) 612 (3.73)  
47 651 (4.05) 609 (3.79)  
48 656 (4.02) 616 (3.74) 
49 653 (3.97) 610 (3.68) 
50 656 (4.00) 614 (3.72) 
51 653 (3.84) 615 (3.65) 
52 661 (3.93) 613 (3.61) 
53 653 (3.91) 612 (3.68) 
54 661 (3.95) 610 (3.64) 
55 656 (3.91) 613 (3.68) 
56 651 (3.91) 611 (3.69) 
57 650 (3.86) 609 (3.66) 
58 659 (3.82) 613 (3.48) 
59 655 (3.88) 611 (3.62) 
60 659 (3.97) 614 (3.63) 
61 652 (3.96) 610 (3.68) 
62 656 (4.05) 611 (3.74) 
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In Figure 3.2, the λmax1 and λmax2 values for MB were subtracted from the 
corresponding values in the hybrids and the differences plotted. All hybrids except 53 
showed varying bathochromic (red) or hypsochromic (blue) shifts at both λmax1 and 
λmax2, but the changes were all only small (< 7 nm) and the overall appearance of the 
bands remained unchanged. No obvious trends were observed with respect to the 
different EPI-linker groups attached. For instance, hybrids with piperazine-based linkers 
(red/pink bars) showed no clear trends that distinguish them from N,N’-
dimethylethylenediamine-based linkers (light blue/dark blue bars). 
 
 
Figure 3.2 λmax1 and λmax2 data for hybrids 47-62 relative to MB. λmax1 and λmax2 values 
for MB were subtracted from the corresponding values for hybrids. Colour coding: red 
= N-alkyl piperazine linker, pink = N-acyl piperazine linker, light blue = N-alkyl-N, 
N’-dimethylethylenediamine linker, dark blue = N-acyl-N,N’-dimethylethylenediamine 
linker. 
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 The extinction coefficients at λmax1 and λmax2 for 47-62 were compared to the 
equivalent values for MB by subtracting the log ε values for MB from the log ε values 
for hybrids at the respective maxima and plotting the differences (Figure 3.3).  
 Figure 3.3 Extinction coefficient data for hybrids 47-62 at λmax1 (i.e. log ε1) and λmax2 
(i.e. log ε2). Log ε values for MB (i.e. log ε1 = 4.04, log ε2 = 3.73) were subtracted 
from the log ε values at the respective maxima of hybrids.  Colour coding: red = N-alkyl 
piperazine linker, pink = N-acyl piperazine linker, light blue = N-alkyl-N,N’-
dimethylethylenediamine linker, dark blue = N-acyl-N,N’-dimethylethylenediamine 
linker. 
 
Extinction coefficient of the hybrids were mostly lower than MB at both λmax1 
and λmax2, although the differences were all small (Δlog ε < ± 0.25). The highest Δlog ε 
values were observed with INF55-containing hybrid 58 (Δlog ε1 = 0.24, Δlog ε2 = 0.21). 
INF271-containing hybrid 62 closely matched MB showing a Δlog ε1 deviation of 
almost zero. Minimal Δlog ε changes were also observed in two of the reserpine-
containing hybrids 48 and 50.  
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In summary, the λmax and log ε data confirmed that introduction of the various 
linker groups and EPIs to the C7-position of MB to create hybrids 47-62 had only a 
minor impact on the UV/Vis absorbtion properties of the MB chromophore. 
3.2 Measurement of 
1
O2 and •OH Production by Hybrids 
As described in Chapter 1.9, when PSs are illuminated with appropriate 
wavelengths of light they can produce various types of ROS, including singlet oxygen 
(
1
O2), superoxide radical anion, hydrogen peroxide and hydroxyl radical (•OH). 
Production of these ROS by PSs can be probed experimentally by monitoring the 
fluorescence emitted by fluorescence-based ROS scavengers. Two such probes, singlet 
oxygen sensor green (SOSG) and 3’-p-(hydroxyphenyl) fluorescein (HPF), can be used 
for the selective detection of 
1
O2 and •OH, respectively. Both probes are cell-permeable, 
relatively insensitive to superoxide and nitric oxide and they are resistant to auto-
oxidation processes.
175
  
The SOSG probe shows high selectivity for singlet oxygen and is water soluble 
at mM concentrations. The structure of the probe has not been released by the 
commercial supplier (Invitrogen) but it is believed to be a bichromophoric molecule 
incorporating a photoinduced electron transfer (PET) design, comprising a dimethyl 
anthracene moiety attached to fluorescein (Figure 3.4).  
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Figure 3.4 SOSG fluorescence only in the presence of 
1
O2 after forming SOSG - EP. 
 
Photoelectron transfer processes normally quench the fluorescein emission from 
the SOSG molecule. In the presence of singlet oxygen, the anthracene moiety forms an 
endoperoxide (SOSG-EP) that disrupts the p-dimethylaryl conjugated system, allowing 
the photoexcited fluorescein derivative to relax via fluorescence. The reaction is 
irreversible and the fluorescence signal proportional to the singlet oxygen concentration 
in solution.
176
 
The HPF probe was developed by Setsukinai et al as a tool for stable and 
selective detection of •OH.
177
 Although a related 3′-p-(aminophenyl) fluorescein (APF) 
probe produces ~ 5-fold more fluorescence than HPF in the presence of •OH, HPF is 
substantially less sensitive to 
1
O2, thus making it more selective for •OH and better 
suited for use in our experiments.
175
 In the presence of •OH, the non-fluorescent HPF 
molecule is oxidized to produce a bright green fluorescent product, with a molecule of 
p-benzoquinone being lost in the process. This chemistry is summarized in Figure 3.5. 
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Figure 3.5 Reaction of HPF with •OH produces a green fluorescent molecule. 
 
Cell-free measurements of 
1
O2 and •OH were performed with the hybrids and 
probes in 96-well plates, as summarized in Figure 3.6. Solutions containing hybrids 47-
62 and the SOSG (1 µM) and HPF (1 µM) probes were prepared in phosphate-buffered 
saline (PBS, pH 11). D2O was added to increase the life-time and stability of the 
generated •OH and 
1
O2.
178
 It is known that the relative lifetime of 
1
O2 in the presence of 
D2O is 35 times longer than in H2O.
179
 It is also known that the SOSG and HPF probes 
are stable in the presence of cells and that there are no significant differences between 
the amounts of ROS generated by phenothiazinium PSs in the presence or absence of 
cells.
175
 Thus, the 
1
O2 and •OH measurements obtained here were directly transferable 
to the cell-based aPDT experiments described later in this Chapter. 
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Figure 3.6 Schematic representation of cell-free experiments for the measurement of 
1
O2 and •OH from hybrids upon illumination with red light. 
 
The final assay solutions containing 10 µM hybrids in a total volume of 200 µL 
were illuminated with red light (652 nm) at fluences of 0 to 12 J/cm
2
. A microplate 
spectrophotometer was employed for detecting fluorescence from SOSG using the 
“slow kinetic” mode, with fluorescence emission at 505 nm measured following 
excitation at 525 nm (2 nm monochromator band pass). For HPF, fluorescence emission 
was measured at 525 nm after excitation at 492 nm (2 nm monochromator band pass).  
The effectiveness of hybrids in aPDT was expected to be influenced by the 
efficiency of 
1
O2 and/or •OH production following illumination. The experiments 
Step 1:        Hybrids and MB added to wells 
to a concentration of 50 µM 
in PBS. Well volume = 85 µL 
Step 2:  40 µL probe (5 µM), 40 µL 
D
2
O and 35 µL MeOH 
added to each well 
Step 3:  
10 µM hybrid and MB solutions 
illuminated with red light (652 nm) 
at 0, 2, 4, 6, 8, 10 and 12 J/cm
2 
before transfer to plate reader 
Red light source 
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described were not able to quantitative 
1
O2 and •OH production but they allowed direct 
comparison of the ROS-producing efficiencies of the hybrids to MB.  
3.2.1 Reserpine-Containing Hybrids 
Figure 3.7 shows the relative fluorescence produced by MB and reserpine-
containing hybrids 47-50 in the presence of SOSG and HPF. In these experiments, a 
noncoherent light source with 30 nm-band-pass filters at ranges of 652 ± 15 nm were 
used for illumination. The total power output provided from the fibre bundle was 300 
mW. The plates were arranged to give an irradiance of 100 mW/cm
2
. The power (P) in 
watts was equal to the energy (E) in joules, divided by the time period (t) in seconds: 
 
P(W) = E(J) / t(s) 
 
       So 
Watt/cm
2
 = joule/cm
2
 per second 
Therefore a 30 second illumination with irradiance of 100 mW/cm
2
 over a 3 cm
2
 area 
gave a fluence of 1000 mJ/cm
2
 or 1 J/cm
2
. Fluences were increased by extending the 
period of illumination. 
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Figure 3.7 Comparison of (A) 
1
O2 and (B) •OH production by reserpine-containing 
hybrids 47-50 to MB upon illumination with red light (652 nm). Light with power 
output 300 mW was applied 0.5-5.0 min for (
1
O2) and 0.5-6.0 min for (•OH), 
respectively.  
 
In all cases the reserpine-containing hybrids showed significantly lower levels of 
1
O2 and •OH production than MB. Indeed, all hybrids except 48 showed very little •OH 
production. Although much less than MB, the four compounds did produce significant 
1
O2, with 47 producing the highest levels. 
Figure 3.7(A) shows data point for 
1
O2 production from MB after being 
formulated in cremophore EL
® 
(CrEL). For later cell-based in vitro and in vivo 
experiments it was necessary to identify a suitable aqueous formulation for the hybrids 
as they were not sufficiently water soluble and organic solvents suitable for the hybrids 
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(MeOH and CH2Cl2) are unsuitable for biological experiments. Identifying a 
formulation that did not suppress ROS production was therefore considered crucial. As 
shown in Figure 3.7(A), the data for 
1
O2 production by MB in CrEL tracked closely 
with the data for MB in the PBS/MeOH mixture, confirming that CrEL was an excellent 
formulation for the later in vitro and in vivo experiments. 
Photobleaching is the process whereby photosensitizers decompose during exposure to 
light. The degree of decomposition usually depends on the light intensity and period of 
illumination. As the release of 
1
O2 was measured over a period of 0.5-5.0 min, the 
1
O2 
experiments were able to provide information about photobleaching of hybrids. As 
shown in Figure 3.7, at fluences of more than 6 J/cm
2
 MB showed signs of 
photobleaching, as evidenced by the flattening of the curve. The reserpine-containing 
hybrids on the other hand showed no evidence of photobleaching at fluences up to 10 
J/cm
2
.  
3.2.2 Pterostilbene-Containing Hybrids 
1
O2 and •OH production by pterostilbene-containing hybrids 51-54 is shown in 
Figure 3.8. As observed with the reserpine-containing compounds, the pterostilbene-
based hybrids all showed very little •OH production but they also showed very little 
1
O2 
production. Only hybrid 52 produced significant 
1
O2 but it was markedly less than MB. 
No photobleaching effects were evident with 52. 
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Figure 3.8 Comparison of (A) 
1
O2 and (B) •OH production by pterostilbene-containing 
hybrids 51-54 to MB.  
 
3.2.3 INF55-Containing Hybrids 
1
O2 and •OH production by INF55-containing hybrids 55-58 compared to MB is 
shown in Figure 3.9. Once again, these hybrids all showed very little •OH production 
under the experimental conditions. Importantly, while still less than MB, all INF55-
containing hybrids showed robust 
1
O2 production. For example, at 10 J/cm
2
 55 
produced 83% of the 
1
O2 produced by MB at the same fluence. 
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Figure 3.9 Comparison of (A) 
1
O2 and (B) •OH production by INF55-containing 
hybrids 55-58 to MB. 
3.2.4 INF271-Containing Hybrids 
1
O2 and •OH production by INF271-containing hybrids compared to MB is 
shown in Figure 3.10. As observed with the other three classes, these hybrids produced 
essentially no •OH, although 60 showed evidence of slight •OH production at high 
fluence. Hybrids 59 and 61 showed minimal 
1
O2 production relative to MB even at high 
fluence. At 4 J/cm
2 
60 showed strong 
1
O2 production, however, the 
1
O2 did not increase 
with application of higher fluence, suggesting that photobleaching was occurring. 
1
O2 
production from 62, on the other hand, steadily increased with higher fluence, indicating 
the compound is more photostable than 60. At 10 J/cm
2 
62 produced 86% of the 
1
O2 
produced by MB at the same fluence. 
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Figure 3.10 Comparison of (A) 
1
O2 and (B) •OH production by INF271-containing 
hybrids 59-62 to MB. 
 
3.2.5 Quantum Yields of 
1
O2 and •OH Production by Hybrids 47-62 
While the above analysis provided qualitative comparisons between 
1
O2 and 
•OH production by hybrids 47-62 relative to MB a more quantitative treatment was 
possible based on fluorescence quantum yields. Fluorescence quantum yield is defined 
as the ratio of the number of photons emitted from a fluorophore to the number of 
photons absorbed. Relative fluorescence quantum yields in the SOG and HPF assays 
can be determined by comparing the observed fluorescence for hybrids to MB, which 
produces a known quantum yield (ΦΔ (SOG) = 0.52, ΦΔ (HPF) = 0.46) under the 
experimental conditions. The quantum yields for hybrids in each assay relative to MB 
are then calculated using the equation: 
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Where Int is the area under the emission curve (on a wavelength scale), A is 
optical density at the excitation wavelength and n is the refractive index of the solvent. 
The subscript MB refers to the respective values for methylene blue. Since the same 
energies of light and the same solvent etc. were used for MB and the hybrids the relative 
quantum yields could be obtained by measuring the area under the fluorescence curves 
(Figures 3.7-3.10) and dividing by the area under the MB curve. For each fluorescence 
curve a best-fit trendline was obtained using polynomial regression and the relative 
integration calculated over the appropriate fluence range (0-10 J/cm
2 
for SOG and 0-12 
J/cm
2
 for HPF). The fluorescence quantum yields for hybrids 47-62 relative to MB in 
the SOG and HPF assays are provided in tabular form in Appendix 3.1. The data are 
presented in graphical form in Figure 3.11 where % ΦΔ relative to MB is presented for 
hybrids in both assays. The data are colour-coded as described earlier (Chapter 3.1) 
based on the different linker types. 
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Figure 3.11 Changes in SOG and HPF % quantum yields for hybrids 47-62 relative to 
MB. 
 
Reserpine-containing hybrids 47-50 showed 
1
O2 and •OH quantum yields at 
around 20-55% of MB. Hybrid 48 showed the highest •OH production at around 55%, 
while 47 produced the most 
1
O2 (46%). Pterostilbene-containing hybrids 51-54 all 
showed very low 
1
O2 and •OH quantum yields (less than 20% relative to MB).  
INF55-containing hybrids 55-58 showed much higher 
1
O2 quantum yields than 
•OH. 
1
O2 production for 55 at 65% relative to MB was the highest of all the compounds 
tested. Hybrid 58 also showed strong 
1
O2 production at about 60% of MB and showed 
the strongest •OH production in this series at ~ 30 of MB.  
INF271-containing hybrid 62 produced the third highest amount of 
1
O2 relative 
to MB. Hybrid 60 produced reasonable •OH and 
1
O2 quantum yields, although the 
1
O2 
generation of this hybrid reduced after 6 J/cm
2 
(Figure 3.11), suggesting photobleaching 
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was occurring with this compound. The significantly higher 
1
O2 quantum yields relative 
to •OH quantum yields in the INF55 and INF271-containing hybrid series suggested 
that these compounds would likely undergo Type II processes when applied in PDT 
(See Chapter 1.9).  
3.3 In Vitro Antibacterial Photodynamic Activity 
3.3.1 Formulation Vehicle for Hybrids 
In the above cell free experiments the hybrids were all significantly soluble in 
the aqueous PBS/MeOH solutions. For cell-based in vitro and in vivo aPDT 
experiments, MeOH was unsuitable as a co-solvent due to its toxicity. It was therefore 
necessary to identify a formulation vehicle that was both non-toxic and capable of 
solubilizing the hybrids. Other than MeOH, the best solvents for dissolving the hybrids 
were found to be CH2Cl2 and CHCl3, but these are not miscible with water and were 
thus unsuitable. A range of commercially available detergents were explored as 
formulation vehicles for the hybrids.  
Encapsulation of reserpine-containing hybrid 49 into micelles was examined, 
using the detergents tween 60 (T60), cremophor EL (CrEL), triblock copolymers F127 
(PL-F127) and poloxamer 388 (POL388). Hybrid 49 was chosen as a representative 
hybrid for solubility examinations because it was observed to be particularly insoluble 
in aqueous solution. Micellar solutions of 49 were prepared by initially dissolving the 
compound in CH2Cl2 at 2-3 mM. This solution was added to a 100 mg/mL solution of 
each detergent in CH2Cl2 and the combined mixtures were sonicated until a 
homogenous solution was obtained. The organic solvent was then removed under 
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reduced pressure and the remaining thin film of 49 was redissolved in PBS to create a 
homogenous 500 µM aqueous micellar solution of the compound.  
 
 
 
 
 
 
 
 
 
Figure 3.12 Fluorescence emission spectra of hybrid 49 formulated in micelles 
generated with tween 60 (T60), cremophor EL (CrEL), triblock copolymers F127 (PL-
F127) and poloxamer 388 (POL388). Spectra recorded in PBS and MeOH are shown 
for comparison. 
 
Figure 3.12 shows the fluorescence emission spectra of hybrid 49 in 10 µM 
micellar solutions. The equivalent spectrum of 49 in PBS and MeOH is shown for 
comparison. A large increase in the emission intensity at 680 nm was observed for 49 
when encapsulated in CrEL and T60 (excitation at 600 nm) compared to the other 
micelles, PBS and MeOH.  
The increased fluorescence observed with CrEL and T60 suggests that these 
detergents minimise aggregation and are excellent solubilisers for 49. CrEL is widely 
used as a formulation or drug delivery vehicle for many poorly water-soluble drugs
180
 
and is generally considered to be nontoxic.
181
 As described on 3.2.1, CrEL was also 
found to have no effect on 
1
O2 production from MB. Based on this, CrEL was chosen as 
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the vehicle for formulating the hybrids in all cell-based experiments (Chapter 3) and in 
vivo studies (Chapter 4). 
3.3.2 Preliminary aPDT Screening of Hybrids against MRSA USA300 
MRSA USA300 was chosen as a model Gram-positive organism for preliminary 
screening of hybrids for aPDT activity. USA300 is a major source of community-
acquired MRSA infections in the USA, Canada, and Europe
182
 and is responsible for 
major skin and soft-tissue infections,
183
 community-acquired pneumonia and catheter-
related bloodstream infections.
184
 The strain is isogenic with wild-type MRSA making it 
a good test organism for preliminary screening.  
Increasing concentrations of CrEL-formulated hybrids (1-20 µM in PBS) were 
incubated for 30 min in the dark at room temperature with suspensions of USA300 cells 
(10
8
 CFU/mL). Aliquots were transferred to 96-well plates and illuminated with red 
light (652 nm) at a fluence of 6 J/cm
2
. Remaining colonies were counted after overnight 
growth and the results plotted as survival fractions at the different concentrations. Dark 
controls (same procedure without application of red light) were included in all 
experiments. No significant dark toxicity was observed with any of the hybrids or MB 
over the concentration range and fluences tested. No differences in dark toxicity of MB 
were observed when formulated in CrEL compared to PBS/MeOH (Appendix 3.2). 
Figure 3.13 shows the photodynamic killing of MRSA USA300 by hybrids 47-
62, grouped according to the attached EPI (e.g. reserpine-containing hybrids etc.). Also 
shown for comparison is the photodynamic killing by MB under identical conditions. 
MB showed a dose dependent effect over the concentration range 0-20 µM, producing a 
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~ 2-log reduction in cell viability at the highest concentration. When MB was 
formulated in CrEL an additional 1-log killing of cells was observed at the highest 
concentration (Figure 3.13(A)), suggesting that CrEL potentiates the photodynamic 
activity of MB. This funding further supported for its use as a formulation vehicle for 
exploring the aPDT effects of hybrids. 
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Figure 3.13 Photodynamic inactivation of MRSA USA300 by hybrids 47-62. Cells (10
8
 
CFU) were incubated for 30 min with CrEL-formulated hybrids at 0-20 µM in PBS and 
illuminated with 652 nm light (100 mW/cm
2
, fluence = 6 J/cm
2
). Aliquots were 
removed from the suspensions after light delivery and CFUs determined after overnight 
growth in a 37 
o
C incubator. The remaining cells were plotted as survival fractions. 
Data represent the mean of 3-5 independent experiments ± SEM.  
 
Reserpine-containing hybrids 47-50 showed very little photodynamic 
inactivation, except for hybrid 50, which produced a 2-log reduction in cells at the 
highest concentration (20 µM, Figure 3.13(B)). Similarly, none of the pterostilbene-
containing hybrids 51-54 showed significant photodynamic activity (Figure 3.13(C)). 
More encouraging results were obtained with INF55-containing hybrids, where 
compound 58 showed a very strong dose-dependent effect and produced a 6-log 
reduction in cells at 20 µM. This represented a 3-log increase in killing relative to MB 
(formulated in CrEL) at the same concentration. Hybrid 56 also showed good dose-
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dependency and a 3-log reduction in cells at 20 µM. Hybrids 55 and 57 showed only 
slight activity (Figure 3.13(D)).  
INF271-containing hybrids 59, 60 and 62 all showed dose-dependent killing, 
whereas no activity was observed with 61 (Figure 3.13(E)). At 20 µM, 60 produced a 4-
log reduction in cells, or 1-log greater than MB (in CrEL). Hybrid 59 showed killing 
equivalent to MB (in CrEL) while a 2-log kill was observed with 62.  
To facilitate comparisons between the compounds, the data presented in Figure 
3.13 were combined into a single figure (Figure 3.14). In this analysis, the 20 µM data 
points for each compound were expressed as the log reduction in survival. Hybrids 56-
58 carrying INF55-based EPIs were clearly active compounds, especially 58, which 
showed 3-log greater activity than MB in CrEL. INF271-containing hybrids 59 and 60 
were clearly active and 62 also showed some effect. The only other active hybrid 50 
(containing an appended reserpine) produced an equivalent effect to MB (in CrEL). 
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Figure 3.14 Summary of photodynamic inactivation of MRSA USA300 by MB (in PBS 
and CrEL) and hybrids 47-62. 
 
Examples from each of the four different linker classes were found to show 
activity, suggesting that the structure of the linker may not be crucial. It was noted, 
however, that except for 59, which contained a piperazine-based linker, hybrids that 
showed the greatest photodynamic inactivation carried N,N’-dimethylethylenediamine-
based linkers. As might be expected, active compounds 56, 58, 60 and 62 were strong 
producers of 
1
O2 (Figure 3.11) but, surprisingly, hybrid 55, which was the strongest 
1
O2 
producer (Figure 3.9), showed no photodynamic activity. This observation suggests that 
strong 
1
O2 production is not on its own sufficient to create hybrids with potent aPDT 
activity. 
3.3.3 Photodynamic Activity of Hybrids against S. aureus Mutants 
The above experiments indicated that four hybrids, including two from the 
INF55-containing series (56 and 58) and two from the INF271-containing series (59 and 
0
1
2
3
4
5
6
7log (reduction in 
survival fraction)  
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60), showed the strongest photodynamic inactivation of MRSA USA300. Based on this, 
these compounds were advanced to further study of their photodynamic effects against a 
panel of S. aureus strains. To examine whether the photodynamic effects of the chosen 
hybrids were being influenced by the NorA pump, their aPDT activities were examined 
in NorA knockout (NorA-), wild-type (WT) and NorA-overexpressing (NorA++) S. 
aureus cells. These strains respectively contain none (or reduced), basal and elevated 
levels of the NorA pump. MB was included in the experiments for comparison. Tegos et 
al showed that the aPDT activity of MB varies against NorA knockout (K1758), wild-
type (8325-4) and NorA-overexpressing (K2361) S. aureus cells, where higher NorA 
expression reduced activity.
154
 As explained in Chapter 1.12, this is consistent with MB 
being a NorA substrate.  
In the current experiments, the same three S. aureus strains were incubated with 
the four hybrids (formulated in CrEL) or MB at 20 µM for 30 min before centrifuging 
and washing to remove compound not taken up into or bound to cells. The cells were 
then re-suspended in sterile PBS and transferred to 96-well plates and illuminated with 
652 nm red light of increasing fluence (0-16 J/cm
2
). These solutions were serially 
diluted from 10
-1
-10
-6
 to facilitate final CFU counts. Cells were then incubated 
overnight before performing and determining survival fractions. A summary of the 
assay is provided in Figure 3.15. The phototoxicity results are shown in Figure 3.16.  
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Figure 3.15 Schematic summary of aPDT assay using NorA-, WT and NorA++  
S. aureus cells. 
 
If our hypothesis was correct and the attached NorA inhibitors (INF55 for 56 
and 58 and INF271 for 59 and 60) in the hybrids were blocking the NorA pump, thereby 
increasing intracellular concentrations of the attached MB PS and producing increased 
phototoxicity (Chapter 1.14), the following observations would be expected from these 
experiments: (1) hybrids should show higher relative phototoxicity compared to MB in 
the wild-type and NorA++ strains due to the presence of the NorA pump and (2) no 
change in phototoxicity relative to MB in the NorA- strain.  
In agreement with the Tegos study,
154
 the NorA- strain showed more than 4-log 
units of killing in the presence of MB at the maximum fluence 16 J/cm
2
, while the wild-
type and NorA++ strains showed ~ 2 log lower killing (Figure 3.16 (A)). Phototoxicity 
against the NorA- strain for the four hybrids was very similar to MB, where they all 
produced cell kills within 1 log unit of MB at 16 J/cm
2
. For the wild-type strain, where 
MB produced a 2 log kill at 16 J/cm
2
, hybrids 56, 58 and 59 all showed more than 1 log 
greater killing than MB, while 60 showed equivalent killing to MB. Excitingly, all four 
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strain. 
Collectively these results were in agreement with the proposed hypothesis. A graphical 
summary of the results is provided in Figure 3.17. 
 
 
 
 
 
 
 
 
 
 
 
                                                   
 
 
 
 
 
1.00E-08
1.00E-06
1.00E-04
1.00E-02
1.00E+00
0 4 8 12 16
su
rv
iv
al
 f
ra
ct
io
n
 
fluence (J/cm2) 
C 
WT
Knock out
NorA++
1.00E-08
1.00E-06
1.00E-04
1.00E-02
1.00E+00
0 4 8 12 16
su
rv
iv
al
 f
ra
ct
io
n
 
fluence (J/cm2) 
B 
WT
NorA-
NorA++
 
101 
 
 
 
 
 
 
 
 
 
 
Figure 3.16 Photodynamic inactivation of NorA knockout (NorA-), wild-type (WT), 
and NorA-overexpressing (NorA++) S. aureus strains by: (A) MB, (B) 56, (C) 58, (D) 
59 and (E) 60. All compounds were present at 20 µM. Data represent the mean ± SEM 
from three independent experiments. 
 
Figure 3.17 Summary of photodynamic inactivation of NorA knockout (NorA-), wild-
type (WT) and NorA-overexpressing (NorA++) S. aureus strains by MB and hybrids 
56, 58, 59 and 60. 
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 3.3.4 Concentration-Dependence of Hybrid Phototoxicity 
Three hybrids from the S. aureus mutant aPDT experiments, two INF55-
containing hybrids 56 and 58 and one INF271-containing hybrid 60, were advanced to 
dose-response studies. In these experiments, photodynamic inactivation by each 
compound was measured at increasing concentrations (0-160 µM) against the S. aureus 
panel (i.e. K1758 NorA-, 8325-4 WT and K2361 NorA++) at a constant fluence of 10 
J/cm
2
. MB was also included in the experiments for comparison.  
Solutions of CrEL/PBS-formulated hybrids (0-160 µM) were incubated for 30 
min in the dark with S. aureus cells (10
8
/mL) at room temperature. The cells were 
centrifuged and washed before being resuspended in PBS and illuminated with 10 J/cm
2 
red light. The centrifuge/washing step served to remove hybrid molecules not contained 
within the cells or adhered to their surfaces. CFUs were counted after overnight growth 
and the survival fractions determined. Plots of survival fractions versus concentration as 
shown in figure 3.18. Dark control experiments were also performed where an identical 
procedure was followed without application of light. These dark toxicity data are 
provided in Appendix 3.3.  
Surprisingly, MB showed evidence of dark toxicity, especially against the 
NorA- and NorA++ strains, where it reduced the survival fractions in a dose-dependent 
manner up to a maximum of 3-4 logs at 160 µM. The three hybrids 56, 58 and 60 all 
showed lower dark toxicity than MB, reducing the survival fractions by a maximum of 
2 log units at 160 µM. In most instances, however, only 1 log reductions were observed 
in the dark with the hybrids at this high concentration. 
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When the light was applied, MB at 80 µM provided a 7 log kill against the 
NorA
-
 strain that did not increase as the concentration was raised to 160 µM. MB 
produce similar results against the WT and NorA++ strains, where ~ 5-7 log kills were 
observed at 80 µM. 
INF271-containing hybrid 60 produced more than 3 log units of killing at 40 µM 
against the NorA- strain and 4 logs at 80 µM. Increased killing was not observed as the 
concentration was raised to 160 µM. Similar results were obtained against the WT strain 
but the NorA++ strain showed higher sensitivity, experiencing a 5 log kill at 80 µM and 
7 log at 160 µM.  
INF55-containing hybrids 56 and 58 showed very strong and dose-dependent 
phototoxicity against all three S. aureus strains (Figure 18(C) and 18(D), respectively). 
At 20 µM 56, a 5-log kill was observed against the NorA- strain essentially complete 
eradication was observed at 80 µM. The WT strain showed a 5-log kill at 80 µM and 6-
log kill at 160 µM. The NorA++
 
strain showed an impressive 4-log kill at 20 µM and 
total eradication at 40 µM. Hybrid 58 produced similar results to 56 but with almost 
complete eradication of the NorA- strain occurring at 40 µM.   
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Figure 3.18 Concentration-dependent phototoxicity of (A) MB and hybrids (B) 60, (C) 
56 and (D) 58 against S. aureus NorA knockout (NorA-), wild-type (WT) and NorA-
overexpressing (NorA++) strains. Data represent the mean ± SEM from 3-4 
independent experiments. 
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3.4 Cell Uptake Studies with Hybrids 56, 58 and 60 
Hybrids 56 and 58 showed significantly enhanced cell-killing potency against 
the NorA- and NorA++ S. aureus strains relative to MB, but similar killing to MB 
against the WT strain. These results conflicted with our design hypothesis, where 
hybrids would have been expected to produce stronger activity against the WT strain 
(rather than the NorA- strain) relative to MB.  
The role of the NorA pump in the observed activity of hybrids was further 
probed by measuring the uptake of 56, 58, 60 and MB into the NorA-, WT and NorA++ 
S. aureus cells. 
Fluorescence versus concentration calibration curves were obtained by 
measuring the fluorescence of the hybrids and MB across a concentration range (0-3 
µM) in the presence of sodium dodecyl sulfate (SDS). To measure compound uptake 
into cells, 10
8
 CFUs were incubated for 30 min with 20 µM hybrids or MB. The cells 
were centrifuged and washed to remove compound not bound to or taken up into cells 
and then redissolved in PBS and digested in SDS overnight. The fluorescence of digest 
solutions was measured and the concentrations of hybrids and MB determined from the 
calibration curves. The uptake results for hybrids 56, 58 and 60 are summarized in 
Figure 3.19, with MB included for comparison.  
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Figure 3.19 Uptake of MB and hybrids 56, 58 and 60 (molecules per cell) by S. aureus 
NorA knockout (NorA-), wild-type (WT) and NorA-overexpressing (NorA++) strains. 
Data represent the mean ± SEM from 3-4 independent experiments. 
 
Figure 3.19 shows that uptake of hybrids 56, 58 and 60 by all three S. aureus 
strains was significantly higher than MB. As expected, MB uptake was greatest in the 
NorA- strain and least in the  NorA++ strain, in alignment with it being a NorA 
substrate.
154
 Approximately 4.7 ± 0.3 x 10
9 
molecules of INF55-containing hybrid 56 
were taken up per cell by the NorA- strain, or 1.3 times more than MB. Uptake of 56 
into the other two strains did not differ appreciably (4.6 ± 0.2 x 10
9 
and 4.3 ± 0.2 x 10
9 
molecules/cell for WT and NorA++ strains, respectively). The other two hybrids 58 and 
60 showed uptake levels essentially identical to those of 56 across the three strains. 
Observing that 56, 58 and 60 show identical uptake across the three S. aureus strains, 
despite their differences in NorA expression, suggested that unlike MB, these hybrids 
are not substrates for the NorA pump. The question of whether the hybrids were also 
serving to block was addressed next. 
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3.5 EPI Activity of Hybrids  
The NorA pump inhibitory activity of INF55 and INF271 is well characterized
98
 
but it was unknown whether they retained this activity when part of the hybrids. The 
effects of the structural changes introduced through incorporation within hybrids on 
NorA activity were explored by measuring the photodynamic inactivation of S. aureus 
by MB in the presence of INF55, INF271 and various INF55-containing (84-87) and 
INF271-containing (92-95) synthetic intermediates that contained just the attached 
linker groups and no MB moiety. It was reasoned that if the modified EPIs in the 
synthetic intermediates produced equivalent activity to their parent EPIs then it could be 
inferred that the structural changes introduced had not significantly impacted their NorA 
inhibitory effects. NorA++ cells were used for these experiments to maximise the 
observed differences in photodynamic cell killing by the various MB/EPI treatments. 
NorA++ S. aureus cells were treated with 10 µM INF55/INF271 or 84-87/92-95 
and 20 µM solutions of MB added before incubation for 30 min. Cells were then 
illuminated with increasing fluences of red light (0-16 J/cm
2
) and survival fractions 
determined (as described in Chapter 3.3.2).  
 
108 
 
1.00E-08
1.00E-06
1.00E-04
1.00E-02
1.00E+00
0 4 8 12 16
su
rv
iv
al
 f
ra
ct
io
n
 
fluence (J/cm2) 
MB 33
INF271/ MB
92/MB
94/MB
93/MB
95/MB
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.20 Photodynamic inactivation of NorA++ S. aureus cells by MB alone and in 
combination with INF55, INF271, INF55-containing synthetic intermediates 84-87 and 
INF271-containing intermediates 92-95. Data represent the mean ± SEM from 3-4 
independent experiments. 
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Figure 3.20 shows that MB produced approximately 2-log units of killing in the 
absence of EPIs at the maximum fluence of 16 J/cm
2
. As expected, introduction of 
INF55 and INF271 greatly increased cell killing. At 16 J/cm
2
 an additional 4 log units 
of killing were observed with both EPIs. Similar cell kills were observed with the EPI 
derivatives compared to their parent EPIs, suggesting that the derivatives all retained 
their ability to block the NorA pump. These results imply that at least some of the 
increased uptake of 56, 58 and 60 relative to MB (Figure 3.19) arises from the ability of 
the appended EPI structures in the hybrids to inhibit the NorA pump, rather than simply 
because the hybrids are not substrates from the pump.  
To support these findings, the pump inhibitory activities of hybrids 56, 58 and 
60 were examined in experiments where they were co-administrated with the antibiotic 
ciprofloxacin, a well-known NorA substrate.
31c,185
 In these experiments, the 
antibacterial activity of ciprofloxacin was measured (in the dark) and compared to its 
activity in the presence of MB or the hybrids. A bioluminescent S. aureus strain
126b
 was 
used in these experiments, with the level of bioluminescence observed being 
proportional to the number of surviving cells after treatment. Use of the bioluminescent 
strain eliminated problems that arise from the deep blue colour of the hybrids and MB 
interfering with UV/Vis microplate readings.  
Bioluminescence of S. aureus (100 µL of 10
6
 CFU/mL MRSA USA300) was 
measured after overnight incubation of the cells in the dark with the increasing 
concentrations of ciprofloxacin, either alone or in the presence of MB (20 µM) or 
hybrids (10 µM). Bioluminescence versus [ciprofloxacin] curves are shown in Figure 
3.21. Ciprofloxacin alone showed dose-dependent cell killing above 0.004 µg/mL and 
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essentially full eradication at around 0.128 µg/mL. Surprisingly, MB showed some 
synergic killing with ciprofloxacin in the absence of light. The reasons for this synergy 
are unknown but one possibility is that MB acts as a competitive substrate for NorA, 
thus lowering the rate of NorA-mediated ciprofloxacin efflux. The three hybrids 56, 58 
and 60 all strongly potentiated the cell-killing effects of ciprofloxacin.   
Figure 3.21 Effects of MB and hybrids 56, 58 and 60 on survival of bioluminescent S. 
aureus cells when coadministered with increasing concentrations of ciprofloxacin.  MB 
was present at 20 µM and the hybrids at 10 µM. Data represent the mean ± SEM from 
3-4 independent experiments. 
 
The synergistic effects provided further evidence that these hybrids serve to 
block the NorA pump and not simply evade its action. Blocking of the pump in these 
experiments led to increased intracellular concentrations of the antibiotic to potentiating 
its cell killing effects. 
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3.6 Summary and Conclusions 
 In this Chapter the photophysical properties of hybrids were measured and 
compared with MB. The UV/Visible absorption spectra of MB and all hybrids (Figure 
3.1) showed that the λmax1 and λmax2 bands arising from the MB moiety in the hybrids 
and their extinction coefficients changed only slightly relative to MB, indicating that the 
absorption properties of the MB chromophore had not been markedly changed by 
addition of the appended EPI-linker structures. 
SOSG and HPF probes were used to measure production of 
1
O2 and •OH, 
respectively, from the hybrids relative to MB. Of the four different classes of hybrids, 
the reserpine-containing compounds 47-50 produced the most •OH, although the level 
were quite low (Figure 3.11). The same hybrids showed significant production of 
1
O2. 
In contrast, pterostilbene-containing hybrids 51-54 showed virtually no •OH production 
and very little 
1
O2 relative to MB. Examination of the aPDT activity of 47-50 and 51-54 
against the model organism MRSA USA300 revealed that neither the reserpine-
containing nor pterostilbene-containing hybrid classes showed any significant activity. 
Observing •OH and 
1
O2 production by reserpine-containing hybrids 47-50 but no aPDT 
activity against MRSA USA300 demonstrates that production of ROS is not in itself 
sufficient to create hybrids with robust aPDT activity. 
INF55-containing hybrids 55-58 showed only slight •OH production but they all 
showed stronger production of 
1
O2. INF271-containing hybrids 59-62 also showed very 
little •OH production and only 60 and 62 showed good 
1
O2 production. In the MRSA 
USA300 aPDT assays, INF55-containing hybrids 56 and 58 and INF271-containing 
hybrids 60 and 62 showed the strongest cell killing effects. 
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Lack of •OH production while at the same time producing significant amounts 
of 
1
O2 is evidence that the aPDT activity observed with 56, 58, 60 and 62 was probably 
arising mostly through Type II mechanisms (See Chapter 1.9). Poor •OH production by 
all of the hybrids 47-62 was probably a result of the many additional hydrogen atoms in 
the molecules relative to MB. MB contains only strong aryl C-H bonds, whereas the 
hybrids contain many SP
3
 C-Hs, which might be abstracted by •OH to quench the 
radical. 
The two INF55-containing hybrids 56 and 58 and one of the INF271-containing 
compounds 60 were advanced to experiments examining the dose-dependency of their 
aPDT effects against the NorA-, WT and NorA++ S. aureus strains. Compounds 56 and 
58 showed similar effects, with the slightly more potent 58 completely eradicating the 
NorA- and NorA++ strains at 40 µM and producing a 5-log kill at this concentration 
against the WT strain. Compound 60 showed similar potency to MB against the 
NorA++ strain but was less effective than MB against the NorA- and WT strains. 
Uptake of 56, 58 and 60 was explored next with the S. aureus panel. The key 
observation here was that the three compounds showed significantly greater uptake than 
MB in all strains and showed identical uptake to each other in all three strains. It was 
concluded that 56, 58 and 60 were either evading the NorA pump and/or inhibiting the 
NorA pump. 
The question of whether the compounds were blocking and/or evading the NorA 
pump was addressed by aPDT experiments with combinations of MB and various 
INF55- and INF271-containing synthetic intermediates. These substituted INF55 and 
INF271 analogues all strongly potentiated the aPDT activity of MB, confirming that the 
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structural changes that were introduced into the EPIs did not suppress their EPI activity. 
These results supported that the increased aPDT activity of 56, 58 and 60 relative to MB 
was arising, at least in part, because their EPI portions were serving to block the NorA 
pump, and the resulting increases in intracellular MB were responsible for increase cell 
killing. 
Further confirmation of the NorA pump-blocking activity of the hybrids was 
obtained from experiments with bioluminescent S. aureus strain and the 
fluoroquinolone antibiotic ciprofloxacin. Each of the compounds 56, 58 and 60 showed 
strong potentiation of ciprofloxacin’s antibiotic effects at 10 µM. As ciprofloxacin is a 
known substrate for the S. aureus NorA pump,
31c,185
 its potentiation in the presence of 
the hybrids was further evidence that the compounds block this pump. 
In summary, experiments in this Chapter validated the principal around which 
MB-EPI hybrids were designed for use in aPDT. Hybrid 58, carrying  INF55 as the EPI 
and an N-acyl-N,N’-dimethylethylenediamine linker to MB, was identified as the most 
active compound from these studies and advanced to an in vivo aPDT MRSA infection 
model (Chapter 4). 
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Chapter 4 
In Vivo Antimicrobial 
Photodynamic Activity of Lead 
Hybrid 58 in a Murine MRSA 
Wound Infection Model 
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4.1 Staphylococcus aureus and Humans 
S. aureus is a facultative aerobic Gram-positive coccus belonging to the 
Staphylococcaceae family. It is frequently found as a commensal organism in the 
human respiratory tract and on the skin,
186
 but has also been a well-known human 
pathogen since it was first described by Sir Alexander Ogston in 1880.
187
 Production of 
coagulase and the ability to ferment mannitol are two of the main characteristics that 
distinguish S. aureus from other staphylococci. Mean carriage rates in the general 
population are around 40% and it is estimated that ~ 20% of the population are carriers 
and that 60% are occasionally colonised.
188
  
S. aureus can cause a spectrum of infections ranging from superficial skin 
infections to severe, invasive diseases, including bacteraemias.
189
 Other organs can also 
be infected, such as the eye, skin, connective tissues, bones, joints, heart, lungs and 
gastrointestinal and urinary tracts.
190
 S. aureus is known to degrade a number of host 
proteins and tissues through production of a range of enzymes and toxins in its quest for 
nutrients.
191
 These enzymes include haemolysins, proteases, lipases and hyaluronidase. 
S. aureus proteases are able to modulate numerous host immune responses and can 
interfere with the kallikrein-kinin pathway. This leads to increased vascular 
permeability, which ensures a plentiful supply of nutrients for the bacteria at the site of 
infection.
192
 S. aureus proteases have been implicated in the pathogenesis of skin 
disorders, such as atopic dermatitis.
193
  
In addition to obtaining nutrients, S. aureus must also be able to repel constant 
attacks from the innate and acquired immune systems of its human host. S. aureus 
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produces an extensive array of virulence factors for this purpose. It can produce a 
variety of toxins and factors that kill leukocytes, inhibit neutrophil chemotaxis, resist 
phagocytosis, inactivate complement and neutralise host antimicrobial peptides.
194
 
Many of these virulence factors are multifunctional, for example protein A. This cell 
wall-associated protein causes release of pro-inflammatory cytokines from monocytes 
and fibroblasts
195
 and also binds to the Fc region of human IgG to disturb antibody 
opsonisation.
196
  
While numerous antibiotics have been used effectively against S. aureus 
infections over many decades, the frequency of these infections has increased gradually 
with time and has been accompanied by increases in mortality rates.
197
 Today, S. aureus 
is the most frequent cause of hospital-acquired infections, including surgical site 
infections,
198
 and is the most common causative agent of skin and soft tissue infections 
in the North and Latin Americas and Europe.
199
 An analysis of the burden of skin and 
skin-structure infections in the USA caused by S. aureus found that these infections are 
associated with high treatment costs, estimated at ~ $11,000 per patient per episode.
200
  
4.2 Methicillin-Resistant S. aureus (MRSA) 
MRSA was first reported in 1961
201
 and has since undergone significant 
evolutionary changes and epidemiologic expansion.
202
 It was so-named because it 
expresses penicillin-binding proteins (PBPs) that show reduced affinity for penicillins 
(e.g. methicillin) and other common 𝛽-lactam antibiotics.202 Currently, more than half 
of nosocomial S. aureus infections in many countries are caused by MRSA.
203
 In the 
United States, MRSA accounts for almost 60% of clinical S. aureus strains isolated 
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from intensive care units.
204
 Isolates from blood cultures taken from bacteraemia 
patients in England revealed that the proportion of MRSA infections has increased 
dramatically there from 5% in 1990 to 40% in 2000.
205
 As well as being a major cause 
of hospital-acquired infections all over the world, MRSA is now widespread in the 
community, especially in nursing and residential homes.
200b,206
 Indeed some MRSA 
strains are becoming the dominant pathogen in the community (i.e. community-acquired 
MRSA).
207
  
Vancomycin, from the glycopeptide family of antibiotics, has been used 
extensively in clinical practice for complicated S. aureus and other Gram-positive 
infections over several decades. In the last 20 years, however, concerns have been 
growing over the increasing minimum inhibitory concentration (MIC) of vancomycin 
against MRSA.
208
 As it is expected that vancomycin resistance will continue to increase 
in the coming years, it seems only a matter of time before MRSA becomes resistant to 
this antibiotic. There is thus an urgent need to develop new antibiotics and approaches 
to replace vancomycin as its effectiveness wanes. 
4.3 Skin and Soft Tissue S. aureus Infections and their Treatment 
S. aureus is the most frequently isolated pathogen from skin and skin-structure 
infections.
209
 Optimal treatment regimes for staphylococcal skin and soft tissue 
infections are constantly being modified.
210
 Due to the high incidence of resistance, β-
lactams are no longer an effective treatment choice. Although clindamycin can be 
effective, its use has been connected with increasing rates of Clostridium difficile-
associated diarrhoea, leading to concerns about its use in skin infections.
131
 Linezolid is 
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also active against the majority of MRSA strains but it is costly and can be associated 
with haematological side effects.
211
 Doxycycline and minocycline need to be used with 
caution due to photosensitivity side effects and cannot be used in children under nine 
due to deposition in teeth and bones. There is also a lack of data to support their efficacy 
against community-acquired MRSA. Rifampin is another antibiotic that has been shown 
to be effective against MRSA, but its high frequency generation of resistant mutants 
requires that it not be used alone.
212
 Fluoroquinolones are no longer indicated for the 
treatment of skin and soft tissue S. aureus infections due to resistance.
213
  
Vancomycin remains as the antibiotic of choice for invasive staphylococcal 
infections. In more severe skin and soft tissue infections, tigecycline and daptomycin 
may also be used,
213
 although tigecycline is expensive and both drugs can only be 
administered intravenously.
214
 While several effective therapies have been developed 
for staphylococcal infections their use is primarily reserved for severe, complicated 
infections.
215
 Because of this and the other problems noted above, especially resistance, 
there is a continuing need to develop new therapeutics and strategies for treating MRSA 
and other staphylococcal skin infections.   
aPDT presents an attractive alternative due to the ease of applying light to the 
infected skin surface and because of its effectiveness against resistant organisms 
(Chapter 1.8). For example, in wound infection operations, which are often complicated 
by antibiotic-resistant strains of bacteria and account for 25% of all nosocomial 
infections,
216
 aPDT could present a very practical and effective treatment.
217
 However, 
it is unlikely that aPDT could be the only treatment modality employed due to the 
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severe nature of some of these infections. Nevertheless, it could be useful for lowering 
the bacterial burden and thus the amount of surgical debridement required.
216
  
4.4 aPDT as a Potential Treatment for MRSA Skin Infections  
As alluded to above, aPDT is particularly suited to superficial staphylococcal 
infections due to the accessibility of the infection site and ease of topical application of 
a photosensitiser and its subsequent illumination.
218
 Additionally, the vulnerability of S. 
aureus to toxic photosensitisation is well recognized.
219
 Effects of photosensitisation on 
the activities of virulence factors produced by the pathogen has generated some resent 
interest.
220
  
One of the advantages of aPDT for skin infections is that the treatment can be 
focussed directly on the infection site using laser light from an optical fibre that 
produces a beam diameter of only millimetres. This ensures that inadvertent exposure of 
host tissues to photosensitisation can be minimised. It has been suggested that the 
specificity of aPDT might be further increased by conjugating antibodies to 
photosensitizers that target specific antigens on organisms of interest. This approach has 
been explored, for example, with an IgG-tin(IV) chlorin e6 conjugate.
221
 In practice, 
however, such a strategy would be costly to implement clinically and would require the 
infecting organism to be properly identified before treatment. While such selectively is 
very attractive from a scientific perspective, if aPDT does not cause considerable 
damage to human cells in clinical practice then the need for targeting methods may not 
be necessary. In support of these simpler and cheaper approaches, treatment of 
keratinocytes with MB and visible light has been shown not to cause DNA damage, 
indicating that the treatment is unlikely to be accompanied by genotoxicity.
222
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A number of in vitro studies have reported the use of aPDT for inactivating 
MRSA
223
 but there have been relatively few in vivo studies. One in vivo study explored 
the effects of aPDT in a skin abrasion wound infection mouse model that made use of a 
bioluminescent MRSA (Xen31) strain.
126b
 This strain allowed real-time monitoring of 
the infection using a bioluminescence camera. Treatment with a polyethylenimine- 
(PEI-)ce6 photosensitizing agent (Figure 4.1) and a range of noncoherent red light 
fluences applied 30 minutes after bacterial inoculation produced up to 2.7 log reductions 
in MRSA, as measured by loss of bioluminescence from the wounds. Application of 
aPDT also accelerated wound healing by 8.6 days compared to untreated wound 
infections.
126b
  
In another mouse skin abrasion infection model, a tetracationic 
Zn(II)phthalocyanine derivative (RLP068/Cl, Figure 4.1) was used as the 
photosensitizer and shown to inactivate MRSA, inhibit regrowth and accelerate wound 
healing.
224
 In this study, full-thickness wounds of 0.8 cm diameter were established in 
the subcutaneous back tissue of BALB/c mice and inoculated with 5 × 10
7
 CFU 
MRSA.
225
 Strong bacterial inactivation (> 3 log kill) was observed after two days when 
mice were treated with the agent and illuminated with visible light. For this in vivo 
study, Complete re-epithelialization was observed in aPDT-treated mice 9 days after 
therapy.
225
  
In a third mouse skin wound EMRSA-16 (epidemic MRSA) infection study, 
treatment of infected mice with 100 𝜇g/mL MB followed by illumination with 670 nm 
laser light (total fluence 360 J/cm
2
) resulted in a 25-fold reduction in the number of 
EMRSA-16.
226
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Figure 4.1 Structures of polyethylenimine-ce6 (PEI-ce6) and tetracationic Zn(II) 
phthalocyanine chloride (RLP068/Cl) photosensitizers used in mouse skin abrasion 
infection studies.
126b,224
 
 
The effectiveness of aPDT against MRSA arthritis has been tested in vivo in a 
mouse model. MRSA arthritis is a disease affecting joints, where bacteria from the skin 
are introduced into the joint synovial fluid, usually via percutaneous instrumentation. 
This study revealed that ~ 30% of intra-articular leukocytes, mainly neutrophils, died 
immediately after aPDT with photofrin.
227
 After 24 h aPDT treatment an additional 
reduction in the number of intra-articular leukocytes and atrophy of the synovial tissue 
were observed. Isolated peripheral neutrophils were shown to have significant affinity 
for photofrin and displayed substantial morphological damage after aPDT.
227
 These 
results suggest that aPDT would probably not be useful in MRSA arthritis because of 
the damage to intra-articular neutrophils and synovial tissues.  
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In an attempt to increase bacterial inactivation and reduce damage to host 
neutrophils, the same group later studied the effects of intra-articular injection of 
photofrin rather than intravenous administration.
228
 Each animal received a knee 
injection of MRSA (5 × 10
7
 CFU) and after 3 days Photofrin (1 mg) was applied and 
illuminated 635 nm light as a range of fluences. The maximum reduction of MRSA was 
achieved at a 20 J/cm
2
. Lesser effects were observed at lower fluences.
228
 The authors 
concluded that aPDT for murine MRSA arthritis would require optimised light 
dosimetry to rapidly inactivate bacteria without affecting neutrophils at the infected site. 
aPDT with too low a fluence might inactivate insufficient bacteria, whereas too much 
light could inactivate neutrophils and damage host tissues, allowing bacteria to regrow 
in an environment where the immune response had been compromised. 
An artificial skin construct has been developed for simulating MRSA skin 
infections.
229
 The artificial skin is constructed from human-derived epidermal 
keratinocytes and dermal fibroblasts, cultured at a media interface to form a stratified 
model of full-thickness, epithelialized human skin. aPDT with MB in this model 
produced a strong reduction (> 5 log kill) compared to controls and the effect was 
sustained over multiple days. Application of MB without light resulted in only a small 
reduction in MRSA viability.
229
 
4.5 aPDT Activity of Lead Hybrid 58 in a Murine MRSA Wound Infection Model 
The final part of this thesis work involved examining the aPDT activity of lead 
hybrid 58 in an in vivo murine MRSA wound infection model. Compound 58 was 
chosen for the study due to its potent in vitro aPDT activities, as detailed in Chapter 3, 
where its superior effects relative to MB were clearly evident. The primary goal of this 
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in vivo study was to demonstrate that the superior in vitro activities of 58 relative to MB 
translated to a real MRSA infection. The needle scratch model, developed by Dai et 
al,
126b
 was chosen for the study. This model reflects the initial colonisation stage of the 
wound infection process and uses a bioluminescent variant of a strain of MRSA (MRSA 
Xen 30)
230
 that is known to cause wound infections of significant clinical relevance, 
sometimes with fatal outcomes.
231
 
4.5.1 Experiment Protocol and Results 
Female BALB/c mice were divided into 5 cohorts (Table 4.1). Group A animals 
(n = 6) were absolute controls that received no treatment, Group B (n = 6) were dark 
controls for MB (no light), Group C (n = 6) received aPDT treatment with MB. Group 
D (n = 6) were dark controls for hybrid 58 (no light) and Group E (n = 6) received 
aPDT treatment with hybrid 58. 
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Table 4.1 Animal cohorts for murine MRSA wound infection study. 
         Group                        Animals                             Treatment 
A - Absolute control                  6          No treatment 
B - Dark control for MB           6          MB (40 µL of 200 µM) 
C - aPDT with MB                    6          MB + light (12, 36, 84, 120 J/cm
2
; 652 nm) 
D - Dark control for 58             6          58 (40 µL of 200 µM) 
E - aPDT with 58                       6          58 + light (12, 36, 84, 108, 120 J/cm
2
; 652 nm) 
 
Inoculation of 10
8
 CFU MRSA Xen 30 into scratch wounds (using a needle) on 
the shaved backs of immunosuppressed female BALB/c mice, led to a stable infection, 
as confirmed by bioluminescence imaging (Figure 4.2, Group A). Pictures were 
captured using a bioluminescence camera immediately after MRSA inoculation and 30 
mins post-inoculation. Light was then applied to the aPDT cohorts (Groups C and E; 
Time 0) and images were captured for all cohorts after 2, 6, 14, 18 and 20 min. 
Application of 652 nm light in the aPDT cohorts for these periods corresponded to 
fluences of 12, 36, 84, 108 and 120 J/cm
2
, respectively. Images obtained from a 
representative animal in Groups A, C and E are shown in Figure 4.2.  
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Group A  
(Absolute Control) 
 
Group C  
(aPDT with MB) 
Group E 
(aPDT with 58) 
Immediately 
after MRSA 
inoculation 
   
30 min 
post-inoculation 
   
 
Time = 0 
 
   
Time = 2 min 
E = 12 J/cm
2
 
   
Time = 6 min 
E = 36 J/cm
2
 
   
Time = 14 min 
E = 84 J/cm
2
 
   
Time = 18 min 
E = 108 J/cm
2
 
   
Time = 20 min 
E = 120 J/cm
2
 
   
Figure 4.2 Bioluminescence images obtained from a representative animal in Groups A 
C and E in the murine MRSA wound infection model. Images were captured post-
inoculation and at the times indicated. Application of 652 nm light for these periods in 
the aPDT Groups C and E corresponded to the fluences indicated. MB in Group C and 
compound 58 in Group E were applied by delivering 40 µL of 200 µM solutions 
(formulated in CrEL, see Section 3.3.1) via micropipette directly to the infection site.  
 
The bioluminescence image data from Figure 4.2 is presented graphically in 
Figure 4.3. These data represent the mean ± SEM of normalized bioluminescence 
emanating from the wounds of the 6 mice in each cohort. In the absence of 
photosensitizers (Absolute control – Group A), the relative bioluminescence units 
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(RLU) decreased only marginally, indicating that infection was stable over the course of 
the experiment and relatively unaffected by application of light alone. 
In the MB dark control (Group B), there was no significant reduction in 
bioluminescence after 6 min, and after 18 min bioluminescence reduction was less than 
0.6 RLU (Appendix 4.1(A)). A clear light dose-dependent response was observed in the 
aPDT cohort treated with MB (Group C). After 2 min of light application (E = 12 J/cm
2
) 
luminescence was reduced by 45%, which increased to 70% after 6 min (E = 36 J/cm
2
). 
Disappearance of the luminescence signal was observed after 18 min (E = 108 J/cm
2
). 
In Group D, where hybrid 58 was applied without light only a small (0.1 RLU) 
reduction in luminescence was observed at the highest incubation (Time = 20 min) 
(Appendix 4.1(B)). In Group E, where aPDT with 58 was applied, a remarkable 98% 
reduction in luminescence was observed after applying light for only 2 min (E = 12 
J/cm
2
), and total loss of the luminescence signal was observed after 6 mins (E = 36 
J/cm
2
). 
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Figure 4.3 Light-dose response (mean ± SEM) for Groups A, C and E in the 
bioluminescence MRSA wound infection model. Data are presented as normalized 
relative luminescence units (RLU). Dark control Groups B and D showed only small 
reductions in RLU at 120 J/cm
2 
(Appendix 4.1). 
 
4.5.2 Post-Treatment Monitoring of Infections  
Post-treatment monitoring of the bioluminescence signal was carried out daily 
from the treatment day (Day 0) until to Day 10. As shown in Figure 4.4, a rebound in 
the bacterial load (as indicated by a 1.6 fold increase in luminescence) was observed in 
each of the non-aPDT control groups (Group A, B and D) after 1 day. These infections 
resolved naturally over the course of the following 10 days. For the MB-aPDT cohort 
(Group C) a smaller (1.3 fold) rebound was observed after 1 day and the infection was 
completely resolved after 7 days. For the 58-aPDT cohort (Group E), essentially no 
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rebound in bacterial load was observed after 1 day and the infection completely resolve 
after 4 days. 
 
 
Figure 4.4 Ten day post-treatment monitoring of bacterial loads for Group A-E in the 
MRSA wound infection study. Luminescence (normalized) emanating from animal 
infection sites was measured using a luminescence camera. Data represent mean ± SEM 
obtained from 4-6 animals in each cohort. The luminescence images from which the 
data were derived (from representative animals in each cohort) are provided in 
Appendix 4.2. 
 
4.5.4 Wound Healing 
During experiments all mice were monitored visually for signs of poor health, 
suggesting that they might have developed a systemic infection. Weights of animals 
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were monitored as a proxy for general health. Slight reduction on body weights of 
animals was included in the formulae used for calculation of total RLU. 
Wounds of all animals were also inspected visually for signs of healing. As 
shown in Figure 4.5, cohorts that received no aPDT treatments (Group A, B and D) 
showed few signs of wound healing on days 4-6 of the post-treatment monitoring 
period. In contrast, the MB-aPDT cohort (Group C) showed considerable healing by 
day 6 and had formed a visible scab by day 7 (not shown). Animals treated with aPDT 
and 58 (Group E) showed much faster wound healing, with a visible scab formed after 
only 4 days and the wound visibly healed by Day 6. 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.5 Images showing wound healing in representative animals from Groups A-E 
on Days 4-6 post-treatment. 
 Day 4 Day 5 Day 6 
Group A 
control 
   
Group B 
MB-dark 
   
Group C 
MB-aPDT 
   
Group D 
58-dark 
   
Group E 
58-PDT 
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4.6 Summary and Conclusions 
In this Chapter, a mouse skin abrasion wound infection was established by the 
topical application of an MRSA suspension to superficial scratch wounds on the shaved 
dorsal surfaces of BALB/c female mice. Use of bioluminescent bacteria allowed real-
time monitoring of the extent of the infection in the mice wounds following treatment 
with MB and lead hybrid 58. The images captured after aPDT treatments using a 200 
μM solution (40 µL) of 58 showed a very strong light-dose response effect, where all 
bacterial luminescence had disappeared after application of only 36 J/cm
2
 of 652 nm 
light. 3-Fold higher light doses (108 J/cm
2
) were required to effect total loss of 
luminescence using MB at the same concentration. 
In the days post-aPDT treatment with 58, minimal bacterial re-growth was 
observed and total disappearance of the bioluminescence signal occurred by day 4. 
Complete loss of bacterial luminescence in dark controls with 58 was not observed until 
Day 9. For MB, significant bacterial regrowth was observed in the day following aPDT 
treatment and total disappearance of the bioluminescence signal was not observed until 
Day 7. The wound healing process after aPDT treatment with 58 occurred earlier (Day 
4) than with MB (Day 7), as observed by scab formation in the treated area. Wound 
healing in Groups treated with MB and 58 alone (i.e. no light) or with no compound 
treatment did not heal until Days 12-14. These results demonstrated that aPDT with 
hybrid 58 enhances bacterial inactivation and improves wound healing compared to the 
parent photosensitizer MB in this infection model. This finding strongly supported our 
original hypothesis that attachment of an EPI to MB can enhance its aPDT activity. 
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Chapter 5 
Conclusions and Future Directions 
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This thesis explored novel light-activated antimicrobial photosensitizers as 
potential new agents for inactivating MDR bacteria using aPDT. The overall goal was 
to identify an MB-EPI hybrid that showed improved efficacy relative to MB as a 
potential treatment for superficial, localised infections, such as S. aureus skin infections.  
Evidence has revealed that MDR pumps contribute to antibiotic resistance by 
transporting a wide variety of structurally diverse compounds, including the 
phenothiazinium dye MB.
19
 Pharmacological inhibition of pumps, where small 
molecule inhibitors are used to block pump activity, is one of the strategies that have 
been investigated to date.
62a
 Potentiation of the aPDT effects of MB upon co-incubation 
of MDR bacterial strains with MB and EPIs had previously been reported.
99a
 As 
discussed in Chapter 1, EPIs can raise the concentration of MB within bacterial cells. 
Upon irradiation with visible light, MB generates toxic ROS via Type I and II 
photosensitization processes to kill bacterial cells. 
Chapter 1 summarized several issues with using combinations of MB with EPIs 
and proposed that MB-EPI hybrids could potentially be used to address efflux pump-
mediated resistance in aPDT.
154
 The concept of MB-EPI hybrids evolved from the 
reported “dual antimicrobial action” observed with berberine-EPI  hybrids (i.e. SS14) 
that target the NorA pump in S. aureus.
162
 The physicochemical similarities between 
berberine and MB and evidence that they are overlapping substrates for various efflux 
pumps, including NorA, suggested that an analogous MB-EPI hybrids strategy might be 
successfully applied in aPDT.
99a,154
  
In Chapter 2, a convergent synthetic strategy was described for the synthesis of 
16 hybrids that conjugated MB to the EPIs reserpine, pterostilbene, INF55 and INF271. 
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Piperazine and N,N’-dimethylethylenediamine-based linkers were used to attach the 
EPIs to MB. Requisite EPI-alkyl/acyl-piperazine and EPI-alkyl/acyl-ethylenediamine-
based precursors were prepared and then reacted according to Strekowski’s method with 
a key phenothiazinium common intermediate 63 to form the target hybrids. It was 
observed that the Strekowski reactions were best carried out in the absence of light to 
minimise photodegradation. All compounds were purified by preparative TLC, eluting 
with a very uncommon solvent system (3% NH4OAc(aq):MeOH 15:85) and subsequently 
converted to chloride salts using Cl
- 
anion exchange resin (Chapter 6). Sufficient 
quantities (25-95 mg) of the final hybrids were obtained for the photophysical and 
photobiological studies. High resolution mass spectroscopy, NMR and UV/Vis 
spectroscopy of these hybrids were used to characterize their structures.  
As discussed in Chapter 1.14, when designing the hybrids, it was considered 
crucial that the photosensitization properties of MB be maintained and that this might be 
achieved by substituting the C-7 N-Me groups of MB with N-alkyl and piperazinyl 
linkages. To measure the effects of the structural changes we compared the absorption 
properties of MB to hybrids by examining the λmax1 and λmax2 values and extinction 
coefficients. The λmax and log ε data confirmed that introduction of the various linker 
groups and EPIs did not significantly impact the absorption properties of the MB 
chromophore. An interesting observation from these experiments was that the highest 
Δlog ε1 value (0.22), meaning that the compound had the greatest reduction in 
chromophore absorptivity of all the hybrids relative to MB, was observed with 58, the 
compound that was ultimately shown to produce the best activity. It was concluded that 
absorptivity of the chromophore was not a critical parameter in these hybrids for 
showing good aPDT activity.  
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We hypothesized that these light-activated antimicrobial hybrids would show 
increased effectiveness over the parent PS MB against S. aureus in aPDT by generating 
increased intracellular ROS through inactivation of MDR pumps, namely NorA. Two 
important assays were performed to explore whether hybrids maintained the PS and EPI 
properties:  
1- Measurement of 1O2 and •OH phototoxic species. 
2- Assays to demonstrate retention of efflux pump inhibitory activities. 
Production of ROS by PSs can be probed experimentally by fluorescence-based 
ROS scavengers. SOSG and HPF probes were used to measure production of 
1
O2 and 
•OH, respectively, from the hybrids. All hybrids were found to produce less 
1
O2 and 
•OH than MB. Reserpine-containing hybrids 47-50 showed 
1
O2 and •OH quantum 
yields at around 20-55% of MB, with 48 showing the highest •OH production (55%) of 
all hybrids. Pterostilbene-containing hybrids 51-54 all showed 
1
O2 and •OH quantum 
yields less than 20% relative to MB. INF55-containing hybrids 55-58 and INF271-
containing hybrid 59-62 generally showed higher 
1
O2 and •OH quantum yields. 
1
O2 
production for 55, 56, 58 and 62 were at 65%, 50%, 60% and 55% relative to MB. It 
was observed that production of 
1
O2 was in general stronger than production of •OH, 
indicating that any observed phototoxicity effects would probably occur via Type II 
mechanisms. 
Aqueous solubilisation of hybrids was achieved by encapsulation in cremophor 
EL (CrEL). This was determined to be the best detergent out of tween 60 (T60), triblock 
copolymers F127 (PL-F127) and poloxamer 388 (POL388) for solubilising reserpine-
containing hybrid 49, a particularly insoluble hybrid in aqueous solutions. Due to its 
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powerful solubilizing effect on 49 and its widespread use as a vehicle for many poorly 
water-soluble compounds, as well as its  low toxicity properties,
180-181
 CrEL was chosen 
as the vehicle for formulating all hybrids in this study. 
Preliminary in vitro aPDT screening against S. aureus USA300 revealed that 
hybrids 56, 58, 59 and 60 showed a better killing than MB at equivalent concentrations 
and fluence. MB was found to reduce the viability of S. aureus USA300 by 2 log units, 
whereas hybrids 56, 58, 59 and 60 showed killing effects of 3-6 logs (Figure 3.14). This 
result provided the first evidence that some of the hybrids could function as designed; 
i.e. with the EPI serving to block MDRs and generate higher intracellular concentrations 
of the attached MB PS and better aPDT cell killing. To support this, MICs were 
measured with the antibiotic ciprofloxacin, a known MDR substrate for NorA pump in 
the presence of hybrids and MB in the dark. The MIC of ciprofloxacin was greatly 
potentiated in the presence of hybrids, leading us to conclude that they are able block 
MDR pumps in S. aureus, specified NorA.   
In Chapters 3.3.3, the aPDT activities of the four lead hybrids were explored 
against NorA knockout (NorA-), wild-type (WT) and NorA-overexpressing (NorA++) 
mutant S. aureus strains. These experiments aimed to obtain further evidence that 
hybrids show photodynamic effects that were influenced by their action on the NorA 
pump. aPDT with MB against these strains displayed the hallmarks of it being a 
substrate for the NorA pump. MB produced a 2 log kill against the NorA++ strain upon 
irradiation with 16 J/cm
2
 of light, and a 4 log reduction was obtained under the same 
conditions in the NorA- strain. In contrast, phototoxicity of the three hybrids 56, 58 and 
60 remained unchanged (3 log killing) against all three strains, consistent with these 
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compounds not being substrates for the NorA pumps, and possibly serving to block this 
pump. 
Of the three best hybrids identified from the in vitro aPDT experiments, two -
contained INF55 (56 and 58) and one contained INF271 (i.e. 60). Hybrids incorporating 
the natural product EPIs reserpine and pterostilbene showed no aPDT activity, 
demonstrating the crucial role that molecular structure plays in the activity. The study 
also demonstrated the importance of linker groups in the structures, where hybrids with 
piperazine-based linkers (indicated as red/pink data in the Chapter 3 figures) generally 
showed poorer aPDT activities in comparison to equivalent compounds with N,N’-
dimethylethylenediamine-based linkers (indicated as light blue/dark blue data in the 
Chapter 3 figures). This was highlighted with INF55-containing hybrids 55-58, where 
hybrid 58 containing an N,N’-dimethylethylenediamine linker was found to be the best 
performing hybrid overall, whereas the equivalent hybrid 55 with a piperazine-based 
linker showed very little in vitro aPDT activity. The better performance of the N,N’-
dimethylethylenediamine linker may arise from its increased flexibity compared to the 
rigid piperazine linker. 
The efflux pump inhibitory activity of 56, 58 and 60 was explored by measuring 
uptake of these compounds into WT, NorA- and NorA++ S. aureus cells. The hybrids 
showed identical uptake in all three strains, consistent with them not being NorA 
substrates.  
aPDT concentration response experiments with NorA++ S. aureus cells 
identified hybrid 58 as a highly potent lead. At 40 µM this hybrid showed complete 
eradication of cells at 10 J/cm
2
 fluence (Figure 3.18). Under the same conditions, MB 
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produced a 5 log kill. It was also noted that, increasing the concentration of MB to 160 
µM did not lead to complete eradication, as was observed with 58. On the basis of all of 
the photophysical an in vitro aPDT experiments hybrid 58 was advanced to an in vivo 
aPDT infection model. 
A murine MRSA wound infection model was used to study the in vivo activity 
of lead hybrid 58.
232
 This model reflects the early stages of an infectious process, i.e. 
initial colonisation of a wound by a potential pathogen. Infections were established by 
inoculating scratch wounds on the dorsal surfaces of mice with bioluminescence 
MRSA. MRSA was found to be highly susceptible to photodynamic killing by 58, 
where irradiation with 36 J/cm
2
 of 652 nm light in the presence of 200 μM 58 resulted 
in complete disappearance of luminescent MRSA. A 3-fold higher light dose (108 
J/cm
2
) was required for the same effects using MB at the same concentration. Post-
treatment monitoring of the bacterial loads showed that total disappearance of the 
bioluminescence signal had occurred by Day 4 with 58, which was not observed until 
Day 7 with MB. Significant bacterial regrowth had occurred one day after treatment 
with MB but this rebound growth was not observed with 58. 
This study has demonstrated that Gram-positive bacteria are susceptible to 
hybrid-photosensitization and low light energies were found to kill the bacteria. It has 
been reported that higher light energies are often necessary to kill the Gram-negative 
species.
233
 It would be of interest to explore the activity of 58 against Gram-negative, 
e.g. P. aeruginosa, in future experiments, and it would be worthwhile using higher light 
fluences in these studies. 
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MB has been used clinically and is known to show low toxicity towards normal 
cells.
234
 In this thesis it was shown that the effects of 58 occur at lower concentration 
than MB, suggesting it would likely show little toxicity in humans. The low irradiation 
times required for the successful killing of bacteria and reduction of their virulence 
potential are attractive features for the clinical setting, where short treatment durations 
would cause less discomfort to patients and minimise damage to host tissues. Further 
investigations are needed to fully understand the toxicity of these hybrids. 
As shown in chapter 2, a library of four compounds using four different linker 
groups were synthesized for each EPI used in this study. The importance of linker group 
as well as EPIs was revealed by this study. Hybrids 55 and 58 have the same EPI but 
different linker group and the result shows that hybrid 58 with N,N’-
dimethylethylenediamine linker showed 4 logs killing of S. aureus NorA-
overexpressing whilst the hybrids 55 with piperazine linker group did not reveal any 
activity. Further pharmacophore study need to perform to find the best non-cleavable or 
any possibility of using cleavable linker groups for these hybrids. 
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Chapter 6 
Experimental 
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6.1 Experimental Procedure - Chemistry 
6.1.1 Chemistry - General 
All reactions were performed under an argon atmosphere in flame or oven-dried 
glassware with magnetic stirring unless otherwise stated. Pterostilbene was purchased 
from ChromaDex (NV, USA). Reserpine, IRA-904 quaternary ammonium Cl
- 
anion 
exchange resin and all other commercial reagents were purchased from Sigma-Aldrich 
(St. Louis, MO) and used without further purification, unless otherwise noted. 
Anhydrous acetonitrile and toluene were obtained using a PureSolv system. N,N-
dimethylformamide (DMF) was dried over barium oxide and distilled under reduced 
pressure onto 4Å molecular sieves. Anhydrous tetrahydrofuran (THF) and diethyl ether 
(Et2O) were freshly distilled from sodium benzophenone ketyl. All other solvents were 
of analytical reagent (AR) grade and used as received. The term petroleum spirit refers 
to petroleum spirit within the boiling range 40-60 
o
C.   
Reaction monitoring was performed using thin layer chromatography (TLC) 
analysis on Merck Silica Gel 60 F254 (0.2 mm) aluminium plates. Purification by flash 
column chromatography used silica gel 60 (230-400 mesh, Merck) with the indicated 
eluents. Purification of hybrids 47-62 was performed using Merck 60 F254 preparative 
TLC plates (1000 µm). 
Melting points were determined on a Buchi digital M-560 melting point 
apparatus and are uncorrected. 
1
H and 
13
C NMR spectra were recorded on either Varian 
Unity-300 MHz or Varian-Inova-500 MHz spectrometers in deuterated solvents. 
Spectra were referenced internally using the chemical shifts of solvent resonances 
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relative to TMS. UV/Vis spectra were recorded on a Shimadzu UV-1700 PharmaSpec 
UV/Vis spectrophotometer. Infrared spectra were obtained as neat samples using an 
Avator ESP spectrometer. Low resolution electrospray ionisation mass spectra (EI-
LCMS) were measured using a Shimadzu LC-MS (2010) spectrophotometer. High 
resolution electrospray ionisation mass spectroscopy (HRESI-MS) were recorded using 
a factory modified Waters QToF Ultima
TM 
Spectrometer (Wyntheshawe, UK). 
6.1.2 Synthesis of 3-(Dimethylamino)phenothiazin-5-ium triiodide 63 
Dimethylamine in methanol (6.2 g, 11.9 mmol) was added 
dropwise to a solution of phenothiazin-5-ium tetraiodide 
hydrate 65 (5.0 g, 6.90 mmol) in 80 mL chloroform at room 
temperature. The reaction was stirred for 5 h while monitoring by TLC (3% NH4OAc 
(aq)/MeOH, 15:85). The resulting precipitate was filtered, washed with chloroform and 
air dried to give 63 (205 mg, 60%) as a dark blue solid. TLC Rf (3% NH4OAc 
(aq)/MeOH, 15:85) = 0.28; Mp 144 -145 ºC. 
1
H NMR (500 MHz, (CD3)2SO) δ 8.18 (dd, 
J = 8.0, 1.6 Hz, 1H, H9), 8.13 (dd, J = 8.0, 1.6 Hz, 1H, H6), 8.06 (d, J = 10.0 Hz, 1H, 
H1), 7.98 (dd, J = 10.0, 2.4 Hz, 1H, H2), 7.94 (d, J = 2.4 Hz, 1H, H4), 7.82 (m, 2H, H7, 
H8), 3.64 and 3.60 (2s, 6H, N(CH3)2); 
13
C NMR (125 MHz, (CD3)2SO) δ 156.1, 144.1, 
139.8, 139.6, 138.0, 134.6, 133.2, 129.8, 126.3, 126.1, 125.8, 109.7, 43.4, 42.9; IR 
(neat) ν 2800, 1617, 1559, 1489, 1429, 1411, 1252, 1118, 1078, 887, 835, 772 cm
-1
; 
HRESI-MS: m/z calcd for [C14H13N2S] 241.2051, found 241.2067.  
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6.1.3 Synthesis of Piperazine and N,N’-Dimethylethylenediamine Linkers 
Tert-butyl 4-(2-bromoacetyl)piperazine-1-carboxylate 76 
Bromoacetylchloride (500 g, 3.2 mmol) was added dropwise 
during 30 min to a solution of tert-butyl piperazine-1-
carboxylate (500 mg, 2.7 mmol) and K2CO3 (2.0 g, 14.6 
mmol) in 50 mL anhydrous THF. The reaction was stirred for 12 h while monitoring by 
TLC (Pet. spirit:EtOAc, 50:50). The reaction mixture was concentrated and the residue 
re-dissolved in CH2Cl2. The organic layer was washed with water and brine, dried over 
anhydrous Na2SO4 and concentrated. The crude residue was purified by silica gel 
column chromatography (30% EtOAc/Pet, Spirit) to afford 77 (250 mg, 35%) as an off-
white solid. TLC Rf (Pet. spirit:EtOAc, 50:50) = 0.48; Mp 114 -115 ºC. 
1
H NMR (500 
MHz, CDCl3) δ 3.85 (s, 2H, H9), 3.62-3.42 (m, 8H, H3, H4, H6, H7), 1.45 (s, 9H, H13, 
H14, H15); 
13
C NMR (125 MHz, CDCl3) δ 165.1, 154.3, 80.4, 46.5 (2C), 41.9 (2C), 
28.3 (3C), 25.6; IR (neat) ν 1762, 1723, 1560, 1498, 1429, 1413, 1250, 1120 cm
-1
; 
HRESI-MS: m/z calcd for C11H19 
79
BrN2O3) 306.0581, found 306.0590.  
Tert-butyl (2-(2-bromo-N-methylacetamido)ethyl)(methyl) carbamate 77 
Bromoacetylchloride (500 g, 3.2 mmol) was added dropwise 
during 30 min to a solution of tert-butyl methyl(2-
(methylamino)ethyl)carbamate (500 mg, 2.7 mmol) and 
K2CO3 (1.2 g, 8.7 mmol) in 30 mL anhydrous CH2Cl2. The reaction was stirred for 16 h 
while monitoring by TLC (Pet. spirit:EtOAc, 50:50). The reaction mixture was 
concentrated and the residue re-dissolved in CH2Cl2. The organic layer was washed 
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with water and brine, dried over anhydrous Na2SO4 and concentrated. The crude residue 
was purified by silica gel column chromatography (30% EtOAc/Pet, Spirit) to afford 77 
(330 mg, 40%) as an off-white solid. TLC Rf (Pet. spirit:EtOAc, 50:50) = 0.46; Mp 129 
-131 ºC. 
1
H NMR (500 MHz, CDCl3) δ 4.26 (s, 2H, H9), 3.46 (t, 2H, H7), 3.28 (t, 2H, 
H6), 3.25 (s, 3H, H3), 2.89 (s, 3H, H4), 1.45 (s, 9H, H13, H14, H15); 
13
C NMR (125 
MHz, CDCl3) δ 165.3, 153.9, 79.6, 51.8, 47.5, 35.3, 34.9, 28.2 (3C), 27.6; IR (neat) ν 
1752, 1717, 1559, 1489, 1429, 1411, 1252, 1118 cm
-1
; HRESI-MS: m/z calcd for C11H21 
79
BrN2O3) 308.0535, found 308.0552.  
6.1.4 Synthesis of Reserpine-Containing Intermediates 
Methyl (1S,2R,3R,4aS,13bR,14aS)-3-((4-hydroxy-3,5-dimethoxy benzoyl)oxy)-2,11-
dimethoxy-1,2,3,4,4a,5,7,8,13,13b,14,14a-dodecahydroindolo [2',3':3,4]pyrido[1,2-
b]isoquinoline-1-carboxylate 70
165
 
Aluminium chloride (1.0 g, 7.63 mmol) was 
added in one portion to a stirring solution of 
reserpine 8 (100 mg, 0.16 mmol) in dry 
CH2Cl2 (20 mL) at room temperature. The 
reaction was stirred for 2 h while monitoring 
by TLC (EtOAc). The reaction was quenched by addition of 5% aqueous HCl (15 mL) 
and the mixture diluted with CH2Cl2 (30 mL) and the layers separated. The aqueous 
layer was extracted twice more with CH2Cl2 and the combined organic fractions were 
washed with water and brine, dried over anhydrous MgSO4 and concentrated to yield 70 
(90 mg, 95%) as a yellowish solid. TLC Rf (EtOAc) = 0.45; Mp 154-156 ºC; 
1
H NMR 
(500 MHz, CDCl3) δ 7.54 (br s, 1H, H7), 7.33 (s, 2H, H25, H29),7.31 (d, J = 10.0 Hz, 
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1H, H1), 6.88 (s, 1H, H4), 6.78 (d, J = 10.0 Hz, 1H, H2), 4.97 (sextet, J = 4.5 Hz, 1H, 
H20), 4.74 (app s, 1H, H19), 3.98 (t, J = 10.0 Hz, 1H, H38), 3.92 (s, 6H, H31, H33), 
3.86 (s, 3H, H30), 3.81 (s, 3H, H37), 3.50 (s, 3H, H34), 3.28 (d, J = 7.1 Hz, 2H, H17), 
3.21 (d, J = 7.1 Hz, 1H, H18), 2.95 (sextet, J = 7.1 Hz, 1H, H36) 2.77-2.45 (m, 5H, 
H14, H21, H35), 2.15-1.95 (m, 4H, H12, H13); 
13
C NMR (125 MHz, CDCl3) δ 172.4 
(C39), 165.6 (C23), 156.7 (C3), 146.8 (C26, C28), 139.7 (C5, C8), 137.1 (C27), 121.2 
(C24), 120.87 (C6, C9), 118.6 (C1), 109.7 (C2), 106.8 (C25, C29), 95.3 (C4), 60.7 
(C19, C20), 56.9 (C30, C31, C33), 55.9 (C34), 54.5 (C0), 52.2 (C37), 51.4 (C18), 50.9 
(C17), 48.5 (C12), 33.2 (C36), 31.3 (C35), 29.4 (C36), 23.7 (C21), 16.3 (C13); IR 
(neat) ν 3736, 2921, 1732, 1691, 1550, 1436, 1181, 1118 cm
-1
; HRESI-MS: m/z calcd 
for [C32H38N2O9] 595.2656, found 595.2671.  
Methyl (1S,2R,3R,4aS,13bR,14aS)-3-((4-(2-hydroxyethoxy)-3,5-dimethoxy 
benzoyl) oxy)-2,11-dimethoxy-1,2,3,4,4a,5,7,8,13,13b,14,14a-
dodecahydroindolo[2',3':3,4] pyrido[1,2-b]isoquinoline-1-carboxylate 71  
The phenolic reserpine 70 (100 mg, 17 
mmol) was dissolved in dry DMF (5 mL) 
in a 25 mL flame-dried round bottom 
flask under Ar and K2CO3 (1.00 g, 17.8 
mmol) was added. The mixture was 
stirred at room temperature for 30 min before adding 2-bromoethanol (50 mg, 40 mmol) 
and warming to 80 
o
C. After overnight stirring and monitoring by TLC (EtOAc) the 
reaction mixture was concentrated and the residue re-dissolved in CH2Cl2. The organic 
layer was washed with water and brine, dried over anhydrous Na2SO4 and concentrated. 
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The crude residue was purified by silica gel column chromatography (60% EtOAc/Pet, 
Spirit) to afford 71 (100 mg, 96%) as a yellow solid. TLC Rf (EtOAc) = 0.38; Mp 121-
123 ºC; 
1
H NMR (500 MHz, CDCl3) δ 7.58 (br s, 1H, H7), 7.33 (m, 3H, H25, H29, H1), 
6.84 (app d, J = 2 Hz, 1H, H4), 6.78 (d, J = 10.0 Hz, 2.0 Hz, 1H, H2), 5.05 (sextet, J = 
4.5 Hz, 1H, H20), 4.47 (app s, 1H, H19), 4.25 (t, J = 10.0 Hz, 2H, H40), 3.92 (s, 6H, 
H31, H33), 3.89 (t, J = 10.0 Hz, 1H, H38), 3.84 (s, 3H, H30), 3.82 (s, 3H, H37), 3.73 (t, 
J = 10.0 Hz, 2H, H41), 3.50 (s, 3H, H34), 3.18 (d, J = 7.1 Hz, 2H, H17), 3.05 (d, J = 7.1 
Hz, 1H, H18), 2.96 (sextet, J = 7.1 Hz, 1H, H36) 2.70 (dd, J = 10.0 Hz, 5.0 Hz, 2H, 
H14), 2.52-2.27 (m, 3H, H21, H35), 2.15-1.95 (m, 4H, H12, H13) ; 
13
C NMR (125 
MHz, CDCl3) δ 171.8 (C39), 165.8 (C23), 156.4 (C3), 149.2 (C26, C28), 140.1 (C5, 
C8), 137.5 (C27), 121.5 (C24), 120.84 (C6, C9), 118.3 (C1), 109.2 (C2), 106.5 (C25, 
C29), 94.9 (C4), 69.8 (C40), 60.7 (C19, C20), 59.5 (C41), 56.9 (C30, C31, C33), 55.9 
(C34), 54.5 (C0), 52.2 (C37), 51.4 (C18), 50.9 (C17), 48.5 (C12), 33.2 (C36), 31.3 
(C35), 29.4 (C36), 23.7 (C21), 16.3 (C13) ; IR (neat) ν 3741, 2918, 1731, 1688, 1553, 
1437, 1182, 1121 cm
-1
; HRESI-MS: m/z calcd for [C34H42N2O10] 639.2839, found 
639.2844. 
Methyl (1S,2R,3R,4aS,13bR,14aS)-3-((4-(2-bromoethoxy)-3,5-dimethoxybenzoyl) 
oxy)-2,11-dimethoxy-1,2,3,4,4a,5,7,8,13,13b,14,14a-dodeca-hydroindolo[2',3': 3,4] 
pyrido[1,2-b]isoquinoline-1-carboxylate 72  
O-alkylated reserpine alcohol 71 (100 mg, 
0.16 mmol) was dissolved in dry THF (20 
mL) in a 50 mL flame-dried round bottom 
flask under Ar. CBr4 (200 mg, 0.60 mmol) 
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was added and the mixture stirred at room temperature for 10 min before adding PPh3 
(100 mg, 0.38 mmol) in one portion. Stirring was continued at room temperature for a 
further 3 h while monitoring by TLC (Pet. spirit:EtOAc, 70:30). The solvent was 
evaporated and the residue purified by silica gel column chromatography using a 
gradient (Pet. spirit:EtOAc, 60:40 → 100% EtOAc) to give 72 (98 mg, 91%) as a 
yellow-brown solid. TLC Rf (Pet. spirit:EtOAc, 60:40) = 0.55; Mp 140-143 ºC; 
1
H 
NMR (500 MHz, CDCl3) δ 7.58 (br s, 1H, H7), 7.32 (m, 3H, H25, H29, H1), 6.85 (app 
d, J = 2.0 Hz, 1H, H4), 6.78 (d, J = 10.0 Hz , 2.0 Hz, 1H, H2), 5.10 (sextet, J = 4.5 Hz, 
1H, H20), 4.75 (t, J = 10.0 Hz, 2H, H40), 3.91 (s, 7H, H31, H33, H19), 3.77 (app t, 7H, 
H30, H37, H38), 3.63 (t, J = 10.0 Hz, 2H, H41), 3.52 (s, 3H, H34), 3.18 (d, J = 7.1 Hz, 
2H, H17), 3.05 (d, J = 7.1 Hz, 1H, H18), 2.97 (sextet, J = 7.1 Hz, 1H, H36) 2.73 (dd, J 
= 10.0 Hz, 5.0 Hz, 2H, H14), 2.54-2.22 (m, 3H, H21, H35), 2.12-1.88 (m, 4H, H12, 
H13); 
13
C NMR (125 MHz, CDCl3) δ 172.1 (C39), 165.4 (C23), 156.6 (C3), 149.0 
(C26, C28), 140.5 (C5, C8), 137.0 (C27), 122.0 (C24), 120.2 (C6, C9), 118.8 (C1), 
109.0 (C2), 106.0 (C25, C29), 94.7 (C4), 69.3 (C40), 60.2 (C19, C20), 57.2 (C30, C31, 
C33), 56.1 (C34), 54.5 (C0), 52.0 (C37), 51.1 (C18), 51.2 (C17), 48.2 (C12), 33.0 
(C36), 31.6 (C41), 31.1 (C35), 29.6 (C36), 23.9 (C21), 18.1 (C13); IR (neat) ν 3744, 
2916, 1734, 1683, 1558, 1437, 1183, 1119 cm
-1
; HRESI-MS: m/z calcd for 
[C34H41BrN2O9] 701.2633, found 701.2645. 
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Methyl (1S,2R,3R,4aS,13bR,14aS)-3-((4-(2-(4-(tert-butoxy carbonyl) piperazin-1-
yl)ethoxy)-3,5-dimethoxybenzoyl)oxy)-2,11-dimethoxy-1,2,3,4,4a,5,7,8,13,13b,14, 
14a-dodecahydroindolo[2',3':3,4]pyrido[1,2-b]isoquin- oline-1-carboxylate 66  
Bromide 72 (200 mg, 0.28 mmol) 
was dissolved in dry THF (25 mL) 
in a 50 mL flame-dried round 
bottom flask under Ar and N-Boc-
piperazine (150 mg, 0.78 mmol) and 
triethylamine (500 mg, 5.0 mmol) were successively added. A reflux condenser was 
attached and the mixture heated at 100 
o
C with stirring 16 h while monitoring by TLC 
(60% EtOAc/Pet. spirit). The solvent was evaporated and the residue purified by silica 
gel column chromatography (Pet. spirit:EtOAc, 50:50) to provide 66 (184 mg, 80%) as 
a yellow-brown solid. TLC Rf (Pet. spirit:EtOAc, 60:40) = 0.25; Mp 170-172 ºC; 
1
H 
NMR (500 MHz, CDCl3) δ 7.55 (br s, 1H, H7), 7.31 (m, 3H, H25, H29, H1), 6.78 (app 
d, J = 2.0 Hz, 1H, H4), 6.69 (d, J = 10.0 Hz, 2.0 Hz, 1H, H2), 5.03 (sextet, J = 4.5 Hz, 
1H, H20), 4.46 (app s, 1H, H19), 4.27 (t, J = 10.0, 2H, H40), 3.90 (s, 6H, H31, H33), 
3.87 (t, J = 10.0 Hz, 1H, H38), 3.83 (s, 3H, H30), 3.80 (s, 3H, H37), 3.71 (t, J = 10.0 
Hz, 2H, H41), 3.50 (s, 3H, H34), 3.41 (app dd, J = 8.5 Hz, 4H, H43, H45), 3.18 (d, J = 
7.1 Hz, 2H, H17), 3.08 (d, J = 7.1 Hz, 1H, H18), 2.94 (sextet, J = 7.1 Hz, 1H, H36) 2.68 
(dd, J = 10.0 Hz, 5.0 Hz, 2H, H14), 2.56 (app dd, J = 8.5 Hz, 4H, H42, H44), 2.50-2.24 
(m, 3H, H21, H35), 2.18-1.92 (m, 4H, H12, H13), 1.45 (s, 9H, H46); 
13
C NMR (125 
MHz, CDCl3) δ 172.1 (C32), 166.0 (C23), 158.8 (C46), 156.2 (C3), 148.9 (C26, C28), 
138.8 (C5, C8), 137.3 (C27), 121.2 (C24), 120.82 (C6, C9), 118.1 (C1), 109.0 (C2), 
106.3 (C25, C29), 94.5 (C4), 79.4 (C46), 69.8 (C40), 68.5 (C10), 60.6 (C19, C20), 59.1 
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(C41), 57.2 (C30, C31, C33), 56.1(C42, C44), 56.1 (C34), 52.0 (C37), 51.6 (C18), 51.1 
(C17), 48.8 (C12), 45.8 (C43, C45), 33.0 (C15), 32.0 (C14), 31.5 (C14), 29.2 (C36), 
27.9 (C46), 23.7 (C21), 16.3 (C13); IR (neat) ν 3741, 2935, 2794, 1700, 1695, 1457, 
1418, 1248, 1152 cm
-1
; HRESI-MS: m/z calcd for [C43H58N4O11] 807.4180, found 
807.4188. 
Methyl (1S,2R,3R,4aS,13bR,14aS)-3-((4-(2-(4-(tert-butoxy carbonyl)piperazin-1-
yl)-2-oxoethoxy)-3,5-dimethoxybenzoyl)oxy)-2,11-dimethoxy-1,2,3,4,4a,5,7,8,13,13b 
,14,14a-dodecahydroindolo[2',3':3,4]pyrido[1,2-b]isoquin-oline-1-carboxylate 68  
Phenolic reserpine 70 (50 mg, 0.08 
mmol) was dissolved in DMF (7 
mL) in a 25 mL flame-dried round 
bottom flask under Ar and K2CO3 
(250 mg, 1.79 mmol) was added. 
The mixture was stirred for 20 min before N-bromoacetyl-N’-Boc-piperazine 76 (40 mg, 
0.13 mmol) was added in one portion. The mixture was stirred at 80 
o
C for 48 h while 
monitoring by TLC (EtOAc:MeOH, 95:5). The solvent was evaporated and the residue 
purified by silica gel column chromatography to yield 68 (43 mg, 64%) as a brown 
solid. TLC Rf (EtOAc:MeOH, 95:5) = 0.25; Mp 138-141 ºC; 
1
H NMR (500 MHz, 
CDCl3) δ 7.64 (br s, 1H, H7), 7.35 (m, 3H, H25, H29, H1), 6.82 (s, 1H, H4), 6.77 (d, J 
= 15.0 Hz, 1H, H2), 5.05 (sextet, J = 4.5 Hz, 1H, H20), 4.68 (s, 2H, H40), 4.44 (app s, 
1H, H19), 3.88 (s, 6H, H31, H33), 3.86 (t, J = 10.0 Hz, 1H, H38), 3.85 (s, 3H, H30), 
3.81 (s, 3H, H37), 3.76 (app dd, J = 8.5 Hz, 4H, H42, H44), 3.63 (app dd, J = 8.5 Hz, 
4H, H43, H45), 3.48 (s, 3H, H34), 3.19 (d, J = 7.1 Hz, 2H, H17), 3.07 (d, J = 7.1 Hz, 
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1H, H18), 2.94 (sextet, J = 7.1 Hz, 1H, H36) 2.69 (dd, J = 10.0 Hz, 5.0 Hz, 2H, H14), 
2.56-2.24 (m, 3H, H21, H35), 2.13-1.85 (m, 4H, H12, H13), 1.48 (s, 9H, H46); 
13
C 
NMR (125 MHz, CDCl3) δ 172.0 (C32), 168.2 (41), 165.6 (C23), 158.5 (C46), 156.0 
(C3), 148.8 (C26, C28), 138.9 (C5, C8), 137.2 (C27), 121.1 (C24), 120.8 (C6, C9), 
118.2 (C1), 109.1 (C2), 106.1 (C25, C29), 94.3 (C4), 79.2 (C46), 68.4 (C10), 65.7 
(C40), 60.5 (C19, C20), 57.1 (C30, C31, C33), 56.0 (C34), 52.4 (C37), 51.9 (C43, C45), 
51.5 (C18), 51.0 (C17), 50.6 (C42, C44), 48.6 (C12), 33.1 (C15), 31.8 (C14), 31.4 
(C14), 29.1 (C36), 27.8 (C46), 23.8 (C21), 16.1 (C13); IR (neat) ν 3340, 2931, 2844, 
1707, 1694, 1458, 1415, 1211, 1125 cm
-1
; HRESI-MS: m/z calcd for [C43H56N4O12] 
821.3973, found 821.3987. 
Methyl (1S,2R,3R,4aS,13bR,14aS)-3-((4-(2-((2-((tert-butoxy carbonyl) (methyl) 
amino)ethyl)(methyl)amino)ethoxy)-3,5-dimethoxybenzoyl) oxy)-2,11-dimethoxy-
1,2,3,4,4a,5,7,8,13,13b,14,14a-dodecahydroindolo[2',3':3,4] pyrido[1,2-b]isoquinol 
one-1-carboxylate 67 
Bromide 72 (200 mg, 0.28 mmol) 
was dissolved in dry THF (20 
mL) in a 50 mL flame-dried 
round bottom flask under Ar and 
N-Boc-N,N’-dimethylethylenedi 
amine 75 (150 mg, 0.78 mmol) was added followed by triethylamine (500 mg, 5.0 
mmol). A reflux condenser was attached and the mixture warmed to 100 
o
C and stirred 
for 16 h while monitoring by TLC (Pet. spirit:EtOAc 60:40). The mixture was 
concentrated and the residue purified by a silica gel column chromatography using 30% 
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EtOAc/Pet. spirit to provide 67 (172 mg, 75%) as a brown solid. TLC Rf (Pet. 
spirit:EtOAc 60:40) = 0.23; Mp 188-191 ºC; 
1
H NMR (500 MHz, CDCl3) δ 7.60 (br s, 
1H, H7), 7.24 (m, 3H, H25, H29, H1), 6.91 (app d, J = 2.0 Hz, 1H, H4), 6.78 (d, J = 
10.0 Hz, 2.0 Hz, 1H, H2), 5.04 (sextet, J = 4.5 Hz, 1H, H20), 4.54 (app s, 1H, H19), 
4.21 (t, J = 10.0, 2H, H40), 3.89 (s, 6H, H31, H33), 3.86 (t, J = 10.0 Hz, 1H, H38), 3.81 
(s, 3H, H30), 3.79 (s, 3H, H37), 3.71 (t, J = 10.0 Hz, 2H, H41), 3.48 (s, 3H, H34), 3.22 
(t, J = 10.0 Hz, 2H, H43), 3.16 (d, J = 7.1 Hz, 2H, H17), 3.03 (d, J = 7.1, 1H, H18), 
2.96 (sextet, J = 7.1 Hz, 1H, H36) 2.94 (s, 3H, H45), 2.92 (S, 3H, H44), 2.68 (dd, J = 
10.0 Hz, 5.0 Hz, 2H, H14), 2.55 (t, J = 10.0 Hz, 2H, H42), 2.49-2.22 (m, 3H, H21, 
H35), 2.16-1.90 (m, 4H, H12, H13), 1.44 (s, 9H, H46); 
13
C NMR (125 MHz, CDCl3) δ 
171.6 (C32), 165.8 (C23), 158.5 (C46), 156.0 (C3), 149.1 (C26, C28), 139.0 (C5, C8), 
137.1 (C27), 121.0 (C24), 120.4 (C6, C9), 117.6 (C1), 108.7 (C2), 105.9 (C25, C29), 
94.1 (C4), 79.2 (C46), 69.5 (C40), 68.1 (C10), 60.4 (C19, C20), 59.0 (C41), 57.0 (C30, 
C31, C33), 56.1 (C34), 55.3 (C42), 52.6(C43), 51.8 (C37), 51.4 (C18), 50.8 (C17), 48.6 
(C12), 46.7 (C44), 36.8 (C45), 32.6 (C15), 31.6 (C14), 29.1 (C36), 28.4 (C46), 23.6 
(C21), 16.1 (C13); IR (neat) ν 3419, 2941, 1709, 1684, 1458, 1330, 1216, 1158 cm
-1
; 
HRESI-MS: m/z calcd for [C43H60N4O11] 809.4337, found 809.4369. 
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Methyl (1S,2R,3R,4aS,13bR,14aS)-3-((4-(2-((2-((tert-butoxycarbonyl)(methyl) 
amino)ethyl)(methyl)amino)-2-oxoethoxy)-3,5-dimethoxyben-zoyl)oxy)-2,11-
dimethoxy-1,2,3,4,4a,5,7,8,13,13b,14,14a-dodecahydroindolo[2' ,3':3,4]pyrido[1,2-
b]isoquinoline-1-carboxylate 69 
The phenolic reserpine derivative 
70 (50 mg, 0.08 mmol) was 
dissolved in dry DMF (7 mL) in a 
50 mL oven-dried round bottom 
flask under Ar and K2CO3 (250 
mg, 1.79 mmol) was added. The mixture was stirred at room temperature for 30 min 
before adding N-bromoacetyl-N’-Boc-N,N’-dimethylethylenediamine 77 (40 mg, 0.13 
mmol)  in one portion. The reaction mixture was heated to 80 
o
C and stirred for 48 h 
while monitoring by TLC (EtOAc:MeOH, 95:5). The solvent was evaporated and the 
residue purified by silica gel column chromatography using a gradient (100% EtOAc → 
5% MeOH/EtOAc) to give 69 (47 mg, 70%) as a brown solid. TLC Rf (EtOAc:MeOH, 
95:5) = 0.20; Mp 103-105 ºC; 
1
H NMR (500 MHz, CDCl3) δ 7.63 (br s, 1H, H7), 7.36-
7.28 (m, 3H, H25, H29, H1), 6.91 (app d, J = 1.0 Hz, 1H, H4), 6.78 (d, J = 10.0 Hz, 1.0 
Hz, 1H, H2), 5.04 (sextet, J = 4.5 Hz, 1H, H20), 4.68 (s, 2H, H40), 4.51 (app s, 1H, 
H19), 3.89 (s, 6H, H31, H33), 3.84 (s, 3H, H30), 3.81 (s, 3H, H37), 3. 68 (app s, 1H, 
H38), 3.49 (s, 3H, H34), 3.40 (t, J = 10.0 Hz, 2H, H43), 3.17 (d, J = 7.1 Hz, 2H, H17), 
3.03 (d, J = 7.1 Hz, 1H, H18), 2.94 (s, 3H, H45), 2.92 (S, 3H, H44), 2.88 (sextet, J = 7.1 
Hz, 1H, H36), 2.70 (dd, J = 10.0 Hz, 5.0 Hz, 2H, H14), 2.55 (t, J = 10.0 Hz, 2H, H42), 
2.49-2.22 (m, 3H, H21, H35), 2.16-1.90 (m, 4H, H12, H13), 1.44 (s, 9H, H46); 
13
C 
NMR (125 MHz, CDCl3) δ 171.4 (C32), 166.4 (C41), 165.3 (C23), 158.2 (C46), 156.1 
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(C3), 149.3 (C26, C28), 139.0 (C5, C8), 136.0 (C27), 121.5 (C24), 119.3 (C6, C9), 
117.4 (C1), 108.4 (C2), 104.7 (C25, C29), 93.0 (C4), 79.5 (C46), 69.0 (C40), 67.4 
(C10), 60.2 (C19, C20), 56.8 (C30, C31, C33), 56.0 (C34), 53.3 (C43), 52.4 (C42), 51.6 
(C37), 51.3 (C18), 50.7 (C17), 48.5 (C12), 43.7 (C45), 36.6 (C44), 32.5 (C15), 31.8 
(C14), 29.1 (C36), 28.3 (C46), 23.3 (C21), 16.3 (C13); IR (neat) ν 3291, 2935, 2828, 
2162, 1704, 1696, 1458, 1415, 1213, 1126 cm
-1
; HRESI-MS: m/z calcd for 
[C43H58N4O12] 823.4129, found 823.4135. 
6.1.5 Synthesis of Pterostilbene-Containing Intermediates 
(E)-2-(4-(3,5-Dimethoxystyryl)phenoxy)ethan-1-ol 82 
To a solution of pterostilbene 9 (300 mg, 1.1 mmol) in 
anhydrous DMF (10 mL) in a 25 mL flame-dried 
round bottom flask under Ar was added K2CO3 (260 
mg, 1.1 mmol) and the mixture was stirred at room 
temperature for 20 min. 2-Bromoethanol (300 mg, 2.5 mmol) was added dropwise over 
10 min and the reaction mixture warmed to 80 
o
C and stirred for 16 h while monitoring 
by TLC (Pet. spirit:EtOAc, 50:50). The solvent was evaporated under reduce pressure 
and the residue re-dissolved in CH2Cl2. The organic layer was washed successively with 
water and brine, dried over anhydrous Na2SO4 and concentrated. The crude residue was 
purified by silica gel column chromatography using 10% EtOAc/Pet. spirit to afford 82 
(280 mg, 90%) as an off-white powder. TLC Rf (Pet. spirit:EtOAc, 50:50) = 0.45; Mp 
83-84 ºC; 
1
H NMR (500 MHz, CD3OD) δ 7.46 (d, J = 10.0 Hz, 2H, H6, H2), 7.05 (d, J 
= 15.8 Hz, 1H, H9), 6.93 (m, 3H, H3, H5, H8), 6.67 (s, 2H, H12, H14), 6.38 (s, 1H, 
H16), 4.31 (t, J = 12.0 Hz, 2H, H18), 3.78 (s, 6H, H10, H11), 3.65 (t, J = 14.0 Hz, 2H, 
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H19); 
13
C NMR (125 MHz, CD3OD) δ 162.6 (C4), 161.8 (C15, C17), 141.5 (C13), 
130.8 (C2, C6), 128.3 (C9), 127.9 (C8), 114.9 (C3, C5), 105.0 (C12, C14), 100.4 (C16), 
69.7 (C18), 60.9 (C19), 54.8 (C10, C11); IR (neat) ν 3671, 2927, 2348, 1586, 1146, 
1129, 1110 cm
-1
; HRESI-MS: m/z calcd for [C18H19NaO4] 322.1181, found  322.1189. 
(E)-1-(4-(2-Bromoethoxy)styryl)-3,5-dimethoxybenzene 83  
To a solution of alcohol 82 (200 mg, 0.67 mmol) in 
anhydrous THF (25 mL) in a 50 mL flame-dried round 
bottom flask under Ar was added CBr4 (850 mg, 2.5 
mmol). PPh3 (262 mg, 1.0 mmol) was then added in 
one portion and the reaction stirred for 3 h at room temperature while monitoring by 
TLC (Pet. spirit:EtOAc, 50:50). The solvent was evaporated and the residue re-
dissolved in EtOAc. The organic layer was washed successively with water and brine, 
dried over anhydrous MgSO4 and concentrated. The crude residue was purified by silica 
gel column chromatography to afford 83 (225 mg, 94%) as an off-white foam. TLC Rf 
(Pet. spirit:EtOAc, 50:50) = 0.69; Mp 76-77 ºC; 
1
H NMR (500 MHz, CD3OD) δ 7.45 (d, 
J = 10.0 Hz, 2H, H6, H2), 7.08 (d, J = 15.8 Hz, 1H, H9), 6.95 (m, 3H, H3, H5, H8), 
6.66 (s, 2H, H12, H14), 6.35 (s, 1H, H16), 4.30 (t, J = 12.0 Hz, 2H, H18), 3.76 (s, 6H, 
H10, H11), 3.63 (t, J = 14.0 Hz, 2H, H19); 
13
C NMR (125 MHz, CD3OD) δ 161.9 (C4), 
161.5 (C15, C17), 141.0 (C13), 130.8 (C2, C6), 127.8 (C9), 127.9 (C8), 115.2 (C3, C5), 
106.1 (C12, C14), 99.8 (C16), 69.5 (C18), 60.8 (C19), 55.01 (C10, C11) ; IR (neat) ν 
2928, 2346, 1583, 1145, 1122, 1115 cm
-1
; HRESI-MS: m/z calcd for [C18H19BrO3] 
362.0518, found 362.0524. 
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Tert-butyl (E)-4-(2-(4-(3,5-dimethoxystyryl)phenoxy)ethyl)piperazine-1-
carboxylate 78  
To a solution of bromide 83 (150 mg, 0.41 
mmol) in anhydrous THF (30 mL) in a 50 mL 
oven-dried round bottom flask under Ar was 
added KI (300 mg, 1.80 mmol). N-Boc-
piperazine (120 mg, 0.63 mol) was then added in one portion, a reflux condenser 
attached and the reaction heated at 100 
o
C with stirring for 48 h while monitoring by 
TLC (Pet. spirit:EtOAc, 50:50). The solvent was evaporated and the residue re-
dissolved in EtOAc (50 mL). The organic layer was washed successively with water 
and brine, dried over anhydrous Na2SO4 and concentrated. The crude residue was 
purified by silica gel column chromatography using a gradient (10 → 15% EtOAc/Pet. 
Spirit) to give 78 (166 mg, 87%) as an off-white solid. TLC Rf (Pet. spirit:EtOAc, 
50:50) = 0.30; Mp 103-105 ºC; 
1
H NMR (500 MHz, CDCl3) δ 7.40 (d, J = 10.0 Hz, 2H, 
H6, H2), 7.12 (d, J = 15.8 Hz, 1H, H9), 6.90 (m, 3H, H3, H5, H8), 6.70 (s, 2H, H12, 
H14), 6.38 (s, 1H, H16), 4.31 (t, J = 12.0 Hz, 2H, H18), 3.75 (s, 6H, H10, H11), 3.43 
(dd, J = 7.5 Hz, 4H, H22, H24), 3.65 (t, J = 14.0 Hz, 2H, H19), 2.65 (dd, J = 7.5 Hz, 
4H, H21, H25), 1.46 (s, 9H, H23) ; 
13
C NMR (125 MHz, CDCl3) δ 161.4 (C23), 160.8 
(C15, C17), 159.9 (C4), 141.5 (C13), 131.6 (C2, C6), 128.1 (C9), 127.6 (C8), 115.0 
(C3, C5), 106.0 (C12, C14), 100.4 (C16), 76.8 (C23), 69.4 (C18), 58.9 (C19), 57.6 
(C21, C25), 54.5 (C10, C11), 47.4 (C22, C24), 28.9 (C23); IR (neat) ν 2934, 2836, 
1685, 1584, 1513, 1425, 1248, 1145 cm
-1
; HRESI-MS: m/z calcd for [C27H36N2O5] 
491.4463, found 491.4487. 
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Tert-butyl (E)-4-(2-(4-(3,5-dimethoxystyryl)phenoxy)acetyl) piperazine-1-carboxy 
late 80 
To a solution of phenolic pterostilbene 9 (256 
mg, 1.0 mmol) in anhydrous DMF (10 mL) in a 
25 mL oven-dried round bottom flask under Ar 
was added K2CO3 (552 mg, 4.0 mmol). N-
bromoacetyl-N’-Boc-piperazine 76 (460 mg, 1.5 mmol) was then added in one portion 
and a reflux condenser attached and the reaction stirred at 100 
o
C for 48 h while 
monitoring by TLC (pet. Spirit:EtOAc, 50:50). The solvent was evaporated and the 
residue redissolved in CH2Cl2 (50 mL). The organic layer was washed successively with 
water and brine, dried over anhydrous NaSO4 and concentrated. The crude residue was 
purified by silica gel column chromatography using 15% EtOAc/Pet. spirit to afford 80 
(371 mg, 77%) as an off-white solid. TLC Rf (Pet. spirit:EtOAc, 55:45) = 0.42; Mp 52-
53 ºC; 
1
H NMR (500 MHz, CDCl3) δ 7.44 (d, J = 10.0 Hz, 2H, H6, H2), 7.11 (d, J = 
15.8 Hz, 1H, H9), 7.05-6.86 (m, 3H, H3, H5, H8), 6.63 (app d, J = 1.5 Hz, 2H, H12, 
H14), 6.37 (s, 1H, H16), 4.71 (s, 2H, H18), 3.81 (s, 6H, H10, H11), 3.57 (dd, J = 7.5 
Hz, 4H, H21, H25), 3.42 (dd, J = 7.5 Hz, 4H, H22, H24), 1.46 (s, 9H, H23); 
13
C NMR 
(125 MHz, CDCl3) δ 166.8 (C19), 161.2 (C15, C17), 157.6 (C4), 154.7 (C23), 139.7 
(C13), 131.1 (C7), 128.6 (C9), 128.1 (C2, C6), 127.5 (C8), 115.0 (C3, C5), 104.5 (C12, 
C14), 100.0 (C16), 80.6 (C23), 68.2 (C18), 55.6 (C10, C11), 45.6 (C22, C24), 42.2 
(C21, C25), 28.6 (C23); IR (neat) ν 2930, 2886, 1684, 1651, 1589, 1510, 1436, 1232, 
1219 cm
-1
; HRESI-MS: m/z calcd for [C27H34N2O6] 505.2315, found 505.2331. 
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Tert-butyl (E)-(2-((2-(4-(3,5-dimethoxystyryl)phenoxy)ethyl) (methyl)amino)ethyl) 
(methyl)carbamate 79 
To a stirring solution of pterostilbene alkyl 
bromide 83 (150 mg, 0.41 mol) in anhydrous 
CH2Cl2 (30 mL) in a 50 mL oven-dried round 
bottom flask under Ar was added K2CO3 (250 
mg, 1.80 mmol). N-Boc-N,N’-dimethylethylenediamine 75 (120 mg, 0.63 mol) was then 
added in one portion, a reflux condenser attached and the reaction heated at 60 
o
C for 48 
h while monitoring by TLC (Pet. spirit:EtOAc, 50:50). The cooled reaction mixture was 
diluted with CH2Cl2 (30 mL) and the organic layer washed successively with water and 
brine, dried over anhydrous Na2CO3 and concentrated. The crude residue was purified 
by silica gel column chromatography using a gradient (15% EtOAc/Pet. spirit to 100% 
EtOAc) to provide 79 (154 mg, 81%) as a pale yellow solid. TLC Rf (Pet. spirit:EtOAc, 
50:50) = 0.27; Mp 131-135 ºC; 
1
H NMR (500 MHz, CDCl3) δ 7.44 (d, J = 10.0 Hz, 2H, 
H6, H2), 7.14 (d, J = 15.8 Hz, 1H, H9), 7.06-6.90 (m, 3H, H3, H5, H8), 6.65 (s, 2H, 
H12, H14), 6.37 (s, 1H, H16), 4.29 (t, J = 12.0 Hz, 2H, H18), 3.75 (s, 6H, H10, H11), 
3.13 (t, J = 7.5 Hz, 2H, H24), 2.75 (t, J = 7.1 Hz, 2H, H19), 2.57 (s, 3H, H22), 2.43 (3, J 
= 7.1 Hz, 2H, H25), 2.19 (s, 3H, H21), 1.45 (s, 9H, H23); 
13
C NMR (125 MHz, CDCl3) 
δ 161.2 (C23), 160.7 (C15, C17), 159.6 (C4), 141.0 (C13), 131.3 (C2, C6), 128.0 (C9), 
127.2 (C8), 114.7 (C3, C5), 105.5 (C12, C14), 99.8 (C16), 78.1 (C23), 67.9 (C18), 58.9 
(C19), 56.2 (C25), 54.4 (C10, C11), 53.1 (C24), 46.4 (C22), 37.5 (C21), 28.7 (C23); IR 
(neat) ν 2944, 2861, 1687, 1585, 1511, 1422, 1247, 1125 cm
-1
; HRESI-MS: m/z calcd 
for [C27H38N2O5] 493.2356, found 493.2364. 
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Tert-butyl (E)-(2-(2-(4-(3,5-dimethoxystyryl)phenoxy)-N-methyl acetamido)ethyl) 
(methyl)carbamate 81 
To a stirring solution of phenolic pterostilbene 
9 (256 mg, 1.0 mmol) in anhydrous DMF (10 
mL) in a 25 mL oven-dried round bottom flask 
under Ar was added K2CO3 (552 mg, 4.0 
mmol). N-bromoacetyl-N’-Boc-N,N’-dimethylethylenediamine 77 (460 mg, 1.5 mmol) 
was added in one portion, a reflux condenser attached and the reaction heated at 80 
o
C 
for 24 h while monitoring by TLC (Pet. spirit:EtOAc, 50:50). The reaction mixture was 
concentrated and the residue redissolved in CH2Cl2 (30 mL). The organic layer was 
washed successively with water and brine, dried over anhydrous MgSO4 and 
concentrated. The residue was purified by silica gel column chromatography using a 
gradient (Pet. spirit:EtOAc, 85:15 to 100% EtOAc) to afford 81 (255 mg, 77%) as a 
pale yellow solid. TLC Rf (Pet. spirit:EtOAc, 50:50) = 0.27; Mp 118-120 ºC; 
1
H NMR 
(500 MHz, CDCl3) δ 7.41 (d, J = 18.0 Hz, 2H, H6, H2), 7.07-6.86 (m, 4H, H3, H5, H8, 
H9), 6.64 (s, 2H, H12, H14), 6.38 (s, 1H, H16), 4.69 (d, J = 18.0 Hz, 2H, H18), 3.82 (s, 
6H, H10, H11), 3.54 (t, J = 8.5 Hz, 2H, H25), 3.39 (t, J = 8.5 Hz, 2H, H24), 3.10 (s, 3H, 
H21), 2.86 (s, 3H, H22), 1.45 (s, 9H, H23); 
13
C NMR (125 MHz, CDCl3) δ 167.8 (C19), 
160.9 (C15, C17), 157.7 (C4), 155.9 (C23), 139.6 (C13), 130.8 (C7), 128.5 (C9), 127.8 
(C2, C6), 127.0 (C8), 114.9 (C3, C5), 104.4 (C12, C14), 97.7 (C16), 79.8 (C23), 67.1 
(C18), 55.3 (C10, C11), 47.4 (C24), 45.5 (C25), 34.8 (C21, C22), 28.4 (C23); IR (neat) 
ν 2935, 2831, 1684, 1659, 1590, 1509, 1457, 1204, 1173, 1148 cm
-1
; HRESI-MS: m/z 
calcd for [C27H36N2O6] 507.2471, found 507.2486. 
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6.1.6 Synthesis of INF55-Containing Intermediates 
2-(4-(Bromomethyl)phenyl)-5-nitro-1H-indole 90 
 To a solution of the methyl ester 88 (80 mg, 0.27 mmol) in 
dry THF (5.0 mL) under Ar was added NaBH4 (50 mg, 1.3 
mmol) and the reaction stirred at room temperature while 
monitoring by TLC (pet. Spirit:EtOAc, 50:50). After 24 h the reaction was quenched by 
slow addition of sat. NH4Cl (aq) until bubbling ceased. The mixture was diluted with 
water (50 mL) and extracted with EtOAc (4 x 50 mL). The combined organic layers 
were dried over anhydrous MgSO4 and concentrated to give benzylic alcohol 89 (85%) 
as a bright yellow powder. TLC Rf (Pet. spirit:EtOAc, 50:50) = 0.42; Mp 215-218 
o
C; 
1
H NMR (500 MHz, (CD3)2CO) δ 11.37 (br.s, 1H, H9), 8.53 (s, 1H, H2), 8.04 (d, J = 
8.5 Hz, 1H, H5), 7.89 (d, J = 8.5 Hz, 2H, H13, H17), 7.59 (d, J = 8.5 Hz, 1H, H4), 7.51 
(d, 2H, J = 8.5 Hz, H14, H16), 7.17 (s, 1H, H7), 4.72 (s, 2H, H18); 
13
C NMR (125 
MHz, (CD3)2CO) δ 146.3 (C6), 143.1 (C15), 141.2 (C8), 140.1 (C12), 131.5 (C3), 130.9 
(C14, C16), 130.0 (C1), 125.8 (C13, C17), 119.1 (C4), 118.4 (C5), 110.6 (C2), 101.7 
(C7), 64.3 (C18). The alcohol 89 (30 mg, 0.10 mmol) and CBr4 (100 mg, 0.30 mmol) 
were added to a flame-dried 25 mL round bottom flask followed by anhydrous 
Et2O/THF (1:1, 5 mL). The mixture was stirred at room temperature for 30 min before 
PPh3 (80 mg, 0.31 mmol) was added in one portion. The reaction was stirred at room 
temperature for 3 h while monitoring by TLC (Pet. spirit:EtOAc, 70:30). The solvent 
was evaporated and the residue purified by silica gel column chromatography using Pet. 
spirit:EtOAc 90:10 to yield 90 (30 mg, 94%) as a yellow powder. TLC Rf (Pet. 
spirit:EtOAc, 50:50) = 0.91; Mp 198-199 
o
C; 
1
H NMR (500 MHz, (CD3)2CO) δ 10.14 
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(br.s, 1H, H9), 9.27 (s, 1H, H2), 8.05 (d, 1H, J = 8.5 Hz, H5), 7.91 (d, 2H, J = 7.5 Hz, 
H4), 7.61-7.57 (m, 4H, H13, H14, H16, H17), 6.92 (s, 1H, H7), 4.51 (s, 2H, H18); 
13
C 
NMR (125 MHz, (CD3)2CO) δ 143.0 (C6), 142.1 (C8), 138.3 (C15), 137.6 (C10), 135.8 
(C12), 132.5 (C3), 129.5 (C14, C16), 129.2 (C7), 125.8 (C13, C17), 113.7 (C4), 112.2 
(C5), 98.6 (C11), 33.3 (C2). HRESI-MS: m/z calcd for [C15H11BrN2O2] 330.0018, 
found 330.0023. 
Tert-butyl 4-(4-(5-nitro-1H-indol-2-yl)benzyl)piperazine-1-carboxylate 84 
Bromide 90 (70 mg, 0.21 mmol) was dissolved in 
anhydrous THF (25 mL) under Ar and KI (175 mg, 1.1 
mmol) added. The mixture was stirred at room 
temperature for 30 min before adding N-Boc-piperazine (100 mg, 0.53 mmol) in one 
portion. The reaction was then heated at reflux for 48 h while monitoring by TLC (Pet. 
spirit:EtOAc, 70:30). The mixture was concentrated and the residue purified by silica 
gel column chromatography using Pet. spirit:EtOAc 85:15 to afford 84 (89 mg, 96%) as 
a yellow solid. TLC Rf (Pet. spirit:EtOAc, 70:30) = 0.43; Mp 208-210 ºC;
 1
H NMR (500 
MHz, (CD3)2SO) δ 12.25 (br.s, 1H, H9), 8.53 (s, 1H, H2), 7.89 (d, J = 7.5 Hz, 2H, H5), 
7.84 (d, J = 8.5 Hz, 2H, H13, H17), 7.53 (d, J = 7.5 Hz,1H, H4), 7.42 (d, J = 8.5, 2H, 
H14, H16), 7.15 (s, 1H, H7), 3.51 (s, 2H, H18), 3.30 (m, 4H, H20, H22), 2.33 (m, 4H, 
H19, H23), 1.37 (s, 9H, H21) ; 
13
C NMR (125 MHz, (CD3)2SO) δ 155.0 (C21), 142.4 
(C6), 141.2 (C15), 139.9 (C8), 139.0 (C12), 130.2 (C3), 130.0 (C14, C16), 128.7 (C1), 
125.5 (C13, C17), 118.0 (C4), 117.7 (C5), 110.9 (C2), 101.6 (C7), 70.9 (C21), 62.7 
(C18), 53.0 (C19, C23, C20, C22), 28.6 (C21) ; IR (neat) ν 3272, 2969, 2811, 2769, 
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1663, 1520, 1476, 1330, 1318, 1216, 1158 cm
-1
; HRESI-MS: m/z calcd for 
[C24H28N4O4] 435.2032, found 435.2043. 
4-(5-nitro-1H-indol-2-yl)benzoic acid 91 
To a solution of methyl ester 88 (250 mg, 0.84 mmol) in 
MeOH/CH2Cl2 (10:90 v/v, 40 mL) was added methanolic 
NaOH (3 N, 2.5 mL). The mixture was stirred at room 
temperature for 30 min before attaching a reflux condenser and heating the reaction 
overnight at reflux while monitoring by TLC (CH2Cl2:MeOH, 90:10). The solvent was 
removed under reduced pressure and the residue redissolved in water (100 mL). The 
aqueous layer was washed with CH2Cl2 (2 x 60 mL) and the pH reduced to 2-3 by 
dropwise addition of 5% HCl. The aqueous layer was extracted with CH2Cl2 (3 x 50 
mL). The combined organic layers were washed with water and brine, dried over 
anhydrous MgSO4 and concentrated to give 91 (230 mg, 96%) as a yellow powder. TLC 
Rf (CH2Cl2:MeOH, 90:10) = 0.21; Mp 138-139 ºC;
 1
H NMR (500 MHz, (CD3)2SO) δ 
12.41 (s, 1H, H9), 8.56 (s, 1H, H2), 8.02 (m, 5H, H5, H13, H14, H16, H17), 7.57 (d, J = 
10.0 Hz, 1H, H4),7.31 (s, 1H, H7); 
13
C NMR (125 MHz, (CD3)2CO) δ 174.2 (C18), 
148.3 (C6), 143.1 (C15), 141.2 (C8), 140.1 (C12), 131.5 (C3), 130.9 (C14, C16), 130.0 
(C1), 125.8 (C13, C17), 119.1 (C4), 118.4 (C5), 110.6 (C2), 101.7 (C7); IR (neat) ν 
3420, 3233, 2891, 2787, 2771, 1793, 1518, 1473, 1321, 1317, 1210, 1151 cm
-1
; HRESI-
MS: m/z calcd for [C15H10N2O4] 281.0689, found 281.0680. 
Tert-butyl 4-(4-(5-nitro-1H-indol-2-yl)benzoyl)piperazine-1-carboxylate 86 
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The acid 91 (20 mg, 0.07 mmol) was dissolved in 
anhydrous THF (10 mL) under Ar and DIEA (9.0 mg, 
0.07 mmol) added. N-Boc-piperazine (16 mg, 0.08 
mmol) and HATU (35 mg, 0.09 mmol) were then successively added and the reaction 
stirred at room temperature for 5 h while monitoring by TLC (Pet. spirit:EtOAc, 30:70). 
The solvent was removed under reduced pressure and the residue redissolved in CH2Cl2. 
The organic layer was washed with 5% aqueous HCl, water and brine and then dried 
over anhydrous Na2SO4 and concentrated. The crude residue was purified by silica gel 
column chromatography using Pet. spirit:EtOAc 60:40 to afford 86 (26 mg, 85%) as a 
yellow solid. TLC Rf (Pet. spirit:EtOAc, 30:70) = 0.50; Mp 210-12 ºC;
 1
H NMR (500 
MHz, (CD3)2CO) δ 11. 05 (br.s, 1H, H9), 8.58 (s, 1H, H2), 8.06 (d, J = 7.5 Hz, 1H, H5), 
7.99 (d, J = 8.5 Hz, 2H, H13, H17), 7.74 (d, J = 8.5, 2H, H14, H16), 7.60 (d, J = 8.5 
Hz,1H, H4), 7.27 (s, 1H, H7), 3.35 (m, 4H, H19, H22), 2.13 (m, 4H, H20, H23), 1.43 (s, 
9H, H21); 
13
C NMR (125 MHz, (CD3)2CO) δ 171.1 (C18), 151.8 (C21), 147.5 (C6), 
142.5 (C15), 140.6 (C8), 139.0 (C12), 131.4 (C3), 130.8 (C14, C16), 129.5 (C1), 125.9 
(C13, C17), 119.1 (C4), 118.3 (C5), 110.5 (C2), 101.8 (C7), 68.2 (C21), 46.0 (C20, 
C23), 40.4 (C19, C22), 29.3 (C21); IR (neat) ν 3267, 2957, 2795, 2768, 1701, 1663, 
1521, 1475, 1322, 1312, 1215, 1119 cm
-1
; HRESI-MS: m/z calcd for [C24H26N4O5] 
449.1825, found 449.1826. 
Tert-butyl methyl(2-(methyl(4-(5-nitro-1H-indol-2-yl)benzyl)amino)ethyl) 
carbamate 85 
Bromide 90 (80 mg, 0.24 mmol) was dissolved in 
anhydrous THF (25 mL) under Ar in a 50 mL oven-
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dried round bottom flask. KI (200 mg, 1.12 mmol) was added and the mixture stirred at 
room temperature for 30 min before adding N-Boc-N,N’-dimethylethylenediamine 75 
(100 mg, 0.53 mmol) in one portion. A reflux condenser was attached and the reaction 
heated to reflux for 48 h while monitoring by TLC (Pet. spirit:EtOAc, 70:30). The 
solvent was evaporated and the residue purified by silica gel column chromatography 
using a gradient from Pet. spirit:EtOAc 60:40  to 100% EtOAc to yield 85 (63 mg, 
78%) as a yellow solid. TLC Rf (Pet. spirit:EtOAc, 70:30) = 0.23; Mp 118-120 ºC;
 1
H 
NMR (500 MHz, (CD3)2SO) δ 12.26 (br.s, 1H, H9), 8.55 (s, 1H, H2), 8.00-7.82 (m, 3H, 
H5, H13, H17), 7.60-7.38 (m, 3H, H4, H14, H16), 7.21 (s, 1H, H7), 4.00 (s, 2H, H18), 
3.37 (m, 4H, H23, H22), 2.66 (s, 3H, H20), 1.96 (s, 3H, H19), 1.36 (s, 9H, H21); 
13
C 
NMR (125 MHz, (CD3)2SO) δ 158.8 (C21), 142.1 (C6), 141.2 (C15), 140.0 (C8), 139.7 
(C12), 129.9 (C3), 129.6 (C14, C16), 128.6 (C1), 125.3 (C13, C17), 117.8 (C4), 117.5 
(C5), 110.7 (C2), 101.2 (C7), 79.4 (C21), 62.0 (C23), 47.1 (C22), 42.7 (C19), 35.0 
(C20), 28.4 (C21); IR (neat) ν 3268, 2961, 2810, 2776, 1668, 1523, 1475, 1396, 1330, 
1317, 1211, 1153 cm
-1
; HRESI-MS: m/z calcd for [C24H30N4O4] 437.2189, found 
437.2180. 
Tert-butyl methyl(2-(N-methyl-4-(5-nitro-1H-indol-2 yl)benzamido)ethyl) 
carbamate 87  
The acid 91 (20 mg, 0.07 mmol) was dissolved in 
anhydrous THF (9 mL) under Ar in a 25 mL flame-
dried round bottom flask. DIEA (9.0 mg, 0.07 
mmol), N-Boc-piperazine (16 mg, 0.088 mmol) and 
HATU (35 mg, 0.09 mmol) were successively added and the reaction stirred at room 
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temperature for 7 h while monitoring by TLC (pet. Spirit:EtOAc, 70:30). The solvent 
was evaporated and the residue redissolved in CH2Cl2 (30 mL). The organic layer was 
washed with 5% aqueous HCl, water and brine, dried over anhydrous Na2SO4 and 
concentrated. The crude residue was purified by silica gel column chromatography 
using a gradient from Pet. spirit:EtOAc 60:40 to 100% EtOAc to provide 87 (23 mg, 
78%) as a yellow solid. TLC Rf (Pet. spirit:EtOAc, 70:30) = 0.45; Mp 162-164 ºC;
 1
H 
NMR (500 MHz, CDCl3) δ 12.20 (br.s, 1H, H9), 8.57 (s, 1H, H2), 7.61 (d, J = 11.5 Hz, 
2H, H13, H17), 7.49 (d, 1H, H5), 7.43-7.27 (m, 3H, H4, H14, H16), 6.91 (d, J = 11.4 
Hz,1H, H7), 3.76-3.32 (m, 4H, H23, H22), 2.76 (s, 3H, H20), 1.68 (s, 3H, H19), 1.46 (s, 
9H, H21); 
13
C NMR (125 MHz, CDCl3) δ 174.0 (C18), 157.0 (C21), 142.0 (C6), 140.4 
(C15), 139.8 (C8), 139.1 (C12), 129.1 (C3), 128.1 (C14, C16), 127.5 (C1), 125.2 (C13, 
C17), 116.9 (C4), 116.3 (C5), 110.3 (C2), 101.2 (C7), 79.8 (C21), 61.9 (C23), 47.1 
(C22), 43.1 (C19), 36.8 (C20), 28.5 (C21); IR (neat) ν 3233, 2981, 2790, 1697, 1675, 
1598, 1472, 1398, 1332, 1317, 1166, 1028 cm
-1
; HRESI-MS: m/z calcd for 
[C24H28N4O5] 451.1981, found 451.1988.  
6.1.7 Synthesis of INF271-Containing Intermediates 
1-(2-hydroxyphenyl)-3-(naphthalen-2-yl)urea 98  
O-Aminophenol (4.0 g, 36.7 mmol) was added to a solution of 
2-naphthaleneisocyanate 97 (4.00 g, 23.6 mmol) in dry CH2Cl2 
(100 mL) in one portion. The reaction was stirred at room 
temperature for 48 h while monitored by TLC (Pet. spirit:EtOAc, 50:50). The white 
precipitate was filtered, washed with dry CH2Cl2:Et2O, 50:50 (2 x 100 mL) and dried in 
vacuo. The residue was additionally washed with 1M aqueous HCl in cases where O-
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aminophenol was observed in the 
1
H NMR spectrum of the product. Compound 98 
(5.20 g, 80%) was obtained as an off-white powder. TLC Rf (Pet. spirit:EtOAc, 50:50) = 
0.48; Mp 163-165 ºC; 
1
H NMR (500 MHz, (CD3)2SO) δ 9.98 (s, 1H, H20), 9.50 (s, 1H, 
H11), 8.24 (s, 1H, H13), 8.12 (s, 1H, H10), 8.08 (d, 1H, J = 9.8 Hz, H3), 7.82 (d, J = 
10.0 Hz, 1H, H6), 7.80 (d, J = 10.0 Hz, 1H, H19), 7.78 (d, J = 10.0 Hz, 1H, H8), 7.45, 
7.40 (dd, J = 10.0 Hz, 2H, H1, H2 ), 7.33 (d, J = 9.8 Hz, 1H, H17), 6.86 (d, J = 10.0 
Hz,1H, H7), 6.96, 6.98 (dd, J = 10.0 Hz, 2H, H16, H18); 
13
C NMR (125 MHz, 
(CD3)2SO) δ 153.3 (C12), 146.3 (C15), 138.3 (C9), 134.5 (C5), 129.7 (C4), 129.1 (C3), 
128.5 (C14), 128.1 (C17), 127.6 (C1), 127.0 (C6), 122.5 (C2), 120.1 (C19), 119.3 (C8), 
115.1 (C10), 113.6 (C16); IR (neat) ν 3669, 3316, 2978, 2923, 1701, 1654, 1602, 1534, 
1460, 1250, 1220 cm
-1
; HRESI-MS: m/z calcd for [C17H14N2O2] 277.0977, found 
277.0973. 
1-(2-(3-Hydroxypropoxy)phenyl)-3-(naphthalen-2-yl)urea 99 
 Phenolic urea 98 (1.0 g, 3.6 mmol) and KOH (1.20 g, 8.63 
mmol) were added to a 50 mL oven-dried round bottom flask 
under argon. Anhydrous DMF (7 mL) was added and the 
mixture cooled to 0 
o
C before adding 3-bromopropanol (600 
mg, 4.3 mmol) over 20 min. The reaction was stirred at room 
temperature for 16 h while monitoring by TLC (Pet. spirit:EtOAc, 50:50). The DMF 
was evaporated and the residue purified by silica gel column chromatography using a 
gradient of EtOAc:Pet. spirit 30:70 to 100% EtOAc. The product isolated was 
redissolved in EtOAc (250 mL) and washed with 1 M KOH and brine. The organic 
layer was dried over anhydrous MgSO4 and concentrated to yield 99 (904 mg, 75%) as 
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an off-white powder. TLC Rf (Pet. spirit:EtOAc, 50:50) = 0.32; Mp 145-146 ºC; 
1
H 
NMR (500 MHz, (CD3)2SO) δ 9.62 (s, 1H, H11), 8.18 (d, J = 7.5 Hz, 1H, H19), 8.15 (s, 
1H, H13), 8.14 (s, 1H, H10), 7.84 (d, J = 7.4 Hz, 1H, H6), 7.80 (dd, J = 7.5 Hz, 2H, H8, 
H3), 7.51 (d, J = 7.5 Hz, 1H, H7), 7.43 (t, J = 7.5 Hz, 1H, H2), 7.34 (t, J = 7.5 Hz, 1H, 
H1), 7.02 (d, J = 7.5 Hz,1H, H16), 6.92 (dd, J = 7.5 Hz, 2H, H17, H18), 4.70 (s, J = 6.5 
Hz, 1H, H24), 4.27 (t, J = 6.5 Hz, 2H, H21), 3.65 (t, J = 6.5 Hz, 2H, H23), 1.97 (q, J = 
6.5 Hz, 2H, H22); 
13
C NMR (125 MHz, (CD3)2SO) δ 155.4 (C15), 149.9 (C12), 140.3 
(C9), 136.6 (C5), 131.9 (C6), 131.6 (C14), 131.3 (C7), 130.3 (C17), 129.85 (C4), 129.2 
(C3), 126.8 (C1), 124.8 (C2), 123.3 (C18), 122.4 (C8), 121.7 (C19), 116.2 (C10), 114.6 
(C16) 68.4 (C21), 60.3 (C23) 34.9 (C22); IR (neat) ν 3672, 3318, 2977, 2921, 1699, 
1653, 1601, 1534, 1461, 1251, 1222 cm
-1
; HRESI-MS: m/z calcd for [C20H20N2O3] 
335.1396, found 335.1402. 
1-(2-(3-Bromopropoxy)phenyl)-3-(naphthalen-2-yl)urea 100  
CBr4 (3.10 g, 9.0 mmol) was added to a solution of alcohol 99 
(800 mg, 2.4 mmol) in dry THF (30mL) in a 50 mL flame-
dried round bottom flask under Ar. After 30 min stirring at 
room temperature PPh3 (2.50 g, 9.5 mmol) was added in one 
portion and stirring continued at room temperature for a further 16 h. The solvent was 
removed under reduced pressure and the residue redissolved in CH2Cl2 (45 mL). The 
organic layer was washed with 1% KOH, water and brine and dried over anhydrous 
Na2SO4. The crude residue was purified by silica gel column chromatography using Pet. 
spirit:EtOAc 90:10 to afford 100 (800 mg, 85%) as grey crystals. TLC Rf (Pet. 
spirit:EtOAc, 50:50) = 0.76; Mp 122-123 ºC; 
1
H NMR (500 MHz, (CD3)2SO) δ 9.58 (s, 
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1H, H11), 8.17 (d, J = 7.5 Hz, 1H, H19), 8.13 (s, 1H, H13), 8.11 (s, 1H, H10), 7.84 (d, J 
= 7.5 Hz, 1H, H6), 7.81 (dd, J = 7.4 Hz, 2H, H8, H3), 7.52 (d, J = 7.5 Hz, 1H, H7), 7.45 
(t, J = 7.5 Hz, 1H, H2), 7.36 (t, J = 7.5 Hz, 1H, H1), 7.05 (d, J = 7.6 Hz, 1H, H16), 6.94 
(dd, J = 7.4 Hz, 2H, H17, H18), 4.18 (t, J = 6.5 Hz, 2H, H21), 3.80 (t, J = 6.5 Hz, 2H, 
H23), 2.35 (q, J = 6.5 Hz, 2H, H22); 
13
C NMR (125 MHz, (CD3)2SO) δ 156.1 (C15), 
149.7 (C12), 139.9 (C9), 136.3 (C5), 132.8 (C6), 131.9 (C14), 131.0 (C7), 129.5 (C17), 
129.0 (C4), 128.8 (C3), 126.9 (C1), 124.7 (C2), 123.0 (C18), 121.9 (C8), 120.9 (C19), 
115.8 (C10), 114.01 (C16) 64.8 (C21), 34.5 (C23) 29.1 (C22); IR (neat) ν 3317, 2996, 
2927, 1696, 1655, 1602, 1534, 1250, 1221 cm
-1
; HRESI-MS: m/z calcd for 
[C20H19BrN2O2] 397.0552, found 397.0566. 
 1-(Naphthalen-2-yl)-3-(2-(3-(piperazin-1-yl)propoxy)phenyl)urea 92  
Bromide 100 (200 mg, 0.5 mmol), N-Boc-piperazine (200 
mg, 1.1 mmol), K2CO3 (800 mg, 5.75 mmol) and KI 400 
mg, 2.39 mol) were successively added to a 50 mL oven-
dried round bottom flask under Ar. Dry THF (30 mL) was 
then added, a reflux condenser attached and the mixture 
stirred at 80 
o
C for 48 h. The reaction mixture was concentrated in vacuo and the 
residue redissolved in EtOAc (200 mL). The organic layer was washed with water and 
brine, dried over anhydrous Na2SO4 and concentrated. The crude residue was purified 
by silica gel column chromatography using a gradient (Pet. spirit:EtOAc, 50:50 to 100% 
EtOAc) to afford 92 (214 mg, 85%) as a brown powder. TLC Rf (Pet. spirit:EtOAc, 
50:50) = 0.28; Mp 98-100 ºC; 
1
H NMR (500 MHz, (CD3)2SO) δ 8.90 (s, 1H, H11), 8.28 
(d, J = 7.5, 1H, H19), 8.09 (s, 1H, H13), 7.76 (d, J = 7.5 Hz, 3H, H3, H6, H8), 7.11 (s, 
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1H, H10), 7.46 (d, J = 7.6 Hz, 1H, H7), 7.43 (d, J = 7.5 Hz, 2H, H1), 7.36 (d, J = 7.5 
Hz, 1H, H2), 7.08 (d, J = 7.4 Hz, 1H, H16), 6.9-6.10 (d, J = 7.6 Hz, 1H, H18), 6.94 (d, J 
= 7.5 Hz, 1H, H17), 4.73 (t, J = 7.1 Hz, 2H, H21), 3.63 (t, J = 7.1 Hz, 2H, H27), 3.44 
(dd, J = 7.1 Hz, 4H, H26, H29), 3.65 (t, J = 7.1, 2H, H30), 2.17 (t, J = 7.1 Hz, 2H, H23), 
1.83 (q, J = 7.1 Hz, 2H, H22), 1.47 (s, 9H, H25); 
13
C NMR (125 MHz, (CD3)2SO) δ 
155.6 (C15), 154.7 (C40), 152.9 (C12), 135.4 (C9), 133.7 (C5), 129.9 (C7), 127.8 
(C17), 126.8 (C4), 126.5 (C3), 125.3 (C1), 124.6 (C6), 124.3 (C14), 121.4 (C2), 120.5 
(C18), 119.9 (C8, C19), 116.7 (C10), 112.9 (C16), 79.8 (C36), 73.1 (C21), 58.2 (C23),  
56.7 (C26, C30), 46.2 (C27, C29), 28.4 (C37, C38, C39), 27.7 (C25); IR (neat) ν 3327, 
2979, 2930, 2741, 1690, 1601, 1528, 1449, 1248, 1233, 1193, 1164, 1117 cm
-1
; HRESI-
MS: m/z calcd for [C29H36N4O4] 505.2815, found 505.2834. 
Tert-butyl 4-(2-(2-(3-(naphthalen-2-yl)ureido)phenoxy)acetyl)piperazine-1-
carboxylate 94 
To a solution of the phenolic urea 98 (200 mg, 0.72 
mmol) in dry DMF (5 mL) in a 50 mL oven-dried 
round bottom flask under Ar was added Cs2CO3 (800 
mg, 2.5 mmol). The mixture was stirred at 40 
o
C for 
30 min before N-bromoacetyl-N’-Boc-piperazine 76 (200 mg, 0.65 mmol) in dry DMF 
(3 mL) was added dropwise over 5 min. The reaction was stirred at 80 
o
C for 16 h while 
monitoring by TLC (Pet. spirit:EtOAc, 50:50). The solvent was removed in vacuo and 
the residue redissolved in EtOAc. The organic phase was washed with water and brine, 
dried over anhydrous Na2SO4 and concentrated. The crude residue was purified by silica 
gel column chromatography using a gradient (Pet. spirit:EtOAc, 50:50 to 100% EtOAc 
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followed by EtOAc:MeOH, 95:5) to yield 94 (237 mg, 66%) as an off-white powder. Rf 
(pet. Spirit:EtOAc, 50:50) = 0.48; Mp 243-244 ºC; 
1
H NMR (500 MHz, (CD3)2SO) δ 
9.57 (s, 1H, H11), 8.36 (s, 1H, H13), 8.15 (d, J = 7.5 Hz, 1H, H19), 7.78 (d, 1H, J = 7.5 
Hz, H3), 7.76 (d, J = 7.5 Hz, 1H, H6), 7.72 (dd, J = 7.5 Hz, 2H, H7, H8), 7.38, 7.43 (dt, 
J = 7.4 Hz, 2H, H1,H2 ), 7.32 (d, J = 7.5 Hz, 1H, H17), 6.94-6.98 (m, J = 7.5 Hz, 3H, 
H10, H16, H18),  4.51 (s, 2H, H29), 3.68-3.31 (m, J = 7.11, 4H, H23, H24), 3.01 (s, 1H, 
H27), 2.93 (s, 1H, H26), 1.41 (s, 9H, H22); 
13
C NMR (125 MHz, (CD3)2SO) δ 166.0 
(C28), 153.7 (C22, C=O), 152.5 (C12), 146.8 (C15),  138.4 (C9), 137.5 (C5), 133.8 
(C4), 129.0 (C14), 128.4 (C7), 127.5 (C17), 127.3 (C3), 126.8 (C1), 126.3 (C6), 123.8 
(C2), 121.7 (C18), 121.1 (C19), 119.4 (C8),114.8 (C10), 113.2 (C16), 79.1 (C22), 66.5 
(C27), 54.8 (C23), 43.8 (C26), 41.1 (24), 36.2 (C29), 27.9 (C22); IR (neat) ν 3363, 
2984, 2925, 1707, 164, 1629, 1601, 1540, 1507, 1430, 1241, 1232, 1193, 1158, 1128, 
1119 cm
-1
; HRESI-MS: m/z calcd for [C28H32N4O5] 505.2833, found 505.2827. 
Tert-butyl methyl(2-(methyl(3-(2-(3-(naphthalen-2-yl)ureido)phenoxy)propyl) 
amino)ethyl)carbamate 93 
Bromide 100 (200 mg, 0.50 mmol), N-Boc-N,N’-
dimethylethylenediamine 75 (200 mg, 1.0 mmol), K2CO3 
(850 mg, 6.11 mmol) and KI (450 mg, 2.69 mmol) were 
added to a 50 mL flame-dried round bottom flask under Ar 
followed by dry THF (40 mL). The reaction was stirred for 
48 h at 80 
o
C while monitoring by TLC (Pet. spirit:EtOAc, 
50:50). The solvent was evaporated and the residue redissolved in EtOAc (50 mL). The 
organic layer was washed with 5% aqueous HCl, water and brine before being dried 
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over anhydrous Na2SO4 and concentrated. The crude residue was purified by silica gel 
column chromatography using a gradient (Pet. spirit:EtOAc, 70:30  to 100% EtoAc 
followed by EtOAc:MeOH, 90:10) to yield 93 (215 mg, 85%) as a pale yellow powder. 
TLC Rf (Pet. spirit:EtOAc, 50:50) = 0.28; Mp 94-97 ºC; 
1
H NMR (500 MHz, (CD3)2SO) 
δ 9.27 (s, 1H, H11), 8.35 (s, 1H, H13), 7.85 (d, J = 7.5 Hz, 1H, H19), 7.78 (d, J = 7.5 
Hz, 1H, H3), 7.71 (d, J = 7.5 Hz, 1H, H6), 7.54 (d, J= 7.5 Hz, 1H, H8), 7.45 (d, J = 7.5 
Hz, 2H, H1), 7.42 (d, J = 7.5 Hz, 1H, H7), 7.40 (d, J = 7.5 Hz, 1H, H2), 7.20 (d, J = 7.5 
Hz, 1H, H16), 7.16 (s, 1H, H10), 7.10 (d, J = 7.5 Hz, 1H, H18), 7.08 (d, J = 7.5 Hz, 1H, 
H17), 4.04 (t, J = 7.1 Hz, 2H, H21), 3.27 (s, 4H, H29), 3.06 (t, J = 7.1 Hz, 3H, H27), 
2.53 (t, J = 7.1 Hz, 2H, H26), 2.46 (t, J = 7.1 Hz, 2H, H23), 2.18 (s, 3H, H30), 1.82 (q, J 
= 7.1 Hz, 2H, H22), 1.42 (s, 9H, H37, H38, H39); 
13
C NMR (125 MHz, (CD3)2SO) δ 
155.6 (C15), 154.7 (C40), 152.9 (C12), 135.4 (C9), 133.7 (C5), 129.9 (C7), 127.8 
(C17), 126.8 (C4), 126.5 (C3), 125.3 (C1), 124.6 (C6), 124.3 (C14), 121.4 (C2), 120.5 
(C18), 119.9 (C8, C19), 116.7 (C10), 112.9 (C16), 79.8 (C36), 73.1 (C21), 55.6 (C26),  
55.4 (C23), 52.4 (27), 46.9 (C30), 36 (C29), 28.4 (C37, C38, C39), 27.4 (C22); IR 
(neat) ν 3360, 2974, 2931, 2802, 1689, 1654, 1600, 1533, 1449, 1249, 1231, 1193, 
1159, 1117 cm
-1
; HRESI-MS: m/z calcd for [C29H38N4O4] 507.2971, found 507.2964. 
Tert-butyl methyl(2-(N-methyl-2-(2-(3-(naphthalen-2-yl)ureido)phenoxy) 
acetamido)ethyl)carbamate 95 
To a stirring solution of the phenolic urea 98 (200 mg, 
0.72 mmol) in dry DMF (5 mL) in a 50 mL oven-dried 
round bottom flask under Ar was added Cs2CO3 (1.0 g, 
3.06 mmol). The mixture was stirred at 40 
o
C for 30 
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min before adding N-bromoacetyl-N’-Boc-N,N’-dimethylethylenediamine 77 (200 mg, 
0.64 mmol) in DMF (3 mL) was added dropwise over 5 min. The reaction was heated to 
80 
o
C and stirred while monitoring by TLC (Pet. spirit:EtOAc, 50:50). The solvent was 
removed and the residue redissolved in EtOAc. The organic layer was washed with 
water and brine and the aqueous layer back-extracted with EtOAc (50 mL). The pooled 
organic fractions were dried over anhydrous MgSO4 and concentrated. The crude 
residue was purified by silica gel column chromatography using a gradient (Pet. 
spirit:EtOAc, 70:30 to 100% EtoAc followed by EtOAc:MeOH, 95:5) to afford 95 (290 
mg, 80%) as an off-white powder. TLC Rf (Pet. spirit:EtOAc, 50:50) = 0.22; Mp 110-
113 ºC; 
1
H NMR (500 MHz, (CD3)2SO) δ  8.70 (s, 1H, H11), 8.50 (s, 1H, H13), 8.43 (d, 
J = 7.5 Hz, 1H, H19), 8.22 (s, 1H, H10), 7.81-7.72 (m, J = 7.5 Hz, 3H, H3, H6, H2), 
7.42 (dd, J = 7.4 Hz, 2H, H7, H8), 7.33 (t, J = 7.4 Hz, 1H, H1), 7.04 (t, J = 7.5 Hz, 1H, 
H17), 6.95 (t, J = 7.5 Hz, 1H, H18), 6.81 (d, J = 7.5 Hz, 1H, H16), 4.52 (s, 2H, H29), 
3.70-3.30 (m, J = 7.11, 4H, H23, H24), 3.1 (s, 1H, H27), 2.95 (s, 1H, H26), 1.41 (s, 9H, 
H22); 
13
C NMR (125 MHz, (CD3)2SO) δ 168.2 (C28), 160.1 (C22), 157.3 (C12), 153.2 
(C15),  146.2 (C9), 137.4 (C5), 134.5 (C7), 132.2 (C4), 130.0 (C14), 128.6 (C17), 127.6 
(C3), 126.4 (C1), 124.2 (C6), 122.9 (C2), 121.9 (C18), 119.7 (C19), 119.2 (C8), 114.4 
(C10), 111.8 (C16), 79.6 (C36), 73.2 (C21), 55.9 (C26),  55.4 (C23), 52.3 (27), 46.8 
(C30), 36.0 (C29), 28.5 (C37, C38, C39), 27.5 (C22); IR (neat) ν 3363, 2977, 2930, 
1704, 1648, 1629, 1601, 1533, 1506, 1454, 1249, 1229, 1193, 1155, 1155, 1115 cm
-1
; 
HRESI-MS: m/z calcd for [C28H34N4O5] 507.2607, found 507.2598. 
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6.1.8 Synthesis of Reserpine-Containing Hybrids 
General Procedure for the Synthesis of Hybrids 47-62. The general procedure is 
exemplified using the synthesis of 3-(4-(2-(4-((((1S,2R,3R,4aS,13bR,14aS)-2,11-
dimethoxy-1-(methoxycarbonyl)-1,2,3, 4 ,4a,5,7,8,13,13b,14,14a-dodecahydroindolo 
[2',3':3,4] pyrido[1,2-b]isoquinolin-3-yl)oxy)carbonyl)-2,6-dimethoxyphenoxy)ethyl) 
piperazin-1-yl)-7-(dimethylamino) phenothiazin-5-ium chloride 47 
 
 
 
 
The Boc-protected intermediate 66 (80 mg, 0.07 mmol) was dissolved in CH2Cl2 (25 
mL) in a 50 mL round bottom flask under Ar and cooled to 0 
o
C. TFA (5 mL) was 
added in one portion and the reaction allowed to warm to room temperature with 
stirring while monitoring by TLC (Pet. spirit:EtOAc, 40:60). Upon consumption of the 
starting material the reaction was quenched with water and extracted with CH2Cl2 (3 x 
30 mL). The pooled organic fractions were dried over anhydrous MgSO4 and 
concentrated under reduced pressure. The crude amine TFA salt was redissolved in dry 
CH2Cl2 (15 mL) in a 25 mL oven-dried round bottom flask under Ar and 3-
dimethylaminophenothiazin-5-ium triiodide 63 (120 mg, 0.19 mmol, 0.9 eq) was added 
in one portion. The reaction was stirred at room temperature for 72 h while monitoring 
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by TLC (3% NH4OAc(aq):MeOH, 15:85). K2CO3 was added in cases where the reaction 
showed little or no progress after overnight stirring. The completed reaction was 
concentrated and the residue purified by preparative TLC using 3% NH4OAc(aq)/MeOH 
15:85. The dark blue product obtained was dissolved in dry MeOH (25 mL) and stirred 
at room temperature with quaternary ammonium chloride-anion exchange resin (350 
mg, 10% w/w). After 1 h the mixture was filtered through a plug of cotton and the 
filtrate concentrated to give 47 (15.3 mg, 18%) as a dark blue powder. The light-
sensitive compound was stored in a vial under Ar wrapped in aluminium foil at -20 
o
C. 
TLC Rf (3% NH4OAc (aq):MeOH 15:85) = 0.03; Mp > 250 ºC; UV (MeOH): 292 (log ε 
5.06, λmax), 3.29 (log ε 4.59), 386 (log ε 4,45), 510 (log ε 4.00, λmin), 610 (log ε 4.80), 
651 (log ε 5.04, λmax) nm; IR (neat) ν 3419, 2926, 2843, 1708, 1591, 1459, 1387, 1330, 
1222, 1126 cm
-1
; L HRESI-MS: m/z calcd for [C52H61N6O9S] 946.4299, found 
946.4276. 
3-(4-(2-(4-((((1S,2R,3R,4aS,13bR,14aS)-2,11-dimethoxy-1-(methoxycarbonyl)-
1,2,3,4,4a,5,7,8,13,13b,14,14a-dodecahydroindolo[2',3':3,4]pyrido[1,2-b]iso 
quinolin-3-yl)oxy)carbonyl)-2,6-dimethoxyphenoxy)acetyl)piperazin-1-yl)-7-
(dimethylamino)phenothiazin-5-ium chloride 49 
 
 
 
The general procedure was used with Boc-protected intermediate 68 (80 mg, 0.01 
mmol). Stirring at room temperature for 96 h yielded 49 (13.6 mg, 14%) as a dark blue 
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powder after preparative TLC and anion exchange. TLC Rf (3% NH4OAc(aq):MeOH 
15:85) = 0.02; Mp > 250 ºC; UV (MeOH): 292 (log ε 4.88, λmax), 3.27 (log ε 4.46), 392 
(log ε 4,45), 512 (log ε 3.79, λmin), 609 (log ε 4.67), 653 (log ε 4.97, λmax) nm; IR (neat): 
3744, 2933, 2845, 1714, 1700, 1592, 1458, 1384, 1329, 1209, 1179, 1152 cm
-1
; HRESI-
MS: m/z calcd for [C52H59N6O10S] 960.4092, found 960.4063. 
3-((2-((2-(4-((((1S,2R,3R,4aS,13bR,14aS)-2,11-dimethoxy-1-(methoxycarbonyl)-1,2, 
3,4,4a,5,7,8,13,13b,14,14a-dodecahydroindolo[2',3':3,4]pyrido[1,2-b]isoquin olin-3-
yl )oxy)carbonyl)-2,6-dimethoxyphenoxy)ethyl)(methyl)amino)ethyl)(methyl) amin 
o)-7-(dimethylamino)phenothiazin-5-ium chloride 48 
 
 
 
 
The general procedure was used with Boc-protected intermediate 67 (100 mg, 0.12 
mmol). Stirring for 72 h at room temperature in the presence of K2CO3 (0.4 eq) afforded 
48 (22 mg, 18%) as a dark blue powder after preparative TLC and anion exchange. TLC 
Rf (3% NH4OAc(aq):MeOH 15:85) = 0.03; Mp = 212-214 ºC; UV (MeOH): 292 (log ε 
4.86, λmax), 327 (log ε 4.31), 392 (log ε 4.17), 512 (log ε 3.75, λmin), 609 (log ε 4.70), 
656 (log ε 5.02, λmax) nm; IR (neat) ν 3416, 2931, 2870, 1709, 1594, 1454, 1383, 1327, 
1229, 1216 1123 cm
-1
; HRESI-MS: m/z calcd for [C52H63N6O9S] 948.4456, found 
948.4423. 
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3-((2-(2-(4-((((1S,2R,3R,4aS,13bR,14aS)-2,11-dimethoxy-1-(methoxycarbonyl)-1,2, 
3,4,4a,5,7,8,13,13b,14,14a-dodecahydroindolo[2',3':3,4]pyrido[1,2-b]isoquinolin-3-
yl)oxy)carbonyl)-2,6-dimethoxyphenoxy)-N-methylacetamido)ethyl)(methyl)amino 
)-7-(dimethylamino)phenothiazin-5-ium chloride 50 
 
 
 
 
The general procedure was used with Boc-protected intermediate 69 (90 mg, 0.11 
mmol). Stirring for 96 h at room temperature in the presence of K2CO3 (0.4 eq) afforded 
50 (12 mg, 11%) as a dark blue powder after preparative TLC and anion exchange. TLC 
Rf (3% NH4OAc(aq):MeOH 15:85) = 0.02; Mp > 250 ºC; UV (MeOH): 292 (log ε 4.85, 
λmax), 329 (log ε 4.29), 392 (log ε 4.23), 512 (log ε 3.77, λmin), 609 (log ε 4.70), 656 (log 
ε 5.00, λmax) nm; IR (neat) ν 3363, 2926, 2848, 1716, 1710, 1594, 1462, 1387, 1330, 
1217, 1183, 1124 cm
-1
; HRESI-MS: m/z calcd for [C52H61N6O10S] 961.4170, found 
961.4199. 
6.1.9 Synthesis of Pterostilbene-Containing Hybrids 
 (E)-3-((2-((2-(4-(3,5-dimethoxystyryl)phenoxy)ethyl)(methyl) amino)ethyl)(methyl) 
amino)-7-(dimethylamino)phenothiazin-5-ium chloride 51  
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The general procedure was 
used with Boc-protected 
intermediate 78 (100 mg, 0.21 
mmol). Stirring at room 
temperature for 72 h in the presence of K2CO3 (0.3 eq) afforded 51 (35 mg, 26%) as a 
dark blue powder after preparative TLC and anion exchange. TLC Rf (3% 
NH4OAc(aq):MeOH 15:85) = 0.03; Mp = 162-163 ºC; 
1
H NMR (500 MHz, CD2Cl2) δ 
7.98 (dd, J = 8.0, 1.6 Hz, 1H, H36), 7.44 (d, J = 10.0 Hz, 2H, H6, H2), 7.42 (dd, J = 8.0, 
1.6 Hz, 1H, H33), 7.37 (d, J = 10.0 Hz, 1H, H26), 7.35 (dd, J = 10.0, 2.4 Hz, 1H, H27), 
7.08 (d, J = 2.4 Hz, 1H, H29), 6.86 (m, 5H, H35, H9, H3, H5, H8), 6.67 (s, 2H, H12, 
H14), 6.38 (s, 1H, H16), 4.31 (t, J = 12.0 Hz, 2H, H18), 3.75 (s, 6H, H10, H11), 3.64 
and 3.60 (2s, 6H, N(CH3)2), 2.95 (t, J = 14.0 Hz, 2H, H19), 2.93 (dd, J = 7.5 Hz, 4H, 
H22, H24), 2.08 (dd, J = 7.5 Hz, 4H, H21, H25); 
13
C NMR (125 MHz, (CD3)2SO) δ 
13
C 
NMR (125 MHz, CD2Cl2) δ 161.4, 158.8, 139.9, 139.1, 130.5, 128.8, 128.1, 126.9, 
122.2, 119.8, 115.10, 106.7, 106.4, 104.5, 99.9, 66.3, 60.9, 57.0, 55.6, 54.2, 54.0, 48.4, 
30.0, 28.9; UV (MeOH): 294 (log ε 4.86, λmax), 323 (log ε 4.70),  415 (log ε 4.10, λmin), 
612 (log ε 4.60), 655 (log ε 4.84, λmax) nm; IR (neat) ν 2921, 1589, 1386, 1146, 1129, 
1110 cm
-1
; HRESI-MS: m/z calcd for [C36H39N4O3S] 607.2743, found 607.2764. 
(E)-3-(4-(2-(4-(3,5-dimethoxystyryl)phenoxy)acetyl)piperazin-1-yl)-7-(dimethyl 
amino)phenothiazin-5-ium chloride 53 
The general procedure was used 
with Boc-protected intermediate 
80 (60 mg, 0.12 mmol). Stirring 
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at room temperature for 72 h in the presence of K2CO3 (0.2 eq) yielded 53 (25 mg, 
30%) as a dark blue powder after preparative TLC and anion exchange. TLC  Rf (3% 
NH4OAc(aq):MeOH 15:85) = 0.04; Mp = 85-87 ºC; UV (MeOH): 292 (log ε 5.10, λmax), 
320 (log ε 4.91),  412 (log ε 3.37, λmin), 615 (log ε 4.64), 654 (log ε 4.87, λmax) nm; IR 
(neat) ν 3261, 2921, 1589, 1386, 1146, 1129, 1110 cm
-1
; HRESI-MS: m/z calcd for 
[C36H37N4O4S] 621.2536, found 607.2546. 
(E)-3-((2-((2-(4-(3,5-dimethoxystyryl)phenoxy)ethyl)(methyl) amino)ethyl)(methyl) 
amino)-7-(dimethylamino)phenothiazin-5-ium chloride 52  
 The general procedure was 
used with Boc-protected 
intermediate 79 (70 mg, 0.15 
mmol). Stirring for 72 h at 
room temperature in the presence of K2CO3 (0.4 eq) provided 52 (27 mg, 28%) as a 
dark blue powder after preparative TLC and anion exchange. TLC Rf (3% 
NH4OAc(aq):MeOH 15:85) = 0.02; Mp = 178-180 ºC; UV (MeOH): 293 (log ε 5.10, 
λmax), 324 (log ε 4.95),  413 (log ε 3.26, λmin), 611 (log ε 4.63), 661 (log ε 4.92, λmax) 
nm; IR (neat) ν 2919, 2848, 1589, 1455, 1386, 1174, 1145, 1137 cm
-1
; HRESI-MS: m/z 
calcd for [C36H41N4O3S] 609.2899, found 609.2901. 
(E)-3-((2-(2-(4-(3,5-dimethoxystyryl)phenoxy)-N-methylacetamido)ethyl)(methyl) 
amino)-7-(dimethylamino)phenothiazin-5-ium chloride 54 
The general procedure was 
used with Boc-protected 
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intermediate 81 (80 mg, 0.16 mmol). Stirring for 48 h at room temperature in the 
presence of K2CO3 (0.2 eq) afforded 54 (28 mg, 26%) as a dark blue powder after 
preparative TLC and anion exchange. TLC Rf (3% NH4OAc(aq):MeOH 15:85) = 0.02; 
Mp = 194-196 ºC; UV (MeOH): 293 (log ε 5.17, λmax), 324 (log ε 4.99),  415 (log ε 
3.29, λmin), 613 (log ε 4.67), 661 (log ε 4.95, λmax) nm; IR (neat) ν 2938, 2842, 1664, 
1589, 1456, 1203, 1149, 1065, 1055 cm
-1
; HRESI-MS: m/z calcd for [C36H41N4O3S] 
623.2692, found 623.2703. 
6.1.10 Synthesis of INF55-Containing Hybrids 
3-(Dimethylamino)-7-(4-(4-(5-nitro-1H-indol-2-yl)benzyl)piperazin-1-yl)pheno 
thiazine-5-ium chloride 55  
The general procedure was used with 
Boc-protected intermediate 84 (90 
mg, 0.20 mmol). Stirring at room 
temperature for 48 h gave 55 (29 mg, 23%) as a dark blue powder after preparative TLC 
and anion exchange. TLC Rf (3% NH4OAc(aq):MeOH 15:85) = 0.04; Mp > 250 ºC; UV 
(MeOH): 295 (log ε 4.99, λmax), 415 (log ε 3.43, λmin), 610 (log ε 4.62), 656 (log ε 4.91, 
λmax) nm; IR (neat) ν 3205, 2924, 1683, 1591, 1517, 1472, 1387, 1329, 1220, 1134, 
1045; HRESI-MS: m/z calcd for [C33H31N6O2S] 575.2229, found 575.2236. 
3-(Dimethylamino)-7-(methyl(2-(methyl(4-(5-nitro-1H-indol-2-yl)benzyl)amino) 
ethyl)amino)phenothiazin-5-ium chloride 57  
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 The general procedure was used 
with Boc-protected intermediate 86 
(100 mg, 0.23 mmol). Stirring at 
room temperature for 76 h in the 
presence of K2CO3 (0.3 eq) provided 57 (25 mg, 18%) as a dark blue powder after 
preparative TLC and anion exchange. TLC Rf (3% NH4OAc(aq):MeOH 15:85) = 0.03; 
Mp > 250 ºC; UV (MeOH): 297 (log ε 5.06, λmax), 419 (log ε 3.49, λmin), 609 (log ε 
4.68), 651 (log ε 4.91, λmax) nm; IR (neat) ν 3305, 2975, 2922, 1695, 1558, 1553, 1549, 
1540, 1472, 1409, 1400, 1331, 1220, 1134 cm
-1
; HRESI-MS: m/z calcd for 
[C33H33N6O2S] 577.2386, found 577.2400. 
3-(Dimethylamino)-7-(4-(4-(5-nitro-1H-indol-2-yl)benzoyl)piperazin-1-yl)phenol 
thiazine-5-ium chloride 56  
The general procedure was used 
with Boc-protected intermediate 85 
(80 mg, 0.18 mmol). Stirring at 
room temperature for 48 h yielded 
56 (25 mg, 22%) as dark blue powder after preparative TLC and anion exchange. TLC 
Rf (3% NH4OAc(aq):MeOH 15:85) = 0.02; Mp > 250 ºC; UV (MeOH): 295 (log ε 5.03, 
λmax), 415 (log ε 3.65, λmin), 609 (log ε 4.66), 650 (log ε 4.86, λmax) nm; IR (neat) ν 
3245, 2922, 2850, 1663, 1591, 1519, 1458, 1386, 1329, 1230, 1219, 1135 cm
-1
; HRESI-
MS: m/z calcd for [C33H29N6O3S] 589.2022, found 589.2048. 
3-(Dimethylamino)-7-(methyl(2-(N-methyl-4-(5-nitro-1H-indol-2-yl)benzamido) 
ethyl)amino)phenothiazin-5-ium chloride 58  
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The general procedure was used 
with Boc-protected intermediate 87 
(120 mg, 0.26 mmol). Stirring at 
room temperature for 76 h in the 
presence of K2CO3 (0.4 eq) afforded 58 (30 mg, 18%) as a dark blue powder after 
preparative TLC and anion exchange. TLC Rf (3% NH4OAc(aq):MeOH 15:85) = 0.02; 
Mp > 250 ºC; UV (MeOH): 294 (log ε 5.02, λmax), 413 (log ε 3.39, λmin), 610 (log ε 
4.46), 659 (log ε 4.82, λmax) nm; IR (neat) ν 3240, 2921, 2853, 1665, 1591, 1516, 1456, 
1387, 1328, 1226, 1218, 1130 cm
-1
; HRESI-MS: m/z calcd for [C33H31N6O3S] 
591.2175, found 591.2183. 
6.1.11 Synthesis of INF271-Containing Hybrids 
3-(Dimethylamino)-7-(4-(3-(2-(3-(naphthalen-2-yl)ureido)phenoxy)propyl) 
piperazin-1-yl)phenothiazin-5-ium chloride 59 
The general procedure was used with 
Boc-protected intermediate 92 (100 mg, 
0.19 mmol). Stirring at room temperature 
for 48 h afforded 59 (34 mg, 25%) as a 
dark blue powder after preparative TLC 
and anion exchange. TLC Rf (3% NH4OAc(aq):MeOH, 15:85) = 0.04; Mp > 250 ºC; UV 
(MeOH): 287 (log ε 4.86), 295 (log ε 4.88, λmax), 323 (log ε 4.14), 368 (log ε 3.37, λmin), 
608 (log ε 4.61), 655 (log ε 4.88, λmax) nm; IR (neat) ν 3355, 2972, 2921, 2740, 1704, 
1595, 1458, 1353, 1136, 1127, 1118 cm
-1
; HRESI-MS: m/z calcd for [C38H39N6O2S] 
643.2855, found 643.2870. 
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3-(Dimethylamino)-7-(4-(2-(2-(3-(naphthalen-2-yl)ureido)phenoxy)acetyl) 
piperazin-1-yl)phenothiazin-5-ium chloride 61 
The general procedure was used with 
Boc-protected intermediate 94 (90 mg, 
0.18 mmol). Stirring at room temperature 
for 72 h with K2CO3 (0.3 eq) yielded 61 
(21 mg, 17%) as a dark blue powder after preparative TLC and anion exchange. TLC Rf 
(3% NH4OAc(aq):MeOH 15:85) = 0.03; Mp 228-231 ºC; UV (MeOH): 289 (log ε 4.93), 
293 (log ε 4.94, λmax), 324 (log ε 4.10), 410 (log ε 2.04, λmin), 608 (log ε 4.67), 652 (log 
ε 4.96, λmax) nm; IR (neat) ν 3324, 2989, 2923, 2738, 1700, 1653, 1593, 1458, 1386, 
1215, 1196, 1136, 1127 cm
-1
; HRESI-MS: m/z calcd for [C37H35N6O3S] 643.2491, 
found 643.2508. 
3-(Dimethylamino)-7-(methyl(2-(methyl(3-(2-(3-(naphthalen-2-
yl)ureido)phenoxy)propyl)amino)ethyl)amino)phenothiazin-5-ium chloride 60 
The general procedure was used with Boc-
protected intermediate 93 (100 mg, 0.19 
mmol). Stirring at room temperature for 
48 h provided 60 (34 mg, 25%) as a dark 
blue powder after preparative TLC and 
anion exchange. TLC Rf (3% NH4OAc(aq):MeOH 15:85) = 0.03; Mp = 239-241 ºC; UV 
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(MeOH): 290 (log ε 4.86), 327 (log ε 4.06), 415 (log ε 3.03, λmin), 610 (log ε 4.60), 659 
(log ε 4.97, λmax) nm; IR (neat) ν 3299, 2968, 2925, 2710, 1700, 1593, 1450, 1386, 
1327, 1231, 1195, 1136, 1126, 1117 cm
-1
; HRESI-MS: m/z calcd for [C38H41N6O2S] 
645.3012, found 645.2993. 
3-(Dimethylamino)-7-(methyl(2-(N-methyl-2-(2-(3-(naphthalen-2-yl)ureido) 
phenoxy)acetamido)ethyl)amino)phenothiazin-5-ium chloride 62 
The general procedure was used with 
Boc-protected intermediate 95 (80.0 
mg, 0.16 mmol). Stirring at room 
temperature for 72 h with K2CO3 (0.3 
eq) afforded hybrid 62 (15 mg, 15%) 
as a dark blue powder after preparative TLC and anion exchange. TLC Rf (3% 
NH4OAc(aq):MeOH 15:85) = 0.02; Mp = 246-248 ºC; UV (MeOH): 293 (log ε 4.93, 
λmax), 325 (log ε 4.16), 413 (log ε 3.09, λmin), 610 (log ε 4.73), 656 (log ε 5.05, λmax) nm; 
IR (neat) ν 3311, 2968, 2923, 2851, 2736, 1706, 1654, 1593, 1457, 1387, 1327, 1231, 
1192, 1136, 1126, 1119 cm
-1
; HRESI-MS: m/z calcd for [C37H37N6O3S] 645.2648, 
found 645.2663. 
6.2 Experimental Procedures - Photochemical and In Vitro Studies 
6.2.1 Microbial Strains and Culture Conditions 
The following bacterial strains were used: S. aureus 8325-4 (wild-type), K1902 
(8325-4, NorA-), K2378 (NorA++), S. aureus Community Associated (CA)-MRSA 
USA300 (Human isolate/Clinical Microbiology, MGH). The NorA-overexpressing 
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strain K2378 was obtained from Prof Kim Lewis at Northeastern University, Boston. 
All other strains were obtained from Dr George Tegos at The University of New 
Mexico.  
Bacterial cells were cultured in Mueller-Hinton Broth (MHB) or brain heart 
infusion (BHI) medium at 37 °C with shaking at 100 rpm. Cell growth was assessed 
using an Evolution 300 UV/Vis Spectrophotometer (Thermo Scientific, Waltham, MA). 
Cultures were grown to an optical density (OD600) of 0.6, corresponding to a bacterial 
cell density of 10
8
 CFU/mL, and then washed and resuspended in phosphate-buffered 
saline (PBS) (Dulbecco) at 2 × 10
9
 CFU/mL. Cell growth was assessed using a 
spectrophotometer (Shimadzu, Mini 1240) measuring absorbance at 600 nm (OD600). 
6.2.2 Chemicals 
Purified H2O was produced in-house (Milli-Q Water Purification System, 
Millipore). D2O (99.8%) was obtained from Cambridge Isotope Laboratories 
(Apeldoorn, The Netherlands). Ciprofloxacin was obtained from the Massachusetts 
General Hospital Pharmacy and MB was obtained from Sigma-Aldrich (St. Louis, MO). 
6.2.3 Photosensitizers and Light Source 
Stock solutions of MB and the synthesized hybrids were prepared in phosphate-
buffered saline (PBS) (2 mM) after encapsulation in Cremophore EL (CrEL) (See 
Chapter 6.2.5). For all photodynamic experiments, the stock solutions were stored for a 
maximum of 2 weeks at 4°C in the dark. For UV/Vis experiments, stock solutions of PS 
(10 µM) in methanol were prepared immediately prior to use.  
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A noncoherent light source with interchangeable fiber bundles (LC122; 
LumaCare, London, United Kingdom) was employed in all photodynamic experiments. 
Thirty nanometre band-pass filters at ranges of 652 ± 15 nm were used for both MB and 
hybrids. The total power output provided from the fibre bundle was 300 mW and plates 
were positioned to give an irradiance of 100 mW/cm
2
. 
6.2.4 ROS Generation Assay 
Cell-free ROS assays were performed in 96-well plates. SOSG and HPF probes 
(Molecular Probes Invitrogen
TM
) were prepared as 5 µM stocks in MeOH before use. 
Solutions of hybrids and MB in PBS were added to each well to give 50 µM solutions 
in a volume of 85 µL. Probe solutions (40 µL) and deuterium oxide (40 µL) were then 
added followed by MeOH (35 µL) to produce a final volume of 200 µL, with 
compounds present at 10 µM. Plates were illuminated with light delivered in increasing 
doses (1-10 J/cm
2
 for SOG and 1-12 J/cm
2
 for HPF). A microplate spectrophotometer 
(Spectra Max M5, Molecular Devices) was used to monitor the fluorescence signals in 
the “slow kinetic” mode. For HPF, fluorescence emission at 525 nm was measured upon 
excitation at 492 nm using a 2 nm monochromator band pass for both excitation and 
emission. With SOSG, the corresponding values were 505 nm and 525 nm, respectively. 
Data are expressed as mean ± SEM from three independent experiments, each 
performed in quadruplicate to sextuplicate. 
6.2.5 Preparation of Micellar Solutions of Compounds 
Triblock copolymers F127 (PL-F127) and poloxamer 388 (POL388) were 
purchased from BASF chemical company. Cremophor EL (CrEL) and Tween 60 (T60) 
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were obtained from Sigma-Aldrich. Micellar suspensions were prepared by mixing 
solutions containing 2-3 mM hybrids or MB in CH2Cl2 with 500 mL of detergent 
solution (100 mg/mL) in dry CH2Cl2. An additional 2 mL of CH2Cl2 was added and the 
mixtures stirred and sonicated until a homogenous solution was obtained. The final 
detergent /compounds ratios were ~ 250:1. The solvent was then removed in vacuo and 
the resulting dry film redissolved in 1 mL of sterile PBS with agitation. The micellar 
suspensions were filtered through a 0.22 µm mixed-cellulose-ester (MCE) filter under 
sterile conditions.  
6.2.6 Photodynamic Studies 
Bacterial suspensions in PBS (10
8
 cells/mL) were incubated with CrEL-
formulated hybrids in PBS (1-20 µM) in the dark at room temperature for 30 min. The 
suspensions were centrifuged at 12,000 rpm and then washed twice with sterile PBS 
before being placed into wells of a 96-well microtiter plate (Fisher Scientific) and 
illuminated with light at room temperature. Fluences ranged from 0-20 J/cm
2
 at 100 
mW/cm
2
. Contents of the wells were mixed before sampling, with aliquots being 
serially diluted 10-fold in PBS to give 10
-1
-10
-6
-fold dilutions. The diluted samples were 
streaked horizontally onto square BHI agar plates, as described by Jett et al.
235
 Plates 
were incubated at 37 °C overnight and CFUs counted. The limit of detection in these 
experiments was 8 log units of killing. 
6.2.7 Cell Uptake Studies 
Bacterial suspensions (10
8
 cells/mL) were incubated in PBS in the dark at room 
temperature for 30 min with hybrids at the same final concentrations (20 µM) used for 
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the photodynamic experiments. Incubations were carried out in triplicate. The cell 
suspensions were centrifuged (9000 rpm) and the supernatants aspirated. The cells were 
then washed twice with sterile PBS (1 mL) and centrifuged. Cell pellets were digested 
in 3 mL of sodium dodecyl sulfate (SDS) solution (10% in PBS) for at least 24 h or 
until homogenous solutions were obtained. Fluorescence of the extracts was measured 
using a spectrofluorometer (FluoroMax3; SPEX Industries, Edison, N.J.). The 
excitation wavelength for both MB and hybrids was 650 nm and the emission range was 
655 to 720 nm. Calibration curves were prepared from samples of the pure hybrids and 
MB (dissolved at equivalent concentrations in SDS) and used for determination of 
hybrid concentrations in the cell extracts. Uptake values were obtained by dividing the 
number of nanomoles of PS in the extract by the number of CFUs obtained by serial 
dilution, with the number of PS molecules/cell then being calculated using Avogadro’s 
number. 
6.2.8 MIC Determinations with Ciprofloxacin 
The pump inhibitory activities of hybrids and MB were determined by MIC 
measurements in sterile 96-well, black-sided plates using bioluminescence rather than 
traditional turbidity measurements. A bioluminescent S. aureus suspension (MRSA 
USA300, 100 µL containing 10
6
 CFU/mL) was incubated at 37 °C for 15 h with 
vigorous shaking in the dark with 100 µL ciprofloxacin alone (dilution series from 
0.001 to 1.024 µg/mL) and ciprofloxacin in the presence of 100 µL MB (20 µM) and 
100 µL (10 µM) of hybrids 56, 58 and 60. The luminescence was monitored using a 
luminescence plate reader (MicroBeta Trilux 1450; PerkinElmer Life and Analytical 
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Sciences Inc., Wellesley, MA). MIC values were plotted from 3-4 independent 
experiments. 
6.3 Murine MRSA Wound Infection Experiments 
6.3.1 Photosensitizers, Light Source and Bacterial Species  
Methylene blue (MB) was purchased from Sigma (UK). Stock solutions of MB 
and hybrid 58 were freshly prepared as Cremophor EL Micelles in sterile PBS (see 
Chapter 6.2.5 for details) to a final concentration of 200 μM. A noncoherent light source 
(LC122; LumaCare, London, UK) with interchangeable fibre bundles and 30 nm band-
pass filters (652 ± 15 nm) was used for all experiments. Power output from the fibre 
bundle was 300 mW. The spot was positioned at a constant distance from the wound to 
give an irradiance of 100 mW over the 1 cm
2
 wound area.  
Bioluminescent MRSA (Xen 30)
230
 was obtained from the Dai Lab (Wellman 
Center for Photomedicine). Cultures were prepared by growing overnight in brain heart 
infusion (BHI) at 37 °C with 100 rpm orbital shaking. Bacterial growth was assessed 
with an Evolution 300 UV/Vis Spectrophotometer (Thermo Scientific, Waltham, MA). 
Optical density (OD) at 600 nm of 0.8 corresponded to a bacterial cell density of 10
8
 
CFU/mL. Cells were washed and re-suspended in PBS and used at a density of 10
8
 
CFU/mL. 
6.3.2 Animal Preparation and Infection 
Six to eight week old adult female BALB/c mice (Charles River Laboratories, 
Wilmington, MA) weighing 17-21 g were used in the study. Animals were housed one 
per cage and maintained on a 12-hour light/dark cycle with ad libitum access to food 
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and water. All procedures were approved by the Subcommittee on Research Animal 
Care (IACUC) (Massachusetts General Hospital) and met guidelines of the US National 
Institutes of Health (NIH). Mice were administered cyclophosphamide at 4 days and 1 
day prior to MRSA inoculation. The first dose was 150 mg/kg and the second dose 100 
mg/kg (both injected i.p.). Cyclophosphamide reduces peripheral blood neutrophils to 
<100/μL blood, making mice more vulnerable to infection.
224
 
Mice were anesthetized with i.p. injections of a ketamine/xylazine cocktail and 
their dorsal surfaces shaved. Skin abrasion wounds were introduced on the dorsal 
surfaces using a 28-gauge needle (Micro-Fine IV, Becton Dickinson, Franklin Lakes, 
NJ), creating 6 x 6 crossed scratch lines covering on area of 1 cm
2
. The scratches were 
applied such that they damaged only the stratum corneum and upper-layer of the 
epidermis (i.e. not the dermis). Five minutes after wounding, a 40 μL aliquot was taken 
from a suspension containing 10
8
 CFU/mL bioluminescent MRSA (Xen 30) in PBS and 
inoculated over the scratched areas using a micropipette. 
6.3.3 Bioluminescence Imaging 
A Hamamatsu Photonics KK (Bridgewater, NJ) bioluminescence imaging 
system was used in the study.
126b
 The setup consisted of an intensified charge-coupled-
device (ICCD), camera (C2400-30H; Hamamatsu), camera controller, imaging box, 
image processor (C5510-50; Hamamatsu) and a color monitor (PVM 1454Q; 
Hamamatsu). Light-emitting diodes were mounted inside the imaging box to supply 
light for dimensional imaging of the sample. This setup allowed a grayscale background 
image of each mouse to be captured. Using the photo-counting mode, clear images were 
obtained at very low-light levels through detection and integration of individual 
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photons. Luminescence emanating from bacteria was captured using an integration time 
of 2 min with a maximum setting on the image-intensifier control module.  
ARGUS software (Hamamatsu) was used to present luminescence images as 
false-colour images superimposed on the grayscale background image. The software 
calculated total pixel values (relative luminescence units RLU) from the luminescence 
images of the infected wound areas. Wounds were observed daily and photographs 
captured using a Nikon Coolpix L20 camera until wounds had healed. Wound area 
analysis was performed using ImageJ software. 
Prior to imaging, mice were anesthetized by i.p. injections of a 
ketamine/xylazine cocktail. The mice were placed on an adjustable stage in the 
specimen chamber and their infected areas positioned directly under the camera. A 
grayscale background image of each wound was taken followed by a photon count of 
the same region. This total wound photon count was obtained as relative luminescence 
units (RLUs) and displayed in a false-color scale ranging from pink (most intense) to 
blue (least intense).  
6.3.4 Application of aPDT 
Photosensitizers MB and 58 (40 µL of 200 µM stock solutions) were added to 
infection sites of animals in Groups B-E 30 minutes after bacterial inoculation. Fifteen 
minutes after addition of PS (time to allow compounds to bind/penetrate bacteria) the 
mice were again imaged to quantify any dark toxicity of the PS. Mice were illuminated 
with light from a non-coherent light source as described above, receiving total light 
doses of 120 J/cm
2
 delivered in aliquots in periods of 2, 4, 8, 4 and 2 min for a total of 
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20 min. Bioluminescence imaging were captured after each light dose (12, 36, 84, 108 
and 120 J/cm
2
). Dark controls (animals receiving PS without light treatment) were 
assessed at the times corresponding to light delivery in the aPDT treatment groups. 
Control Group A received light and no PS, with images capture at the same time 
intervals as other groups. 
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Appendix 2.1 LRESI-MS of some selected hybrids. 
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Appendix 3.1 SOG
 
and HPF quantum yields for MB and hybrids 47-62. 
    Compound ΦΔ(SOG) ΦΔ(HPF) 
MB 0.52 0.46 
47 0.24 0.13 
48 0.19 0.25 
49 0.12 0.17 
50 0.17 0.14 
51 0.03 0.06 
52 0.09 0.04 
53 0.06 0.08 
54 0.05 0.10 
55 0.34 0.07 
56 0.25 0.09 
57 0.20 0.06 
58 0.30 0.14 
59 0.11 0.08 
60 0.22 0.14 
61 0.11 0.08 
62 0.28 0.09 
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Appendix 3.2 Dark toxicity of MB and hybrids 47-62 against S. aureus MRSA 
USA300. Cells (10
8
 per mL) were incubated for 30 min with CrEL-formulated hybrids 
at 0-20 µM in PBS and subsequently illuminated with 652 nm light (fluence 6 J/cm
2
). 
CFUs were determined after overnight growth at 37 
o
C and survival fractions 
calculated. Data represent the mean of 3-5 independent experiments ± SEM. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1.00E-08
1.00E-06
1.00E-04
1.00E-02
1.00E+00
0 5 10 15 20
su
rv
iv
al
 f
ra
ct
io
n
 
concentration (µM) 
MB dark
1.00E-08
1.00E-06
1.00E-04
1.00E-02
1.00E+00
0 5 10 15 20
su
rv
iv
al
 f
ra
ct
io
n
 
concentration (µM) 
MB+crEL dark
1.00E-08
1.00E-06
1.00E-04
1.00E-02
1.00E+00
0 5 10 15 20
su
rv
iv
al
 f
ra
ct
io
n
 
concentration (µM) 
47 dark
1.00E-08
1.00E-06
1.00E-04
1.00E-02
1.00E+00
0 5 10 15 20
su
rv
iv
al
 f
ra
ct
io
n
 
concentration (µM) 
49 dark
 
209 
 
 
 
                                             
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1.00E-08
1.00E-06
1.00E-04
1.00E-02
1.00E+00
0 5 10 15 20
su
rv
iv
al
 f
ra
ct
io
n
 
concentration (µM) 
48 dark
1.00E-08
1.00E-06
1.00E-04
1.00E-02
1.00E+00
0 5 10 15 20
su
rv
iv
al
 f
ra
ct
io
n
 
concentration (µM) 
50 dark
1.00E-08
1.00E-06
1.00E-04
1.00E-02
1.00E+00
0 5 10 15 20
su
rv
iv
al
 f
ra
ct
io
n
 
concentration (µM) 
53 dark
1.00E-08
1.00E-06
1.00E-04
1.00E-02
1.00E+00
0 5 10 15 20
su
rv
iv
al
 f
ra
ct
io
n
 
concentration (µM) 
51 dark
 
210 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1.00E-08
1.00E-06
1.00E-04
1.00E-02
1.00E+00
0 5 10 15 20
su
rv
iv
al
 f
ra
ct
io
n
 
concentration (µM) 
54 dark
1.00E-08
1.00E-06
1.00E-04
1.00E-02
1.00E+00
0 5 10 15 20
su
rv
iv
al
 f
ra
ct
io
n
 
concentration (µM) 
52 dark
1.00E-08
1.00E-06
1.00E-04
1.00E-02
1.00E+00
0 5 10 15 20
su
rv
iv
al
 f
ra
ct
io
n
 
concentration (µM) 
55 dark
1.00E-08
1.00E-06
1.00E-04
1.00E-02
1.00E+00
0 5 10 15 20
su
rv
iv
al
 f
ra
ct
io
n
 
concentration (µM) 
57 dark
 
211 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
                             
 
 
 
1.00E-08
1.00E-06
1.00E-04
1.00E-02
1.00E+00
0 5 10 15 20
su
rv
iv
al
 f
ra
ct
io
n
 
concentration (µM) 
56 dark
1.00E-08
1.00E-06
1.00E-04
1.00E-02
1.00E+00
0 5 10 15 20
su
rv
iv
al
 f
ra
ct
io
n
 
concentration (µM) 
58 dark
1.00E-08
1.00E-06
1.00E-04
1.00E-02
1.00E+00
0 5 10 15 20
su
rv
iv
al
 f
ra
ct
io
n
 
concentration (µM) 
59 dark
1.00E-08
1.00E-06
1.00E-04
1.00E-02
1.00E+00
0 5 10 15 20
su
rv
iv
al
 f
ra
ct
io
n
 
concentration (µM) 
61 dark
 
212 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1.00E-08
1.00E-06
1.00E-04
1.00E-02
1.00E+00
0 5 10 15 20
su
rv
iv
al
 f
ra
ct
io
n
 
concentration (µM) 
60 dark
1.00E-08
1.00E-06
1.00E-04
1.00E-02
1.00E+00
0 5 10 15 20
su
rv
iv
al
 f
ra
ct
io
n
 
concentration (µM) 
62 dark
 
213 
 
Appendix 3.3 Dark toxicity over the concentration range 0-16 µM of (A) MB, (B) 56, 
(C) 58 and (D) 60 against NorA knockout (NorA-), wild-type (WT), and NorA-
overexpressing (NorA++) S. aureus strains. Data represent the mean ± SEM from 3-4 
independent experiments.  
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Appendix 4.1 Light-dose responses (mean ± SEM) for dark controls in (A) Groups B 
and (B) Group D in the bioluminescence MRSA wound infection model. Data are 
presented as normalized relative luminescence units (RLU). Data from Figure 4.3 for 
the equivalent aPDT Groups C (MB) and D (58) are included for comparison. 
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Appendix 4.2 Daily bioluminescence images obtained from representative animals in 
Groups A-E during 10 days of post-treatment monitoring. 
 Group A 
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Group B  
MB dark 
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MB PDT 
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